WO2012130166A1 - 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof - Google Patents

1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof Download PDF

Info

Publication number
WO2012130166A1
WO2012130166A1 PCT/CN2012/073362 CN2012073362W WO2012130166A1 WO 2012130166 A1 WO2012130166 A1 WO 2012130166A1 CN 2012073362 W CN2012073362 W CN 2012073362W WO 2012130166 A1 WO2012130166 A1 WO 2012130166A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbonyl
dione
piperazine
quinazoline
benzyl
Prior art date
Application number
PCT/CN2012/073362
Other languages
French (fr)
Inventor
Sui Xiong Cai
Ye Edward Tian
Haijun Dong
Qingbing XU
Lizhen Wu
Lijun Liu
Yangzhen JIANG
Qingli BAO
Guoxiang WANG
Feng Yin
Chengyun GU
Xiuhua HU
Xiaozhu WANG
Sishun Kang
Shengzhi CHEN
Original Assignee
Impact Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2011100824756A external-priority patent/CN102731416A/en
Priority to CA2831015A priority Critical patent/CA2831015C/en
Priority to SG2013071543A priority patent/SG193599A1/en
Priority to SI201231630T priority patent/SI2709990T1/en
Priority to US14/006,722 priority patent/US9290460B2/en
Priority to JP2014501428A priority patent/JP6270713B2/en
Priority to CN201280001822.0A priority patent/CN103097361B/en
Priority to DK12765230.3T priority patent/DK2709990T3/en
Priority to AU2012237776A priority patent/AU2012237776B2/en
Priority to EP12765230.3A priority patent/EP2709990B1/en
Priority to PL12765230T priority patent/PL2709990T3/en
Priority to RS20190877A priority patent/RS59091B1/en
Priority to ES12765230T priority patent/ES2736299T3/en
Application filed by Impact Therapeutics, Inc. filed Critical Impact Therapeutics, Inc.
Publication of WO2012130166A1 publication Critical patent/WO2012130166A1/en
Priority to US15/042,366 priority patent/US9926304B2/en
Priority to US15/935,694 priority patent/US10316027B2/en
Priority to US16/415,803 priority patent/US11358955B2/en
Priority to HRP20191273TT priority patent/HRP20191273T1/en
Priority to CY20191100769T priority patent/CY1121847T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention is in the field of medicinal chemistry.
  • the invention relates to l-(aiylmethyl)quinazoline-2,4(lH,3H)-diones, and the use of these compounds as PARP inhibitors and anti-cancer drugs.
  • PARP Poly (ADP-ribose) polymerase
  • PARP-1 inhibitors may be used as effective anti-cancer drugs to treat a variety of cancers.
  • the applications of PARP-1 inhibitors for the treatment of cancer are mainly based on two mechanisms. First, because of the rapid growth, DNA replication is much higher in cancer cells than in normal cells. Drugs that cause DNA damage will induce cancer cell death selectively. However, due to the presence of DNA repair enzymes such as PARP-1, the therapeutic effects of these drugs can not be fully materialized. By inhibiting the DNA repair mechanism, PARP-1 inhibitors in combination with commonly used
  • DNA damaging anti-cancer drugs such as temozolomide
  • PARP-1 inhibitors can directly kill the cancer cells and function as anticancer drugs independently. According to statistics, about 10-15% of breast cancer pateints have family history of genetic factors, in which the BRCA1 or BRCA2 gene mutations account for 15-20% of all hereditary breast cancers. Since PARP-1 is involved in DNA repair, utilization of PARP-1 inhibitors to inhibit DNA repair may be an effective and selective treatment for cancers with DNA repair genetic defect, including triple-negative breast cancers.
  • PARP-1 inhibitors may also be used to treat diseases due to excessive cell death, including central nervous system diseases such as stroke and neurodegenerative diseases (Akinori Iwashita et al, 2004, J. Pharmacol. Exp. Thera. 310: 425).
  • the inhibitory activity of PARP-1 inhibitors can be measured by directly using PARP-1 enzymes.
  • PARP-1 inhibitors can increase the cytotoxicity of DNA damaging anti-cancer drugs such as methyl mathanesulfonate (MMS) on cancer cells
  • the activity of PARP-1 inhibitors can also be determined by measuring cell viability, such as using a MTT assay, in the presence of MMS and PARP-1 inhibitors.
  • Cancer cells with deficiency in DNA repair such as in the case of BRCA1 or BRCA2 deficient triple-negative breast cancer, can be killed by PARP-1 inhibitors alone. Therefore the anticancer activity of PARP-1 inhibitors can be determined by measuring the inhibitory effect of these compounds on cell growth of BRCA-2 deficient CAPAN-1 human pancreatic cancer cells.
  • caspases are a family of cysteine proteases that require aspartic acid residues at the Pi position of substrates for efficient cleavage.
  • caspase-3, 6, and 7 are key effector caspases that cleave multiple protein substrates in cells, leading to cell death.
  • Cellular caspase activity can be determined using caspase substrates and used as a measurement of cell apoptosis.
  • PARP-1 inhibitors can increase the apoptosis- inducing activity of many DNA damaging anticancer drugs such as MMS. Therefore, the activity of PARP-1 inhibitors can be determined via measuring the intracelluar caspase activity of cancer cells treated with DNA damaging anticancer drugs in combination with PARP-1 inhibitors.
  • PARP poly(ADP-ribose) polymerase
  • the invention provides novel l-(arylmethyl)quinazoline-2,4(lH,3H)-diones, as represented in Formulae I, II and III. These compounds have PARP inhibitory activities.
  • the present invention also provides pharmaceutical compositions comprising a compound of Formula I, II or III in an effective amount for the treatment of cancer.
  • the invention also provides a pharmaceutical composition useful for the treatment of cancer, containing an effective amount of a compound of one of the Formula I, II or III in admixture with one or more pharmaceutically acceptable carriers or diluents.
  • the invention also provides a pharmaceutical composition useful for the treatment of cancer, containing an effective amount of a compound of one of the Formula I, II or III, in combination with one known anticancer drugs or its pharmaceutically acceptable salts.
  • the invention also is directed to methods for the preparation of novel compounds of
  • novel and potent PARP inhibitors of the present invention include 1-
  • Ar is an optionally substituted aryl or an optionally substituted heteroaryl
  • Ri-P6 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C 1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol.
  • Preferred compounds of Formula I include compounds wherein Ar is an optionally substituted phenyl, pyridyl or furanyl. More preferably, Ar is phenyl, pyridyl or furanyl, optionally substituted with a substituted carbonyl or methyl, preferably carbonyl, at the meta- position.
  • Another group of preferred compounds of Formula I include compounds wherein R 5 and P6 are hydrogen.
  • R 1 -R4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C 1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol;
  • R7-R 10 independently are hydrogen, halo, optionally substituted amino, alkoxy, C 1-10 alkyl, haloalkyl, aryl, heteroaryl, a carbocyclic group, a heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alkylthi
  • Rn is an optionally substituted amino, hydrazine, alkoxy, C 1-10 alkyl, haloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, acylamido, hydroxy, thiol, acyloxy, carbonylamido, or alkylthiol.
  • One group of preferred compounds of Formula II includes compounds wherein R 7 , R 8 ,
  • R9 or Rio is hydrogen or halo, preferably fluoro.
  • Another group of preferred compounds of Formula II includes compounds wherein Ri or R 2 is hydrogen, fluoro, chloro, bromo or methyl.
  • Another group of preferred compounds of Formula II includes compounds wherein R 4 is hydrogen, fluoro, methyl, methoxy or hydroxy.
  • Another group of preferred compounds of Formula II includes compounds wherein Rn is an optionally substituted amino, more preferably substituted piperazine or piperidine.
  • R 1 -R 4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C 1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol;
  • R 7 -Rio independently are hydrogen, halo, optionally substituted amino, alkoxy, C 1-10 alkyl, haloalkyl, aryl, heteroaryl, a carbocyclic group, a heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alky
  • Ri 2 is selected from the group consisting of cycloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, arylalkyl, heteroarylalkyl, carbocycloalkyl, heterocycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl or heterocyclocarbonyl.
  • Another group of preferred compounds of Formula III includes
  • Ri or R 2 is hydrogen, fluoro, chloro, bromo or methyl
  • R4 is hydrogen, fluoro, methoxy or hydroxy
  • R 7 , R 8 , R9 or R 10 is hydrogen or fluoro.
  • Exemplary preferred compounds of Formulae I, II and III include, without limitation:
  • alkyl refers to both straight and branched chain radicals of up to ten carbons.
  • Useful alkyl groups include straight- chained and branched C 1-10 alkyl groups, more preferably C 1-6 alkyl groups.
  • Typical C 1-10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, hexyl and octyl groups, which may be optionally substituted.
  • alkenyl as employed herein by itself or as part of another group means a straigh or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including at least one double bond between two of the carbon atoms in the chain.
  • Typical alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1- butenyl and 2-butenyl.
  • alkynyl is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, wherein there is at least one triple bond between two of the carbon atoms in the chain.
  • Typical alkynyl groups include ethynyl, 1- propynyl, l-methyl-2-propynyl, 2-propynyl, 1-butynyl and 2-butynyl.
  • Useful alkoxy groups include oxygen substituted by one of the C 1-10 alkyl groups mentioned above, which may be optionally substituted.
  • Alkoxy substituents include, without limitation, halo, morpholino, amino including alkylamino and dialkylamino, and carboxy including esters thereof.
  • Useful alkylthio groups include sulfur substituted by one of the C 1-10 alkyl groups mentioned above, which may be optionally substituted. Also included are the sulfoxides and sulfones of such alkylthio groups.
  • Useful amino and optionally substituted amino groups include - H 2 , - HR 15 and - R 15 R 16 , wherein R 5 and Ri 6 are optionally substituted C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, or amino; or R 15 and Ri 6 are combined with the N to form a 5-8 membered heterocyclic ring structure, such as a piperidine; or R 15 and Ri 6 are combined with the N and an additional N or O atom to form a 5-8 membered heterocyclic ring, such as a piperazine, which are optionally substituted.
  • the groups as described herein such as alkyl, alkoxy, alkylthio, alkenyl, alkynyl, cycloalkyl, carbonyl, carbocyclic and heterocyclic groups, aryl, arylalkyl, arylalkenyl, arylalkynyl and heteroaryl and heteroarylalkyl groups, may be optionally substituted.
  • the term "optionally substituted” used herein indicates that the group that is “optionally subsitutited” may be optionally substituted by one or more (such as 1, 2, 3, or 4) substituents selected from the group consisting of halo, hydroxy, carboxyl, amino, nitro, cyano, Ci-C 6 acylamino, Ci-C 6 acyloxy, Ci-C 6 alkoxy, aryloxy, alkylthio, Ci-C 6 alkyl, C 6 -Cio aryl, C3-C8 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -Cio aryl(C 2 -Ce)alkenyl, C 6 -Cio aryl(C 2 -C 6 )alkynyl, saturated and unsaturated heterocyclic and heteroaryl, methylenedioxy, Ci-C 6 haloalkyl, C 6 C 6 C 6 C
  • Optional substituents on the alkyl, alkoxy, alkylthio, alkenyl, alkynyl, cycloalkyl, carbonyl, carbocyclic and heterocyclic groups may be one or more (such as 1, 2, 3, or 4) groups selected from the group consisting of halo, hydroxy, carboxyl, amino, nitro, cyano, Ci-C 6 acylamino, Ci-C 6 acyloxy, Ci-C 6 alkoxy, aryloxy, alkylthio, C 6 -Cio aryl, C 3 -C 8 cycloalkyl, C 2 - C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -Cio aryl(C 2 -Ce)alkenyl, C 6 -Cio aryl(C 2 -Ce)alkynyl, saturated and unsaturated heterocyclic and heteroaryl.
  • Optional substituents on the aryl, arylalkyl, arylalkenyl, arylalkynyl and heteroaryl and heteroarylalkyl groups may be one or more (such as 1, 2, 3, or 4) groups selected from the gourp consisting of halo, methylenedioxy, Ci-C 6 haloalkyl, C 6 -Cio aryl, C 3 -C 8 cycloalkyl, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -Ci 0 aryl(Ci-C 6 )alkyl, C 6 -Ci 0 aryl(C 2 -C 6 )alkenyl, C 6 -Ci 0 aryl(C 2 -Ce)alkynyl, Ci-C 6 hydroxyalkyl, nitro, amino, ureido, cyano, Ci-C 6 acyla
  • aryl as employed herein by itself or as part of another group refers to monocyclic, bicyclic or tricyclic aromatic groups containing from 6 to 14 carbons in the ring portion.
  • Useful aryl groups include C6-14 aryl, preferably Ce- ⁇ aryl.
  • Typical C6-14 aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.
  • Carbocycle as employed herein include cycloalkyl and partially saturated carbocyclic groups.
  • Useful cycloalkyl groups are C 3 -8 cycloalkyl.
  • Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Useful saturated or partially saturated carbocyclic groups are cycloalkyl groups as described above, as well as cycloalkenyl groups, such as cyclopentenyl, cycloheptenyl and cyclooctenyl.
  • halo or halogen groups include fluorine, chlorine, bromine and iodine.
  • arylalkyl is used herein to mean any of the above-mentioned C 1-10 alkyl groups substituted by any of the above-mentioned C 6-14 aryl groups.
  • the arylalkyl group is benzyl, phenethyl or naphthylmethyl.
  • arylalkenyl is used herein to mean any of the above-mentioned C 2-10 alkenyl groups substituted by any of the above-mentioned C 6-14 aryl groups.
  • arylalkynyl is used herein to mean any of the above-mentioned C 2-10 alkynyl groups substituted by any of the above-mentioned C 6-14 aryl groups.
  • aryloxy is used herein to mean oxygen substituted by one of the above- mentioned C 6-14 aryl groups, which may be optionally substituted.
  • Useful aryloxy groups include phenoxy and 4-methylphenoxy.
  • arylalkoxy is used herein to mean any of the above mentioned C 1-10 alkoxy groups substituted by any of the above-mentioned aryl groups, which may be optionally substituted.
  • Useful arylalkoxy groups include benzyloxy and phenethyloxy.
  • Useful haloalkyl groups include alkyl groups, such as C 1-10 alkyl, or preferably C 1-6 alkyl substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1, 1-difluoroethyl, chloromethyl, chlorofluoromethyl and trichloromethyl groups.
  • alkyl groups such as C 1-10 alkyl, or preferably C 1-6 alkyl substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1, 1-difluoroethyl, chloromethyl, chlorofluoromethyl and trichloromethyl groups.
  • Useful acylamino (acylamido) groups are any C 1-6 acyl (alkanoyl) attached to an amino nitrogen, e.g., acetamido, chloroacetamido, propionamido, butanoylamido, pentanoylamido and hexanoylamido, as well as aryl- substituted C 1-6 acylamino groups, e.g., benzoylamido, and pentafluorobenzoylamido.
  • Usefule acyl includes C 1-6 acyl, such as acetyl.
  • Useful acyloxy groups are any C 1-6 acyl (alkanoyl) attached to an oxy (-0-) group, e.g., formyloxy, acetoxy, propionoyloxy, butanoyloxy, pentanoyloxy and hexanoyloxy.
  • heterocycle (heterocyclic group) is used herein to mean a saturated or partially saturated 3-7 membered monocyclic, or 7-10 membered bicyclic ring system, which consists of carbon atoms and one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized.
  • the term also includes any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring of heterocycle can be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • Useful saturated or partially saturated heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl pyrazolinyl, tetronoyl and tetramoyl groups, which are optionally substituted.
  • heteroaryl refers to groups having 5 to 14 ring atoms; 6,
  • Useful heteroaryl groups include thienyl (thiophenyl), benzo[ ⁇ JJisothiazol-3-yl, benzo[£]thienyl, naphtho[2,3-£]thienyl, thianthrenyl, furyl (furanyl), pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl (pyridinyl), including without limitation 2-pyridyl, 3 -pyridyl, and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl,
  • heteroaryl group contains a nitrogen atom in a ring
  • nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N- oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.
  • heteroaryloxy is used herein to mean oxygen substituted by one of the above-mentioned heteroaryl groups, which may be optionally substituted.
  • Useful heteroaryloxy groups include pyridyloxy, pyrazinyloxy, pyrrolyloxy, pyrazolyloxy, imidazolyloxy and thiophenyloxy.
  • heteroarylalkoxy is used herein to mean any of the above-mentioned C 1-10 alkoxy groups substituted by any of the above-mentioned heteroaryl groups, which may be optionally substituted.
  • Some of the compounds of the present invention may exist as stereoisomers including optical isomers.
  • the invention includes all stereoisomers and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well known to those of ordinary skill in the art.
  • Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts, such as hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalate; and inorganic and organic base addition salts with bases, such as sodium hydroxy, Tris(hydroxymethyl)aminomethane (TRIS, tromethane) and N-methyl-glucamine.
  • inorganic and organic acid addition salts such as hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalate
  • bases such as sodium hydroxy, Tris(hydroxymethyl)aminomethane (TRIS, tromethane) and N-methyl-glucamine.
  • Examples of prodrugs of the compounds of the invention include the simple esters of carboxylic acid containing compounds (e.g., those obtained by condensation with a C 1-4 alcohol according to methods known in the art); esters of hydroxy containing compounds (e.g., those obtained by condensation with a C 1-4 carboxylic acid, C3-6 dioic acid or anhydride thereof, such as succinic and fumaric anhydrides according to methods known in the art); imines of amino containing compounds (e.g., those obtained by condensation with a C 1-4 aldehyde or ketone according to methods known in the art); carbamate of amino containing compounds, such as those described by Leu, et. al, (J Med. Chem.
  • the compounds of this invention may be prepared using methods known to those skilled in the art, or the novel methods of this invention. Specifically, the compounds of this invention with Formula I, II or III can be prepared as illustrated by the exemplary reaction in Scheme 1 (Shunsuke Goto et al. Organic Process Research & Development, 2003, 7, 700-706). Reaction of quinazoline-2,4(lH,3H)-dione with hexamethyldisilazane (HMDS) in toluene in the presence of sulfuric acid produced the intermediate 2,4-di(trimethylsiloxy)quinazoline.
  • Scheme 1 Scheme 1
  • HMDS hexamethyldisilazane
  • Coupling of the acid with a substituted amine such as l-(pyridin-2-yl)piperazine
  • a substituted amine such as l-(pyridin-2-yl)piperazine
  • coupling agents such as 2-(7-aza-lH-benzotriazole-l-yl)- 1, 1,3,3- tetramethyluronium hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIPEA) in DMF, produced the targeted compound l-(3-(4-(pyridin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione.
  • coupling agents such as 2-(7-aza-lH-benzotriazole-l-yl)- 1, 1,3,3- tetramethyluronium hexafluorophosphate (HATU) and N,N-diisoprop
  • the mixture can be separared, hydro lyzed, and coupled with a substituted amine to produce the 1- substitued compound and 3-substituted compound, respectively.
  • the 3-substituted compound also can be prepared from reaction of quinazoline-2,4(lH,3H)-dione with methyl 3- (bromomethyl)benzoate and K 2 C0 3 in DMF, followed by hydrolysis and coupling of the acid with a substituted amine.
  • a substituted amine such as 1-cyclopentylcarbonylpiperazine
  • quinazoline-2,4(lH,3H)-dione replacement of quinazoline-2,4(lH,3H)-dione with a substituted quinazoline-2,4(lH,3H)-dione, such as 5- fluoroquinazoline-2,4(lH,3H)-dione, which can be prepared from reaction of 2-amino-6- fluorobenzoic acid with potassium cyanate, produced the targeted compound l-(3-(4- cyclopentylcarbonylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione.
  • the compounds of this invention can be prepared as illustrated by the exemplary reaction in Scheme 3. Reaction of 2-amino-3-methylbenzoic acid with triphosgene in THF produced 8- methyl-lH-benzo[ ⁇ JJ[l,3]oxazine-2,4-dione, which was treated with tert-butylamine and DMAP in DMF to produce 2-amino-N-tert-butyl-3-methylbenzamide.
  • the 1 -phenyl substituted compound can be prepared as illustrated by the exemplary reaction in Scheme 4. Reaction of 2-bromobenzamide with oxalyl chloride in DCM, followed by addition of methyl 3-aminobenzoate produced methyl 3-(3-(2- bromobenzoyl)ureido)benzoate. Reaction of the benzoate with potassium tert-butoxide in DMF produced l-(3-methoxycarbonylphenyl)quinazoline-2,4(lH,3H)-dione. Hydrolysis of the ester with NaOH in water-methanol produced l-(3-carboxyphenyl)quinazoline-2,4(lH,3H)-dione.
  • coupling agents such as HATU and DIPEA in DMF
  • Formula I, II or III are PARP inhibitors. Therefore, these compounds are useful for the treatment of a variety of clinical conditions responsive to the inhibition of PARP activity, such as cancer.
  • the present invention includes a therapeutic method comprising administering to a mammal an effective amount of a compound of Formula I, II or III, or a pharmaceutically acceptable salt or prodrug thereof, wherein said therapeutic method is useful for the treatment of diseases due to to abnormal PARP activity, such as cancer.
  • Such diseases that can be treated or prevented by the method or pharmaceutical composition of the present invention include, but are not limited to, liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyos
  • Compounds of the present invention also are useful for the treatment or prevention of other clinical conditions due to abnormal PARP activity, such as excessive cell death, including central nervous system diseases such as stroke and neurodegenerative diseases.
  • compositions containing therapeutically effective concentrations of the compounds of Formula I, II or III formulated for oral, intravenous, local or topical application, for the treatment of neoplastic diseases and other diseases are administered to an individual exhibiting the symptoms of one or more of these disorders.
  • the amounts are effective to ameliorate or eliminate one or more symptoms of the disorders.
  • An effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce, the symptoms associated with the disease.
  • Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective.
  • the amount may cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Typically, repeated administration is required to achieve the desired amelioration of symptom.
  • a pharmaceutical composition comprising a compound of
  • Formula I, II or III or a pharmaceutically acceptable salt thereof, which functions as PARP inhibitor, in combination with a pharmaceutically acceptable vehicle, is provided.
  • Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound of Formula I, II or III, or a pharmaceutically acceptable salt or prodrug thereof, which functions as a PARP inhibitor, in combination with at least one known anticancer agent or a pharmaceutically acceptable salt thereof.
  • DNA antimetabolites such as 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea and thioguanine
  • antimitotic agents such as colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, and docetaxel
  • antibodies such as campath, Panitumumab, Ofatumumab, Avastin, Herceptin®, Rituxan®
  • kinase inhibitors such as imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus and everolimus
  • HDAC inhibitors such as vorinostat
  • the compound of the invention may be administered together with at least one known anticancer agent as part of a unitary pharmaceutical composition.
  • the compound of the invention may be administered apart from at least one known anticancer agent.
  • the compound of the invention and at least one known anticancer agent are administered substantially simultaneously, i.e. the compounds are administered at the same time or one after the other, so long as the compounds reach therapeutic levels in the blood at the same time.
  • the compound of the invention and at least one known anticancer agent are administered according to their individual dose schedule, so long as the compounds reach therapeutic levels in the blood.
  • Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a bioconjugate of a compound described herein, which functions as a PARP inhibitor, in bioconjugation with at least one known therapeutically useful antibody, such as Herceptin ® or Rituxan ® , growth factors, such as DGF, NGF; cytokines, such as IL-2, IL-4, or any molecule that binds to the cell surface.
  • the antibodies and other molecules will deliver a compound described herein to its targets and make it an effective anticancer agent.
  • the bioconjugates could also enhance the anticancer effect of the therapeutically useful antibodies, such as Herceptin ® or Rituxan ® .
  • another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound of Formula I, II or III, or its pharmaceutically acceptable salt or prodrug, which functions as a PARP inhibitor, in combination with radiation therapy.
  • the compound of the invention may be administered at the same time as the radiation therapy is administered or at a different time.
  • Yet another embodiment of the present invention is directed to a composition effective for post-surgical treatment of cancer, comprising a compound of Formula I, II or III, or its pharmaceutically acceptable salt or prodrug, which functions as a PARP inhibitor.
  • the invention also relates to a method of treating cancer by surgically removing the cancer and then treating the mammal with one of the pharmaceutical compositions described herein.
  • compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount that is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
  • the compounds may be administered to mammals, orally at a dose of 0.0025 to 50 mg/kg of body weight, per day, or an equivalent amount of the pharmaceutically acceptable salt thereof, to a mammal being treated. Preferably, approximately 0.01 to approximately 10 mg/kg of body weight is orally administered.
  • a known anticancer agent is also administered, it is administered in an amount that is effective to achieve its intended purpose. The amounts of such known anticancer agents effective for cancer are well known to those skilled in the art.
  • the unit oral dose may comprise from approximately 0.01 to approximately 50 mg, preferably approximately 0.1 to approximately 10 mg of the compound of the invention.
  • the unit dose may be administered one or more times daily, as one or more tablets, each containing from approximately 0.1 to approximately 50 mg, conveniently approximately 0.25 to 10 mg of the compound or its solvates.
  • the compound in a topical formulation, may be present at a concentration of approximately 0.01 to 100 mg per gram of carrier.
  • the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the compounds into preparations that may be used pharmaceutically.
  • suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the compounds into preparations that may be used pharmaceutically.
  • the preparations particularly those preparations which may be administered orally and that may be used for the preferred type of administration, such as tablets, dragees, and capsules, as well as suitable solutions for administration by injection or orally, contain from approximately 0.01 to 99 percent, preferably from approximately 0.25 to 75 percent of active compound(s), together with the excipient.
  • non-toxic pharmaceutically acceptable salts of the compounds of the present invention are included within the scope of the present invention.
  • Acid addition salts are formed by mixing a solution of the compounds of the present invention with a solution of a pharmaceutically acceptable non-toxic acid, such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, and the like.
  • Base addition salts are formed by mixing a solution of the compounds of the present invention with a solution of a pharmaceutically acceptable non-toxic base, such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, Tris, N-methyl- glucamine and the like.
  • compositions of the invention may be administered to any mammal, which may experience the beneficial effects of the compounds of the invention.
  • mammals Foremost among such mammals are humans and veterinary animals, although the invention is not intended to be so limited.
  • compositions of the present invention may be administered by any means that achieve their intended purpose.
  • administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes.
  • administration may be by the oral route.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • compositions of the present invention are manufactured in a manner, which is itself known, e.g., by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
  • pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular: fillers, such as saccharides, e.g. lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e.g. tricalcium phosphate or calcium hydrogen phosphate; as well as binders, such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • fillers such as saccharides, e.g. lactose or sucrose, mannitol or sorbitol
  • cellulose preparations and/or calcium phosphates e.g. tricalcium phosphate or calcium hydrogen phosphate
  • binders such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato
  • disintegrating agents may be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries are, above all, flow-regulating agents and lubricants, e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
  • concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
  • Dye stuffs or pigments may be added to the tablets or dragee coatings, e.g., for identification or in order to characterize combinations of active compound doses.
  • Other pharmaceutical preparations which may be used orally, include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules may contain the active compounds in the form of: granules, which may be mixed with fillers, such as lactose; binders, such as starches; and/or lubricants, such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
  • suitable liquids such as fatty oils, or liquid paraffin.
  • stabilizers may be added.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, e.g., water-soluble salts and alkaline solutions.
  • suspensions of the active compounds as appropriate oily injection suspensions may be administered.
  • Suitable lipophilic solvents or vehicles include fatty oils, e.g., sesame oil, or synthetic fatty acid esters, e.g., ethyl oleate or triglycerides or polyethylene glycol-400, or cremophor, or cyclodextrins.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, e.g., sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the suspension may also contain stabilizers.
  • compounds of the invention are employed in topical and parenteral formulations and are used for the treatment of skin cancer.
  • the topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
  • Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than Ci 2 ).
  • the preferred carriers are those in which the active ingredient is soluble.
  • Emulsifiers, stabilizers, humectants and antioxidants may also be included, as well as agents imparting color or fragrance, if desired.
  • transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers are found in U.S. Patent Nos. 3,989,816 and 4,444,762.
  • Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture of the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
  • an oil such as almond oil
  • a typical example of such a cream is one which includes approximately 40 parts water, approximately 20 parts beeswax, approximately 40 parts mineral oil and approximately 1 part almond oil.
  • Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
  • a vegetable oil such as almond oil
  • a typical example of such an ointment is one which includes approximately 30 % almond oil and approximately 70 % white soft paraffin by weight.
  • the present invention also includes the use of the compounds of the subject invention in the manufacture of a medicament for treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom.
  • the medicament may include, such as the pharmaceutical compositions as described above.
  • Example 62 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-2-fluorobenzyl)quinazoline-2,4( IH, 3H)- dione
  • Example 85 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-methylquinazoline-
  • Example 138 Compound of Example 138 was prepared from l-(3-carboxybenzyl)- 8-fluoroquinazoline- 2,4(lH,3H)-dione (prepared from 8-fluouoquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.

Description

l-(ARYLMETHYL)QUINAZOLINE-2,4(lH,3H)-DIONES AS PARP INHIBITORS
AND THE USE THEREOF
BACKGROUND OF THE INVENTION
Field of the Invention
[0001] This invention is in the field of medicinal chemistry. In particular, the invention relates to l-(aiylmethyl)quinazoline-2,4(lH,3H)-diones, and the use of these compounds as PARP inhibitors and anti-cancer drugs.
Related Art
[0002] Poly (ADP-ribose) polymerase (PARP) catalyzes the addition of poly (ADP-ribose) to the target protein using NAD+ that is an important process in DNA repair. This is an essential process for maintaining DNA and chromosome integrity and stability, and for ensuring the survival of mammalian cells. PARP-1 catalyzes the majority of the intracellular ADP-ribose polymerization reactions, although PARP-2 and other subtypes also have this function. The
PARP-1 knockout mice do not have the repair function for single-stranded DNA damages
(Krishnakumar and Kraus, 2010, Molecular Cell 39:8). Cancer cells with DNA repair defects, such as BRCA1 (breast cancer 1) or BRCA2 (breast cancer 2) deficiency, are particularly sensitive to DNA damaging anticancer agents, including platinum chemotherapy drugs, DNA methylation anticancer drugs and DNA topoisomerase inhibitors, or radiation therapy. Phase II clinical trial data have shown that PARP-1 inhibitor olaparib (AZD2281) was effective for the treatment of advanced breast cancer (Andrew Tutt et al, 2009, J. Clin. Oncol 27: 18 s ; Andrew
Tutt et al, 2010 Lancet 376:235; RA Dent et al, 2010 J. Clin. Oncol. 28: 15 s). These scientific and clinical results demonstrated that PARP-1 inhibitors may be used as effective anti-cancer drugs to treat a variety of cancers. The applications of PARP-1 inhibitors for the treatment of cancer are mainly based on two mechanisms. First, because of the rapid growth, DNA replication is much higher in cancer cells than in normal cells. Drugs that cause DNA damage will induce cancer cell death selectively. However, due to the presence of DNA repair enzymes such as PARP-1, the therapeutic effects of these drugs can not be fully materialized. By inhibiting the DNA repair mechanism, PARP-1 inhibitors in combination with commonly used
DNA damaging anti-cancer drugs, such as temozolomide, can achieve synergy effects and greatly enhance the anticancer effects of currently used anticancer drugs. Second, for cancer cells with DNA repair deficiency, such as BRCA1 or BRCA2 deficient triple-negative breast cancer, PARP-1 inhibitors can directly kill the cancer cells and function as anticancer drugs independently. According to statistics, about 10-15% of breast cancer pateints have family history of genetic factors, in which the BRCA1 or BRCA2 gene mutations account for 15-20% of all hereditary breast cancers. Since PARP-1 is involved in DNA repair, utilization of PARP-1 inhibitors to inhibit DNA repair may be an effective and selective treatment for cancers with DNA repair genetic defect, including triple-negative breast cancers. Furthermore, PARP-1 inhibitors may also be used to treat diseases due to excessive cell death, including central nervous system diseases such as stroke and neurodegenerative diseases (Akinori Iwashita et al, 2004, J. Pharmacol. Exp. Thera. 310: 425).
[0003] The inhibitory activity of PARP-1 inhibitors can be measured by directly using PARP-1 enzymes. In addition, since PARP-1 inhibitors can increase the cytotoxicity of DNA damaging anti-cancer drugs such as methyl mathanesulfonate (MMS) on cancer cells, the activity of PARP-1 inhibitors can also be determined by measuring cell viability, such as using a MTT assay, in the presence of MMS and PARP-1 inhibitors. Furthermore, Cancer cells with deficiency in DNA repair, such as in the case of BRCA1 or BRCA2 deficient triple-negative breast cancer, can be killed by PARP-1 inhibitors alone. Therefore the anticancer activity of PARP-1 inhibitors can be determined by measuring the inhibitory effect of these compounds on cell growth of BRCA-2 deficient CAPAN-1 human pancreatic cancer cells.
[0004] It has been known that many cancer chemotherapeutic drugs trigger cancer cells to undergo apoptosis. The mechanism of apoptosis involves a cascade of initiator and effector caspases that are activated sequentially. Caspases are a family of cysteine proteases that require aspartic acid residues at the Pi position of substrates for efficient cleavage. Among these caspases, caspase-3, 6, and 7 are key effector caspases that cleave multiple protein substrates in cells, leading to cell death. Cellular caspase activity can be determined using caspase substrates and used as a measurement of cell apoptosis. PARP-1 inhibitors can increase the apoptosis- inducing activity of many DNA damaging anticancer drugs such as MMS. Therefore, the activity of PARP-1 inhibitors can be determined via measuring the intracelluar caspase activity of cancer cells treated with DNA damaging anticancer drugs in combination with PARP-1 inhibitors.
[0005] JP2007137818 disclosed the preparation of 8-hydroxyquinazoline-2,4(lH,3H)-dione derivatives as poly(ADP-ribose) polymerase (PARP) inhibitors, wherein X = (CH2)n; n = an integer of 1-4; Y = H, NRiR2, 1,2,3,4-tetrahydroisoquinolyl, decahydroisoquinolyl, 1,3-dioxo- l,3-dihydro-2H-isoindolyl, 3-oxo-3,4-dihydrobenz[l,4]oxazinyl, pyridyl, benzyl, (un) substituted optionally fused 5-membered N-heterocyclyl, and (un) substituted aryloxy, etc.
Figure imgf000005_0001
[0006] WO2006003148 disclosed the preparation of quinazolinedione derivatives as PARP inhibitors for the treatment of PARP mediated diseases, wherein X and Y are each independently N or CH; Li = a bond or alkylene; L2 = a bond, CO , alkylene, CO-alkylene, etc.; Ri = H or OH; Z = H or (un) substituted hetero)aryl; etc.
Figure imgf000005_0002
SUMMARY OF THE INVENTION
[0007] The invention provides novel l-(arylmethyl)quinazoline-2,4(lH,3H)-diones, as represented in Formulae I, II and III. These compounds have PARP inhibitory activities.
[0008] The present invention also provides pharmaceutical compositions comprising a compound of Formula I, II or III in an effective amount for the treatment of cancer.
[0009] The invention also provides a pharmaceutical composition useful for the treatment of cancer, containing an effective amount of a compound of one of the Formula I, II or III in admixture with one or more pharmaceutically acceptable carriers or diluents.
[0010] The invention also provides a pharmaceutical composition useful for the treatment of cancer, containing an effective amount of a compound of one of the Formula I, II or III, in combination with one known anticancer drugs or its pharmaceutically acceptable salts.
[0011] The invention also is directed to methods for the preparation of novel compounds of
Formulae I, II and III.
DETAILED DESCRIPTION OF THE INVENTION
[0012] The novel and potent PARP inhibitors of the present invention include 1-
(arylmethyl)quinazoline-2,4(lH,3H)-diones, as represented in Formulae I, II and III.
[0013] Specifically, compounds of the present invention are represented by Formula I:
Figure imgf000006_0001
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
Ar is an optionally substituted aryl or an optionally substituted heteroaryl;
Ri-P6 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol.
[0014] Preferred compounds of Formula I include compounds wherein Ar is an optionally substituted phenyl, pyridyl or furanyl. More preferably, Ar is phenyl, pyridyl or furanyl, optionally substituted with a substituted carbonyl or methyl, preferably carbonyl, at the meta- position. Another group of preferred compounds of Formula I include compounds wherein R5 and P6 are hydrogen.
[0015] One group of preferred compounds of the present invention are represented by Formula
II:
Figure imgf000006_0002
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
R1-R4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol;
R7-R10 independently are hydrogen, halo, optionally substituted amino, alkoxy, C1-10 alkyl, haloalkyl, aryl, heteroaryl, a carbocyclic group, a heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alkylthiol, or substituted carbonyl;
Rn is an optionally substituted amino, hydrazine, alkoxy, C1-10 alkyl, haloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, acylamido, hydroxy, thiol, acyloxy, carbonylamido, or alkylthiol.
[0016] One group of preferred compounds of Formula II includes compounds wherein R7, R8,
R9 or Rio is hydrogen or halo, preferably fluoro. Another group of preferred compounds of Formula II includes compounds wherein Ri or R2 is hydrogen, fluoro, chloro, bromo or methyl. Another group of preferred compounds of Formula II includes compounds wherein R4 is hydrogen, fluoro, methyl, methoxy or hydroxy. Another group of preferred compounds of Formula II includes compounds wherein Rn is an optionally substituted amino, more preferably substituted piperazine or piperidine.
[0017] One group of preferred compounds of the present invention are represented by Formula
III:
Figure imgf000007_0001
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
R1-R4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, carbonylamido or optionally substituted alkylthiol;
R7-Rio independently are hydrogen, halo, optionally substituted amino, alkoxy, C1-10 alkyl, haloalkyl, aryl, heteroaryl, a carbocyclic group, a heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alkylthiol, or substituted carbonyl; Ri2 is an optionally substituted C1-10 alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, alkenyl, alkynyl, acyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl, aminocarbonyl, alkylsulfonyl, cycloalkylsulfonyl or aminosulfonyl.
[0018] In one preferred embodiment, one group of preferred compounds of Formula III
includes compounds wherein Ri2 is selected from the group consisting of cycloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, arylalkyl, heteroarylalkyl, carbocycloalkyl, heterocycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl or heterocyclocarbonyl. Another group of preferred compounds of Formula III includes
compounds wherein Ri or R2 is hydrogen, fluoro, chloro, bromo or methyl; R4 is hydrogen, fluoro, methoxy or hydroxy; R7, R8, R9 or R10 is hydrogen or fluoro.
[0019] Exemplary preferred compounds of Formulae I, II and III include, without limitation:
l-(3-Methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-Carboxybenzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-Cyclohexylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
l-(3-(4-([l,2,4]Triazolo[4,3- )]pyridazin-6-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Ethylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-(4-Fluorobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(4-Chlorobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-(4-Bromobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; l-(3-(4-(4-Methoxybenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(Tetrahydro-2H-pyran-4-yl)carbonylpiperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(3-(4-(Ethylsulfonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-Acetylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-Phenylpiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-Phenylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
l-(3-(4-(Pyrazin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(4-Fluoro-3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-Carboxy-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(3-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Piperidin- 1 -yl)piperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Pyridin-4-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione; 1 -(3 -(4-(6-Fluorobenzo[<JJisoxazol-3 -yl)piperidine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
l-(3-(4-(Furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-(Furan-3-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-(Thiophene-3-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Pyridine-3 -carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Pyridine-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Pyridine-4-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-Phenoxypiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione; 1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(pyrazin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Benzo[<JJisothiazol-3 -yl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione; l-(4-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(4-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(6-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
l-(6-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
l-(6-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(6-Chloro-3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(6-Chloro-3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione; l-(2-Chloro-3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(2-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(2-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-2-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
l-(5-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)-5-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(4-Chloro-3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Pyridin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylmethyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; l-(3-(4-(Cyclopentylmethyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(Cyclohexylsulfonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-fluoroquinazoline- 2,4(lH,3H)-dione;
7-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione; 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-methylquinazoline- 2,4(lH,3H)-dione;
7-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
6-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-methylquinazoline- 2,4(lH,3H)-dione;
l-(4-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-6-methylquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- methylquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- methylquinazoline-2,4(lH,3H)-dione;
6-Bromo- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Bromo-l-(3-(4-(cyclopentylcarbonyl)piperazine- l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Bromo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \H, 3H)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline- 2,4(lH,3H)-dione;
6-Nitro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline- 2,4(lH,3H)-dione;
l-(4-(4-Benzoylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(4-(4-(Pyridin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(4-(4-(4-Methoxybenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(4-(4-(4-Fluorobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(4-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(4-(4-(4-Bromobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(4-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione; 5 -Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
5-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro-l-(3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5- Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
6-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
6-Chloro- 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 6-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline)-2,4(lH,3H)-dione;
6-Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5-Fluoro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
5 -Fluoro-( 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline)- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-8-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
6-Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
6-Fluoro- 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 6- Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
5 -Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-methylquinazoline- 2,4(lH,3H)-dione;
7- Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
7-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline)-2,4(lH,3H)-dione;
6-Chloro-( 1 -(3 -(4-benzoylpiperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline)- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione; 5- Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6- Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5- Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(5-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Cyclopentylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 6-Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 - Fluoro- l-(4-fluoro-3 -(4-(thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Cyclohexylcarbamoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione hydrochloride;
5 -Fluoro 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione hydrochloride;
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione hydrochloride;
l-(3-((4-(Pyridin-2-yl)piperazin-l-yl)methyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(Naphthalen-2-yl)acetamidobenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(3,4-Dimethoxyphenyl)acetamidobenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-([l,2,4]Triazolo[4,3-a]pyridine-6-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
6- Fluoro- l-((2-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6- yl)methyl)quinazoline-2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-methoxybenzylcarbamoyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(3-Chlorobenzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione; l-(3-(Benzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione;
5- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(5-Bromopyrimidin-2-aminocarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione; 1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-7-(trifluoromethyl)quinazoline- 2,4(lH,3H)-dione;
6, 7-Ethylenedioxo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-methoxy-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
7- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-(tetrahydrofuran-2-carbonyl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-nitro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Cyclohexylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-phenylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
5- Fluoro-l-(4-fluoro-3-(4-phenylpiperidine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(4-Bromo-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
6,7-Methylenedioxo- 1 -(3-(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclohexylmethyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
8- Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
6- Amino- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \H, 3H)- dione;
l-(2-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 8-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
8-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
8-Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 8-Hydroxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
and pharmaceutically acceptable salts or prodrugs thereof.
[0020] The term "alkyl" as employed herein by itself or as part of another group refers to both straight and branched chain radicals of up to ten carbons. Useful alkyl groups include straight- chained and branched C1-10 alkyl groups, more preferably C1-6 alkyl groups. Typical C1-10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, 3-pentyl, hexyl and octyl groups, which may be optionally substituted.
[0021] The term "alkenyl" as employed herein by itself or as part of another group means a straigh or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including at least one double bond between two of the carbon atoms in the chain. Typical alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1- butenyl and 2-butenyl.
[0022] The term "alkynyl" is used herein to mean a straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, wherein there is at least one triple bond between two of the carbon atoms in the chain. Typical alkynyl groups include ethynyl, 1- propynyl, l-methyl-2-propynyl, 2-propynyl, 1-butynyl and 2-butynyl.
[0023] Useful alkoxy groups include oxygen substituted by one of the C1-10 alkyl groups mentioned above, which may be optionally substituted. Alkoxy substituents include, without limitation, halo, morpholino, amino including alkylamino and dialkylamino, and carboxy including esters thereof.
[0024] Useful alkylthio groups include sulfur substituted by one of the C1-10 alkyl groups mentioned above, which may be optionally substituted. Also included are the sulfoxides and sulfones of such alkylthio groups.
[0025] Useful amino and optionally substituted amino groups include - H2, - HR15 and - R15R16, wherein R 5 and Ri6 are optionally substituted C1-10 alkyl, cycloalkyl, aryl, heteroaryl, or amino; or R15 and Ri6 are combined with the N to form a 5-8 membered heterocyclic ring structure, such as a piperidine; or R15 and Ri6 are combined with the N and an additional N or O atom to form a 5-8 membered heterocyclic ring, such as a piperazine, which are optionally substituted.
[0026] The groups as described herein, such as alkyl, alkoxy, alkylthio, alkenyl, alkynyl, cycloalkyl, carbonyl, carbocyclic and heterocyclic groups, aryl, arylalkyl, arylalkenyl, arylalkynyl and heteroaryl and heteroarylalkyl groups, may be optionally substituted. Generally, the term "optionally substituted" used herein indicates that the group that is "optionally subsitutited" may be optionally substituted by one or more (such as 1, 2, 3, or 4) substituents selected from the group consisting of halo, hydroxy, carboxyl, amino, nitro, cyano, Ci-C6 acylamino, Ci-C6 acyloxy, Ci-C6 alkoxy, aryloxy, alkylthio, Ci-C6 alkyl, C6-Cio aryl, C3-C8 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-Cio aryl(C2-Ce)alkenyl, C6-Cio aryl(C2-C6)alkynyl, saturated and unsaturated heterocyclic and heteroaryl, methylenedioxy, Ci-C6 haloalkyl, C6C6-C10 aryl(Ci-C6)alkyl, Ci-C6 hydroxyalkyl, ureido, thiol, azido, Ci-C6 alkoxy, carbonyl, di(Ci_io alkyl)amino, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, and alkylsulfiniyl, and the like. The substituent itself may also be optionally substituted.
[0027] Optional substituents on the alkyl, alkoxy, alkylthio, alkenyl, alkynyl, cycloalkyl, carbonyl, carbocyclic and heterocyclic groups may be one or more (such as 1, 2, 3, or 4) groups selected from the group consisting of halo, hydroxy, carboxyl, amino, nitro, cyano, Ci-C6 acylamino, Ci-C6 acyloxy, Ci-C6 alkoxy, aryloxy, alkylthio, C6-Cio aryl, C3-C8 cycloalkyl, C2- C6 alkenyl, C2-C6 alkynyl, C6-Cio aryl(C2-Ce)alkenyl, C6-Cio aryl(C2-Ce)alkynyl, saturated and unsaturated heterocyclic and heteroaryl.
[0028] Optional substituents on the aryl, arylalkyl, arylalkenyl, arylalkynyl and heteroaryl and heteroarylalkyl groups may be one or more (such as 1, 2, 3, or 4) groups selected from the gourp consisting of halo, methylenedioxy, Ci-C6 haloalkyl, C6-Cio aryl, C3-C8 cycloalkyl, Ci-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-Ci0 aryl(Ci-C6)alkyl, C6-Ci0 aryl(C2-C6)alkenyl, C6-Ci0 aryl(C2-Ce)alkynyl, Ci-C6 hydroxyalkyl, nitro, amino, ureido, cyano, Ci-C6 acylamino, hydroxy, thiol, Ci-C6 acyloxy, azido, Ci-C6 alkoxy, carbonyl, carboxy, di(Ci_io alkyl)amino, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, and alkylsulfiniyl.
[0029] The term "aryl" as employed herein by itself or as part of another group refers to monocyclic, bicyclic or tricyclic aromatic groups containing from 6 to 14 carbons in the ring portion.
[0030] Useful aryl groups include C6-14 aryl, preferably Ce-ιο aryl. Typical C6-14 aryl groups include phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.
[0031] The term "carbocycle" as employed herein include cycloalkyl and partially saturated carbocyclic groups. Useful cycloalkyl groups are C3-8 cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
[0032] Useful saturated or partially saturated carbocyclic groups are cycloalkyl groups as described above, as well as cycloalkenyl groups, such as cyclopentenyl, cycloheptenyl and cyclooctenyl.
[0033] Useful halo or halogen groups include fluorine, chlorine, bromine and iodine. [0034] The term "arylalkyl" is used herein to mean any of the above-mentioned C1-10 alkyl groups substituted by any of the above-mentioned C6-14 aryl groups. Preferably the arylalkyl group is benzyl, phenethyl or naphthylmethyl.
[0035] The term "arylalkenyl" is used herein to mean any of the above-mentioned C2-10 alkenyl groups substituted by any of the above-mentioned C6-14 aryl groups.
[0036] The term "arylalkynyl" is used herein to mean any of the above-mentioned C2-10 alkynyl groups substituted by any of the above-mentioned C6-14 aryl groups.
[0037] The term "aryloxy" is used herein to mean oxygen substituted by one of the above- mentioned C6-14 aryl groups, which may be optionally substituted. Useful aryloxy groups include phenoxy and 4-methylphenoxy.
[0038] The term "arylalkoxy" is used herein to mean any of the above mentioned C1-10 alkoxy groups substituted by any of the above-mentioned aryl groups, which may be optionally substituted. Useful arylalkoxy groups include benzyloxy and phenethyloxy.
[0039] Useful haloalkyl groups include alkyl groups, such as C1-10 alkyl, or preferably C1-6 alkyl substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1, 1-difluoroethyl, chloromethyl, chlorofluoromethyl and trichloromethyl groups.
[0040] Useful acylamino (acylamido) groups are any C1-6 acyl (alkanoyl) attached to an amino nitrogen, e.g., acetamido, chloroacetamido, propionamido, butanoylamido, pentanoylamido and hexanoylamido, as well as aryl- substituted C1-6 acylamino groups, e.g., benzoylamido, and pentafluorobenzoylamido. Usefule acyl includes C1-6 acyl, such as acetyl.
[0041] Useful acyloxy groups are any C1-6 acyl (alkanoyl) attached to an oxy (-0-) group, e.g., formyloxy, acetoxy, propionoyloxy, butanoyloxy, pentanoyloxy and hexanoyloxy.
[0042] The term heterocycle (heterocyclic group) is used herein to mean a saturated or partially saturated 3-7 membered monocyclic, or 7-10 membered bicyclic ring system, which consists of carbon atoms and one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized. The term also includes any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring of heterocycle can be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
[0043] Useful saturated or partially saturated heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, isochromanyl, chromanyl, pyrazolidinyl pyrazolinyl, tetronoyl and tetramoyl groups, which are optionally substituted. [0044] The term "heteroaryl" as employed herein refers to groups having 5 to 14 ring atoms; 6,
10 or 14 π electrons shared in a cyclic array; and containing, as ring atom, carbon atoms and 1- 3 heteroatoms selected from oxygen, nitrogen and sulfur.
[0045] Useful heteroaryl groups include thienyl (thiophenyl), benzo[<JJisothiazol-3-yl, benzo[£]thienyl, naphtho[2,3-£]thienyl, thianthrenyl, furyl (furanyl), pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthiinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl (pyridinyl), including without limitation 2-pyridyl, 3 -pyridyl, and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, β-carbolinyl, phenanthridinyl, acrindinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, phenoxazinyl, l,4-dihydroquinoxaline-2,3- dione, 7-aminoisocoumarin, pyrido[l,2-a]pyrimidin-4-one, tetrahydrocyclopenta[c]pyrazol-3-yl, pyrazolo[l,5-a]pyrimidinyl, benzoisoxazolyl such as l,2-benzoisoxazol-3-yl, benzimidazolyl, 2-oxindolyl, thiadiazolyl, and 2-oxobenzimidazolyl. Where the heteroaryl group contains a nitrogen atom in a ring, such nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N- oxide, pyrazinyl N-oxide and pyrimidinyl N-oxide.
[0046] The term "heteroaryloxy" is used herein to mean oxygen substituted by one of the above-mentioned heteroaryl groups, which may be optionally substituted. Useful heteroaryloxy groups include pyridyloxy, pyrazinyloxy, pyrrolyloxy, pyrazolyloxy, imidazolyloxy and thiophenyloxy.
[0047] The term "heteroarylalkoxy" is used herein to mean any of the above-mentioned C1-10 alkoxy groups substituted by any of the above-mentioned heteroaryl groups, which may be optionally substituted.
[0048] Some of the compounds of the present invention may exist as stereoisomers including optical isomers. The invention includes all stereoisomers and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well known to those of ordinary skill in the art.
[0049] Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts, such as hydrochloride, hydrobromide, phosphate, sulphate, citrate, lactate, tartrate, maleate, fumarate, mandelate and oxalate; and inorganic and organic base addition salts with bases, such as sodium hydroxy, Tris(hydroxymethyl)aminomethane (TRIS, tromethane) and N-methyl-glucamine.
[0050] Examples of prodrugs of the compounds of the invention include the simple esters of carboxylic acid containing compounds (e.g., those obtained by condensation with a C1-4 alcohol according to methods known in the art); esters of hydroxy containing compounds (e.g., those obtained by condensation with a C1-4 carboxylic acid, C3-6 dioic acid or anhydride thereof, such as succinic and fumaric anhydrides according to methods known in the art); imines of amino containing compounds (e.g., those obtained by condensation with a C1-4 aldehyde or ketone according to methods known in the art); carbamate of amino containing compounds, such as those described by Leu, et. al, (J Med. Chem. ¥2:3623-3628 (1999)) and Greenwald, et al, (J. Med. Chem. ¥2:3657-3667 (1999)); and acetals and ketals of alcohol containing compounds (e.g., those obtained by condensation with chloromethyl methyl ether or chloromethyl ethyl ether according to methods known in the art).
[0051] The compounds of this invention may be prepared using methods known to those skilled in the art, or the novel methods of this invention. Specifically, the compounds of this invention with Formula I, II or III can be prepared as illustrated by the exemplary reaction in Scheme 1 (Shunsuke Goto et al. Organic Process Research & Development, 2003, 7, 700-706). Reaction of quinazoline-2,4(lH,3H)-dione with hexamethyldisilazane (HMDS) in toluene in the presence of sulfuric acid produced the intermediate 2,4-di(trimethylsiloxy)quinazoline. Reaction of 2,4- di(trimethylsiloxy)quinazoline with a substituted alkyl 3-(halomethyl)benzoate, such as methyl 3-(bromomethyl)benzoate in DMF, followed by treatment with 1,4-dioxane and methanol, produced l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione. Treatment of the ester with NaOH in water-methanol produced l-(3-carboxybenzyl)quinazoline-2,4(lH,3H)-dione. Coupling of the acid with a substituted amine, such as l-(pyridin-2-yl)piperazine, in the presence of coupling agents, such as 2-(7-aza-lH-benzotriazole-l-yl)- 1, 1,3,3- tetramethyluronium hexafluorophosphate (HATU) and N,N-diisopropylethylamine (DIPEA) in DMF, produced the targeted compound l-(3-(4-(pyridin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione.
[0052] Other related compounds can be prepared similarly. For example, replacement of methyl 3-(bromomethyl)benzoate with methyl 6-(bromomethyl)pyridine-2-carboxylate produced the targeted compound l-((2-(4-(pyridin-2-yl)piperazine-l-carbonyl)pyridin-6- yl)methyl)quinazoline-2,4(lH,3H)-dione. Replacement of methyl 3-(bromomethyl)benzoate with ethyl 5-(chloromethyl)furan-2-carboxylate produced the targeted compound l-((2-(4- cyclopentylcarbonylpiperazine-l-carbonyl)furan-5-yl)methyl)quinazoline-2,4(lH,3H)-dione. Replacement of methyl 3-(bromomethyl)benzoate with methyl 3-(2-bromoethyl)benzoate produced the targeted compound l-(3-(4-(pyrimidin-2-yl)piperazine-l- carbonyl)phenethyl)quinazoline-2,4(lH,3H)-dione.
[0053] For quinazoline-2,4(lH,3H)-dione with a substituent in the 8-position, such as 8-chloro quinazoline-2,4(lH,3H)-dione, reaction with hexamethyldisilazane (HMDS) followed by treatment of the intermediate 8-chloro-2,4-di(trimethylsiloxy)quinazoline with methyl 3- (bromomethyl)benzoate produced a mixture of l-(3-methoxycarbonylbenzyl)quinazoline- 2,4(lH,3H)-dione and 3-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione. The mixture can be separared, hydro lyzed, and coupled with a substituted amine to produce the 1- substitued compound and 3-substituted compound, respectively. Alternatively, the 3-substituted compound also can be prepared from reaction of quinazoline-2,4(lH,3H)-dione with methyl 3- (bromomethyl)benzoate and K2C03 in DMF, followed by hydrolysis and coupling of the acid with a substituted amine.
Scheme 1
Figure imgf000025_0001
[0054] Compounds of this invention can be prepared as illustrated by the exemplary reaction in
Scheme 2. Reaction of the intermediate 2,4-di(trimethylsiloxy)quinazoline with a substituted alkyl 3-(halomethyl)benzoate, such as methyl 5-(bromomethyl)-2-fluorobenzoate in DMF, followed by treatment with 1,4-dioxane and methanol, produced l-(4-fluoro-3- methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione. Treatment of the ester with NaOH in water-methanol produced l-(3-carboxy-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione. Coupling of the acid with a substituted amine, such as 1-cyclopentylcarbonylpiperazine, in the presence of coupling agents, such as HATU and DIPEA in DMF, produced the targeted compound 1 -(3 -(4-cyclopentylcarbonylpiperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione.
[0055] Other related compounds can be prepared similarly. For example, replacement of quinazoline-2,4(lH,3H)-dione with a substituted quinazoline-2,4(lH,3H)-dione, such as 5- fluoroquinazoline-2,4(lH,3H)-dione, which can be prepared from reaction of 2-amino-6- fluorobenzoic acid with potassium cyanate, produced the targeted compound l-(3-(4- cyclopentylcarbonylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione. Replacement of methyl 5-(bromomethyl)-2-fluorobenzoate with another substituted methyl 3-(bromomethyl)benzoate, such as methyl 3-(bromomethyl)-4-fluorobenzoate, produced the targeted compound l-(3-(4-cyclopentylcarbonylpiperazine-l-carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione. Replacement of 1-cyclopentylcarbonylpiperazine with another substituted amine, such as l-(pyrimidin-2-yl)piperazine, prodcued the targeted compound 1 -(-4-fluoro-3-(4-(pyrimidin-2-yl)carbonylpiperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione.
Scheme 2
Figure imgf000026_0001
The compounds of this invention can be prepared as illustrated by the exemplary reaction in Scheme 3. Reaction of 2-amino-3-methylbenzoic acid with triphosgene in THF produced 8- methyl-lH-benzo[<JJ[l,3]oxazine-2,4-dione, which was treated with tert-butylamine and DMAP in DMF to produce 2-amino-N-tert-butyl-3-methylbenzamide. Reaction of the benzamide with CDI in THF produced 3-tert-butyl-8-methylquinazoline-2,4(lH,3H)-dione, which was reacted with methyl 3-(bromomethyl)benzoate and MeONa in DMF, followed by treatment with hydrochloric acid aqueous solution, to produce 8-methyl-l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione. Coupling of the acid with 2-(piperazin-l-yl)pyrimidine in the presence of coupling agents, such as HATU and DIPEA in DMF, produced the targeted compound 8- methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione.
Other related compounds can be prepared similarly. For example, replacement of 2-amino- 3-methylbenzoic acid with other substituted 2-aminobenzoic acid, such as 2-amino-3- methoxybenzoic acid, produced the targeted compound 8-methoxy-l-(3-(4-(pyrimidin-2- yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione.
Scheme 3
Figure imgf000027_0001
The 1 -phenyl substituted compound can be prepared as illustrated by the exemplary reaction in Scheme 4. Reaction of 2-bromobenzamide with oxalyl chloride in DCM, followed by addition of methyl 3-aminobenzoate produced methyl 3-(3-(2- bromobenzoyl)ureido)benzoate. Reaction of the benzoate with potassium tert-butoxide in DMF produced l-(3-methoxycarbonylphenyl)quinazoline-2,4(lH,3H)-dione. Hydrolysis of the ester with NaOH in water-methanol produced l-(3-carboxyphenyl)quinazoline-2,4(lH,3H)-dione. Coupling of the acid with 2-(piperazin-l-yl)pyrimidine in the presence of coupling agents, such as HATU and DIPEA in DMF, produced the targeted compound l-(3-(l-(pyrimidin-2- yl)piperazine-4-carbonyl)phenyl)quinazoline-2,4(lH,3H)-dione.
Scheme 4
Figure imgf000027_0002
An important aspect of the present invention is the discovery that compounds having
Formula I, II or III are PARP inhibitors. Therefore, these compounds are useful for the treatment of a variety of clinical conditions responsive to the inhibition of PARP activity, such as cancer.
[0057] The present invention includes a therapeutic method comprising administering to a mammal an effective amount of a compound of Formula I, II or III, or a pharmaceutically acceptable salt or prodrug thereof, wherein said therapeutic method is useful for the treatment of diseases due to to abnormal PARP activity, such as cancer. Such diseases that can be treated or prevented by the method or pharmaceutical composition of the present invention include, but are not limited to, liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, and prostatic carcinoma.
[0058] Compounds of the present invention also are useful for the treatment or prevention of other clinical conditions due to abnormal PARP activity, such as excessive cell death, including central nervous system diseases such as stroke and neurodegenerative diseases.
[0059] In practicing the therapeutic methods, effective amounts of compositions containing therapeutically effective concentrations of the compounds of Formula I, II or III formulated for oral, intravenous, local or topical application, for the treatment of neoplastic diseases and other diseases, are administered to an individual exhibiting the symptoms of one or more of these disorders. The amounts are effective to ameliorate or eliminate one or more symptoms of the disorders. An effective amount of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce, the symptoms associated with the disease. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Typically, repeated administration is required to achieve the desired amelioration of symptom. [0060] In another embodiment, a pharmaceutical composition comprising a compound of
Formula I, II or III or a pharmaceutically acceptable salt thereof, which functions as PARP inhibitor, in combination with a pharmaceutically acceptable vehicle, is provided.
[0061] Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound of Formula I, II or III, or a pharmaceutically acceptable salt or prodrug thereof, which functions as a PARP inhibitor, in combination with at least one known anticancer agent or a pharmaceutically acceptable salt thereof. Examples of known anticancer agents which may be used for combination therapy include, but not are limited to alkylating agents, such as busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, and carboplatin; topoisomerase I inhibitors, such as camptothecin, irinotecan, and topotecan; topoisomerase II inhibitors, such as doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium and etoposide; RNA/DNA antimetabolites, such as 5-azacytidine, gemcitabine, 5-fluorouracil and
methotrexate; DNA antimetabolites, such as 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea and thioguanine; antimitotic agents, such as colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, and docetaxel; antibodies, such as campath, Panitumumab, Ofatumumab, Avastin, Herceptin®, Rituxan®; kinase inhibitors such as imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus and everolimus; HDAC inhibitors such as vorinostat and romidepsin. Other known anticancer agents which may be used for combination therapy include tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thalidomide and lenalidomide.
[0062] In practicing the methods of the present invention, the compound of the invention may be administered together with at least one known anticancer agent as part of a unitary pharmaceutical composition. Alternatively, the compound of the invention may be administered apart from at least one known anticancer agent. In one embodiment, the compound of the invention and at least one known anticancer agent are administered substantially simultaneously, i.e. the compounds are administered at the same time or one after the other, so long as the compounds reach therapeutic levels in the blood at the same time. In another embodiment, the compound of the invention and at least one known anticancer agent are administered according to their individual dose schedule, so long as the compounds reach therapeutic levels in the blood.
[0063] Another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a bioconjugate of a compound described herein, which functions as a PARP inhibitor, in bioconjugation with at least one known therapeutically useful antibody, such as Herceptin® or Rituxan®, growth factors, such as DGF, NGF; cytokines, such as IL-2, IL-4, or any molecule that binds to the cell surface. The antibodies and other molecules will deliver a compound described herein to its targets and make it an effective anticancer agent. The bioconjugates could also enhance the anticancer effect of the therapeutically useful antibodies, such as Herceptin® or Rituxan®.
[0064] Similarly, another embodiment of the present invention is directed to a composition effective to inhibit neoplasia comprising a compound of Formula I, II or III, or its pharmaceutically acceptable salt or prodrug, which functions as a PARP inhibitor, in combination with radiation therapy. In this embodiment, the compound of the invention may be administered at the same time as the radiation therapy is administered or at a different time.
[0065] Yet another embodiment of the present invention is directed to a composition effective for post-surgical treatment of cancer, comprising a compound of Formula I, II or III, or its pharmaceutically acceptable salt or prodrug, which functions as a PARP inhibitor. The invention also relates to a method of treating cancer by surgically removing the cancer and then treating the mammal with one of the pharmaceutical compositions described herein.
[0066] Pharmaceutical compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount that is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the compounds may be administered to mammals, orally at a dose of 0.0025 to 50 mg/kg of body weight, per day, or an equivalent amount of the pharmaceutically acceptable salt thereof, to a mammal being treated. Preferably, approximately 0.01 to approximately 10 mg/kg of body weight is orally administered. If a known anticancer agent is also administered, it is administered in an amount that is effective to achieve its intended purpose. The amounts of such known anticancer agents effective for cancer are well known to those skilled in the art.
[0067] The unit oral dose may comprise from approximately 0.01 to approximately 50 mg, preferably approximately 0.1 to approximately 10 mg of the compound of the invention. The unit dose may be administered one or more times daily, as one or more tablets, each containing from approximately 0.1 to approximately 50 mg, conveniently approximately 0.25 to 10 mg of the compound or its solvates.
[0068] In a topical formulation, the compound may be present at a concentration of approximately 0.01 to 100 mg per gram of carrier.
[0069] In addition to administering the compound as a raw chemical, the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the compounds into preparations that may be used pharmaceutically. Preferably, the preparations, particularly those preparations which may be administered orally and that may be used for the preferred type of administration, such as tablets, dragees, and capsules, as well as suitable solutions for administration by injection or orally, contain from approximately 0.01 to 99 percent, preferably from approximately 0.25 to 75 percent of active compound(s), together with the excipient.
[0070] Also included within the scope of the present invention are the non-toxic pharmaceutically acceptable salts of the compounds of the present invention. Acid addition salts are formed by mixing a solution of the compounds of the present invention with a solution of a pharmaceutically acceptable non-toxic acid, such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, and the like. Base addition salts are formed by mixing a solution of the compounds of the present invention with a solution of a pharmaceutically acceptable non-toxic base, such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, Tris, N-methyl- glucamine and the like.
[0071] The pharmaceutical compositions of the invention may be administered to any mammal, which may experience the beneficial effects of the compounds of the invention. Foremost among such mammals are humans and veterinary animals, although the invention is not intended to be so limited.
[0072] The pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
[0073] The pharmaceutical preparations of the present invention are manufactured in a manner, which is itself known, e.g., by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
[0074] Suitable excipients are, in particular: fillers, such as saccharides, e.g. lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates, e.g. tricalcium phosphate or calcium hydrogen phosphate; as well as binders, such as starch paste, using, e.g., maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, e.g., for identification or in order to characterize combinations of active compound doses.
[0075] Other pharmaceutical preparations, which may be used orally, include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active compounds in the form of: granules, which may be mixed with fillers, such as lactose; binders, such as starches; and/or lubricants, such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
[0076] Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, e.g., water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, e.g., sesame oil, or synthetic fatty acid esters, e.g., ethyl oleate or triglycerides or polyethylene glycol-400, or cremophor, or cyclodextrins. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, e.g., sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
[0077] In accordance with one aspect of the present invention, compounds of the invention are employed in topical and parenteral formulations and are used for the treatment of skin cancer.
[0078] The topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than Ci2). The preferred carriers are those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included, as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers are found in U.S. Patent Nos. 3,989,816 and 4,444,762.
[0079] Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture of the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed. A typical example of such a cream is one which includes approximately 40 parts water, approximately 20 parts beeswax, approximately 40 parts mineral oil and approximately 1 part almond oil.
[0080] Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes approximately 30 % almond oil and approximately 70 % white soft paraffin by weight.
[0081] The present invention also includes the use of the compounds of the subject invention in the manufacture of a medicament for treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom. The medicament may include, such as the pharmaceutical compositions as described above.
[0082] The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.
EXAMPLES General remarks
All reagents were of commercial quality. Solvents were dried and purified by standard methods. Mass spectrum analyses were recorded on a Platform II (Agilent 6110) quadrupole mass spectrometer fitted with an electrospray rinterface. 1H MR spectra was recorded at 300 MHz and at 300 K, on a Briicker AMX 300 apparatus. Chemical shifts were recorded as parts per million (ppm) downfield from TMS (0.00 ppm), and J coupling constants were reported in hertz (Hz).
Example 1
l-(3-Methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione Quinazoline-2,4(lH,3H)-dione (1.0 g, 6.2 mmol), hexamethyldisilazane (HMDS, 2.5 g, 15.4 mmol), and toluene (50 mL) were added into 100 mL two-mouth flask. Concentrated sulfuric acid (0.06 g) was added into the flask when stirring. The mixture was refluxed and reacted for 8h. Toluene and excessive HMDS were removed via evaporation under reduced pressure, thus obtaining an intermediate product 2,4-di(trimethylsilyloxy)quinazoline.
The intermediate product 2,4-di(trimethylsilyloxy)quinazoline, methyl 3- (bromomethyl)benzoate (2.1 g, 9.2 mmol) and DMF (1 mL) were added in turn into a 50 mL single-mouth flask, and then the temperature were raised to 115-130°C and reacted for 3 hours. 1,4-dioxane (6 mL) and methanol (10 mL) were added after the reaction mixture was cooled to 100°C. Then the mixture was refluxed for 30 minutes. The mixture was filtered after it was cooled to room temperature. The precipitate was washed with water (20 mL) and methonal (lOmL), respectively, and dried to give the title compound (1.6 g, 83.7% yield) as white powder. 1H MR (DMSO-d6): 11.76 (s, 1H), 8.00 (dd, J = 7.8 and 1.2 Hz, 1H), 7.89 (s, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.65-7.43 (m, 3H), 7.25-7.20 (m, 2H), 5.36 (s, 2H), 3.80 (s, 3H). MS: m/z 311.1 [M+H]+.
Example 2
l-(3-Carboxybenzyl)quinazoline-2,4(lH,3H)-dione l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione (1.6 g, 5.2 mmol), NaOH (0.3 lg, 7.7 mmol), water (40 mL) and methanol (40 mL) were added into a 250 mL three- mouth flask. The mixture was refluxed and reacted for 3 hours. The methanol was removed via evaporation under reduced pressure after the reaction was finished. The mixture was adjusted to pH=2-3 by 3N HC1, forming many precipitates. The mixture was filtered and the solid was washed by water and methonal. The solids were dried to give the title compound as white solid (1.2 g, 78% yield). 1H MR (300 M, DMSO-d6): 13.09 (brs, 1H), 11.77 (s, 1H), 8.01 (dd, J = 7.7 and 1.4 Hz, 1H), 7.84-7.80 (m, 2H), 7.66-7.61 (m, 1H), 7.53 (d, J= 7.8 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.27-7.21 (m, 2H), 5.36 (s, 2H). MS: m/z 297.1 [M+H]+.
Example 3
1 -(3 -(4-(Pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione l-(3-carboxybenzyl)quinazoline-2,4(lH,3H)-dione (0.2 mmol), l-(pyridin-2-yl)piperazine (0.2 mmol), 2-(7-aza-lH-benzotriazole-l-yl)-l, l,3,3-tetramethyluronium hexafluorophosphate (HATU, 0.26 mmol), N,N-diisopropylethylamine (DIPEA, 0.4 mmol) and DMF (5 mL) were added into a 50mL two-mouth flask. The obtained mixture was stirred at room temperature for 3 hours. To the mixture was added 50 mL of water and it was extracted by dichloromethane (DCM, 50 mL x 2). The organic layer was washed by IN HC1 (50 mL x 2) and saturated NaCl aquenous solution (50 mL x 2), dried with anhydrous sodium sulphate, and evaporated under reduced pressure to give the crude product. The crude product was purified by column chromatography (ethyl acetate) to give the title compound as white solid (7.7 mg, 8.6% yield). 1H NMR (DMSO-d6): 11.69 (s, 1H), 8.09 (dd, J= 5.0 and 1.7 Hz, 1H), 7.99 (dd, J= 8.0 and 1.7 Hz, 1H), 7.64 (t, J= 7.1 Hz, 1H), 7.53 (t, J= 7.8 Hz, 1H), 7.40-7.21 (m, 6H), 6.77 (d, J= 8.7 Hz, 1H), 6.64 (dd, J= 7.1 and 5.0 Hz, 1H), 5.34 (s, 2H), 3.40-3.20 (m, 8H). MS: m/z 442.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine or piperidine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 4
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 8.36 (d, J= 4.8 Hz, 2H), 8.01 (d, J= 6.9 Hz, 1H), 7.67-7.61 (m, 1H), 7.42-7.24 (m, 6H), 6.65 (t, J= 4.8 Hz, 1H), 5.35 (s, 2H), 3.40-3.20 (m, 8H). MS: m/z 443.3 [M+H]+.
Example 5
1 -(3 -(4-Cyclohexylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione White solid. 1H NMR (DMSO-d6): 11.74 (s, 1H), 8.00 (d, J= 7.8 Hz, 1H), 7.62 (t, J= 7.5 Hz, 1H), 7.43-7.38 (m, 2H), 7.26-7.20 (m, 4H), 5.33 (s, 2H), 3.40-3.20 (m, 4H), 2.21-2.15 (m, 4H), 1.96-1.70 (m, 5H), 1.21-1.08 (m, 6H). MS: m/z 447.3 [M+H]+.
Example 6
l-(3-(4-([l,2,4]Triazolo[4,3- )]pyridazin-6-yl)piperazine-l-carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
White solid. 1H NMR (DMSO-d6): 11.73 (s, 1H), 9.24 (s, 1H), 8.12 (d, J= 10.2 Hz, 1H), 8.02 (d, J= 7.8 Hz, 1H), 7.66 (t, J= 6.9 Hz, 1H), 7.42-7.24 (m, 7H), 5.36 (s, 2H), 3.40-3.20 (m, 8H). MS: m/z 483.3 [M+H]+.
Example 7
l-(3-(4-Ethylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.72 (s, 1H), 8.01 (dd, J= 7.8 and 1.2 Hz, 1H), 7.63 (t, J= 8.0 Hz, 1H), 7.42-7.38 (m, 2H), 7.26-7.23 (m, 4H), 5.34 (s, 2H), 3.40-3.20 (m, 4H), 2.35- 2.29 (m, 6H), 0.97 (t, J= 7.1 Hz, 3H). MS: m/z 393.2 [M+H]+.
Example 8
1 -(3 -(4-Benzoylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 7.97 (d, J= 8.1 Hz, 1H), 7.60-7.56 (m, 1H), 7.45-7.18 (m, 11H), 5.34 (s, 2H), 3.40-3.20 (m, 8H). MS: m/z 469.3 [M+H]+.
Example 9
1 -(3 -(4-(4-Fluorobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 7.99 (d, J= 7.8 Hz, 1H), 7.60-7.19 (m, 11H), 5.34 (s, 2H), 3.60-3.20 (m, 8H). MS: m/z 487.3 [M+H]+.
Example 10
1 -(3 -(4-(4-Chlorobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.73 (s, 1H), 7.98-7.97 (m, 1H), 7.63-7.57 (m, 1H), 7.48-7.19 (m, 10H), 5.33 (s, 2H), 3.75-3.15 (m, 8H). MS: m/z 503.2, 505.2 [M+H]+.
Example 11
1 -(3 -(4-(4-Bromobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.74 (s, 1H), 8.02-7.95 (m, 2H), 7.68-7.59 (m, 2H), 7.40-7.15 (m, 8H), 5.35 (s, 2H), 3.40-3.20 (m, 8H). MS: m/z 547.2 [M+H]+.
Example 12
1 -(3 -(4-(4-Methoxybenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione White solid. 1H NMR (DMSO-d6): 11.73 (s, 1H), 7.99 (d, J= 7.2 Hz, 1H), 7.70-7.50 (m,
1H), 7.40-7.29 (m, 6H), 7.21-7.18 (m, 2H), 6.99-6.96 (m, 2H), 5.33 (s, 2H), 3.77 (s, 3H), 3.56-
3.15 (m, 8H). MS: m/z 499.3 [M+H]+.
Example 13
1 -(3 -(4-(Tetrahydro-2H-pyran-4-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.74 (s, 1H), 8.02 (d, J= 7.5 Hz, 1H), 7.65 (t, J= 7.8 Hz, 1H), 7.45-7.38 (m, 2H), 7.32-7.23 (m, 4H), 5.36 (s, 2H), 3.86-3.82 (m, 2H), 3.75-3.10 (m, 10H), 2.90-2.80 (m, 1H), 1.64-1.48 (m, 4H). MS: m/z 477.3 [M+H]+.
Example 14
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 8.01 (d, J= 6.9 Hz, 1H), 7.70-7.60 (m, 1H), 7.41-7.39 (m, 2H), 7.30-7.21 (m, 4H), 5.34 (s, 2H), 3.70-3.10 (m, 8H), 2.95-2.89 (m, 1H), 1.80-1.40 (m, 8H). MS: m/z 461.3 [M+H]+.
Example 15
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 8.01 (d, J= 6.6 Hz, 1H), 7.63 (t, J= 7.2 Hz, 1H), 7.41-7.21 (m, 6H), 5.34 (s, 2H), 3.80-3.15 (m, 8H), 1.94-1.91 (m, 1H), 0.72-0.69 (m, 4H). MS: m/z 433.2 [M+H]+.
Example 16
l-(3-(4-(Ethylsulfonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.74 (s, 1H), 8.01 (dd, J= 7.8 and 1.2 Hz, 1H), 7.70- 7.55 (m, 1H), 7.45-7.35 (m, 2H), 7.31-7.19 (m, 4H), 5.35 (s, 2H), 3.75-3.11 (m, 6H), 3.10-2.90 (m, 4H), 1.20 (t, J= 7.4 Hz, 3H). MS: m/z 457.2 [M+H]+.
Example 17
1 -(3 -(4- Acetylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (DMSO-d6): 11.71 (s, 1H), 8.01 (d, J= 6.6 Hz, 1H), 7.63 (t, J= 7.2 Hz, 1H), 7.43-7.37 (m, 2H), 7.30-7.21 (m, 4H), 5.34 (s, 2H), 3.70-3.10 (m, 8H), 1.93 (s, 3H). MS: m/z 407.2 [M+H]+.
Example 18
1 -(3 -(4-Phenylpiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione White solid. 1H NMR (300 M, DMSO-d6): 11.75 (s, 1H), 7.99 (dd, J= 7.8 and 1.2 Hz, 1H), 7.61 (t, J= 7.2 Hz, 1H), 7.41-7.17 (m, 11H), 5.37 (s, 2H), 3.55-3.42 (m, 2H), 3.06-2.99 (m, 1H), 2.78-2.71 (m, 2H), 1.97-1.51 (m, 4H). MS: m/z 407.2 [M+H]+.
Example 19 1 -(3 -(4-Phenylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
White solid. 1H MR (300 M, DMSO-d6): 11.75 (s, 1H), 8.03 (d, J= 6.6 Hz, 1H), 7.67 (t, J= 7.2 Hz, 1H), 7.46-7.39 (m, 2H), 7.34-7.21 (m, 6H), 6.93-6.91 (m, 2H), 6.81 (t, J= 7.2 Hz, 1H), 5.37 (s, 2H), 3.85-2.85 (m, 8H). MS: m/z 441.3 [M+H]+.
Example 20
l-(3-(4-(Pyrazin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione White solid. 1H MR (300 M, DMSO-d6): 11.75 (s, 1H), 8.31 (s, 1H), 8.11 (s, 1H), 8.02 (d, J= 7.8 Hz, 1H), 7.87 (d, J= 2.7 Hz, 1H), 7.67 (t, J= 7.2 Hz, 1H), 7.44-7.24 (m, 6H), 5.37 (s, 2H), 3.80-3.25 (m, 8H). MS: m/z 443.3 [M+H]+.
Example 21
l-(4-Fluoro-3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione The title compound was prepared from quinazoline-2,4(lH,3H)-dione and methyl 5- (bromomethyl)-2-fluorobenzoate using a procedure similar to those described for the synthesis of compound of Example 1. 1H MR (DMSO-i¾): 11.75 (s, 1H), 8.00 (d, J= 7.8 Hz, 1H), 7.84 (d, J= 6.9 Hz, 1H), 7.67-7.55 (m, 2H), 7.32-7.21 (m, 3H), 5.32 (s, 2H), 3.81 (s, 3H). MS: m/z 329.1 [M+H]+.
Example 22
l-(3-Carboxy-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione The title compound was prepared from l-(4-fluoro-3-methoxycarbonylbenzyl)quinazoline- 2,4(lH,3H)-dione using a procedure similar to those described for the synthesis of compound of Example 2. 1H MR (DMSO-d6): 13.23 (brs, 1H), 11.75 (s, 1H), 8.00 (d, J= 7.5 Hz, 1H), 7.80 (dd, J= 6.9 and 2.1 Hz, 1H), 7.67-7.54 (m, 2H), 7.30-7.21 (m, 3H), 5.31 (s, 2H). MS: m/z 315.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 23
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione White solid. 1H NMR (300 M, DMSO-d6): 11.73 (s, 1H), 8.00 (d, J= 6.9 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.43-7.21 (m, 5H), 5.30 (s, 2H), 3.56-2.97 (m, 8H), 2.89-2.84 (m, 1H), 1.80-1.40 (m, 8H). MS: m/z 479.3 [M+H]+.
Example 24
1 -(4-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione White solid. 1H NMR (300 M, DMSO-d6): 11.74 (s, 1H), 8.12 (d, J= 3.3 Hz, 1H), 8.02 (d, J= 6.6 Hz, 1H), 7.67 (t, J= 8.4 Hz, 1H), 7.58-7.53 (m, 1H), 7.47-7.39 (m, 2H), 7.32-7.24 (m, 3H), 6.82 (d, J= 8.4 Hz, 1H), 6.67 (t, J= 6.9 Hz, 1H), 5.32 (s, 2H), 3.75-3.67 (m, 2H), 3.61- 3.53 (m, 2H), 3.42-3.37 (m. 2H), 3.28-3.20 (m, 2H). MS: m/z 460.3 [M+H]+.
Example 25
1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione White solid. 1H NMR (300 M, DMSO-d6): 11.72 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 8.00 (d, J= 7.8 Hz, 1H), 7.65 (t, J= 6.8 Hz, 1H), 7.48-7.38 (m, 2H), 7.30-7.22 (m, 3H), 6.66 (t, J= 4.8 Hz, 1H), 5.31 (s, 2H), 3.70-3.10 (m, 8H). MS: m/z 461.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine or piperidine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 26
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H NMR (DMSO- e): 11.75 (s, 1H), 8.02 (d, J= 7.8 Hz, 1H), 7.64 (t, J= 7.2 Hz, 1H), 7.50-7.45 (m, 2H), 7.35-7.20 (m, 4H), 5.35 (s, 2H), 3.50-3.10 (m, 9H), 1.80-1.25 (m, 10H). MS: m/z 475.3 [M+H]+.
Example 27
l-(3-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione
1H NMR (DMSO-i¾): 11.75 (s, 1H), 8.08-8.06 (m, 2H), 8.01 (d, J= 7.8 Hz, 1H), 7.87 (s, 1H), 7.67-7.54 (m, 2H), 7.48-7.30 (m, 5H), 7.27-7.20 (m, 2H), 5.37 (s, 2H), 3.80-3.31 (m, 8H). MS: m/z 498.3 [M+H]+.
Example 28
1 -(3 -(4-(Piperidin- 1 -yl)piperidine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- e): 11.76 (s, 1H), 8.03 (d, J= 7.2 Hz, 1H), 7.65 (t, J= 7.8 Hz, 1H), 7.42-7.21 (m, 6H), 5.41-5.32 (m, 2H), 3.10-2.60 (m, 9H), 1.90-1.30 (m, 10H). MS: m/z 447.3 [M+H]+.
Example 29
1 -(3 -(4-(Pyridin-4-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione 1H MR (DMSO- e): 11.72 (s, 1H), 8.19 (d, J= 6.6 Hz, 2H), 8.02 (d, J= 6.3 Hz, 1H), 7.68-7.63 (m, 1H), 7.46-7.39 (m, 2H), 7.34-7.23 (m, 4H), 6.89 (d, J= 6.6 Hz, 2H), 5.35 (s, 2H), 3.84-3.31 (m, 8H). MS: m/z 442.3 [M+H]+.
Example 30
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- e): 11.72 (s, 1H), 8.03 (d, J= 6.4 Hz, 1H), 7.66 (t, J= 7.8 Hz, 1H), 7.46-7.39 (m, 2H), 7.32-7.23 (m, 4H), 5.36 (s, 2H), 3.52-3.31 (m, 9H), 2.19-1.75 (m, 6H). MS: m/z 447.3 [M+H]+.
Example 31
l-(3-(4-(6-Fluorobenzo[i¾isoxazol-3-yl)piperidine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- e): 11.72 (s, 1H), 8.06 (dd, J= 8.7 and 6.4 Hz, 1H), 7.95 (dd, J= 7.8 and 1.5 Hz, 1H), 7.70 (dd, J= 9.3 and 2.1 Hz, 1H), 7.64-7.59 (m, 1H), 7.46-7.14 (m, 7H), 5.36 (s, 2H), 3.45-3.28 (m, 5H), 2.10-2.04 (m, 1H), 1.99-1.94 (m, 3H). MS: m/z 499.3[M+H]+.
Example 32
1 -(3 -(4-(Thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione
1H MR (DMSO-i¾): 11.70 (s, 1H), 8.00 (dd, 7= 8.1 and 1.2 Hz, 1H), 7.76 (d, 7= 5.1 Hz, 1H), 7.64-7.59 (m, 1H), 7.44-7.11 (m, 8H), 5.34 (s, 2H), 3.81-3.40 (m, 8H). MS: m/z 475.2 [M+H]+.
Example 33
1 -(3 -(4-(Furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- e): 11.72 (s, 1H), 8.02 (d, 7= 6.9 Hz, 1H), 7.86 (s, 1H), 7.65 (t, 7= 7.5
Hz, 1H), 7.50-7.15 (m, 6H), 7.00 (d, 7= 3.3 Hz, 1H), 6.70-6.60 (m, 1H), 5.37 (s, 2H), 3.85-3.20
(m, 8H). MS: m/z 459.2 [M+H]+. Example 34
1 -(3 -(4-(Furan-3 -carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH, 3H)-dione 1H MR (DMSO- 6): 11.71 (s, 1H), 8.15-7.90 (m, 2H), 7.73 (s, 1H), 7.62 (t, J= 7.5 Hz, 1H), 7.50-7.10 (m, 6H), 6.64 (s, 1H), 5.34 (s, 2H), 3.80-3.10 (m, 8H). MS: m/z 459.3 [M+H]+.
Example 35
1 -(3 -(4-(Thiophene-3 -carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione 1H MR (DMSO- e): 11.70 (s, 1H), 7.99 (d, J= 7.5 Hz, 1H), 7.77 (s, 1H), 7.63-7.58 (m, 2H), 7.41-7.39 (m, 2H), 7.30-7.28 (m, 2H), 7.22-7.17 (m, 3H), 5.34 (s, 2H), 3.81-3.40 (m, 8H). MS: m/z 475.3 [M+H]+.
Example 36
1 -(3 -(4-(Pyridine-3 -carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione 1H MR (DMSO-i¾): 11.72 (s, 1H), 8.67 (dd, J= 4.8 and 1.5 Hz, 1H), 8.61 (s, 1H), 8.01 (d, J= 7.2 Hz, 1H), 7.82 (d, J= 6.8 Hz, 1H), 7.52-7.20 (m, 8H), 5.36 (s, 2H), 3.52-3.31 (m, 8H). MS: m/z 470.3 [M+H]+.
Example 37
1 -(3 -(4-(Pyridine-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO-i¾): 11.78 (s, 1H), 8.68 (d, J= 4.2 Hz, 1H), 8.20-7.95 (m, 2H), 7.68-7.27 (m, 9H), 5.43 (s, 2H), 3.90-3.50 (m, 8H). MS: m/z 470.3 [M+H]+.
Example 38
1 -(3 -(4-(Pyridine-4-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO-i¾): 11.62 (s, 1H), 8.58 (d, J= 4.2 Hz, 2H), 7.91-7.89 (m, 1H), 7.57-7.44 (m, 1H), 7.29-7.10 (m, 8H), 5.25 (s, 2H), 3.80-2.75 (m, 8H). MS: m/z 470.3 [M+H]+.
Example 39
1 -(3 -(4-Phenoxypiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
1H MR (DMSO-i¾): 11.67 (s, 1H), 7.95 (d, 7= 8.1 Hz, 1H), 7.57 (t, 7= 7.8 Hz, 1H),
7.38-7.30 (m, 2H), 7.27-7.14 (m, 6H), 6.92-6.85 (m, 3H), 5.30 (s, 2H), 4.58-4.52 (m, 1H), 3.90-
3.10 (m, 4H), 1.95-1.35 (m, 4H). MS: m/z 456.3 [M+H]+. The following compounds were prepared from l-(3-carboxy-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 40
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione
1H MR (DMSO- e): 11.72 (s, 1H), 8.01 (d, J= 6.6 Hz, 1H), 7.65 (t, J= 7.8 Hz, 1H), 7.39-7.22 (m, 5H), 5.31 (s, 2H), 3.52-3.31 (m, 8H), 2.01-1.86 (m, 1H), 0.73-0.70 (m, 4H). MS: m/z 451.3 [M+H]+.
Example 41
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione
1H MR (DMSO- e): 11.71 (s, 1H), 8.00 (dd, J= 7.8 and 1.2 Hz, 1H), 7.64 (t, J= 7.4 Hz, 1H), 7.43-7.21 (m, 5H), 5.30 (s, 2H), 3.58-3.10 (m, 9H), 1.68-1.00 (m, 10H). MS: m/z 493.3 [M+H]+.
Example 42
1 -(4-Fluoro-3 -(4-(pyrazin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- e): 11.71 (s, 1H), 8.29 (s, 1H), 8.08 (s, 1H), 8.00 (d, J= 7.8 Hz, 1H), 7.86 (d, J= 2.1 Hz, 1H), 7.65 (t, J= 7.5 Hz, 1H), 7.46-7.36 (m, 2H), 7.30-7.22 (m, 3H), 5.31 (s, 2H), 3.81-3.40 (m, 8H). MS: m/z 461.3 [M+H]+.
Example 43
1 -(3 -(4-(Benzo[d]isothiazol-3 -yl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO- e): 11.72 (s, 1H), 8.08-8.05 (m, 2H), 8.00 (dd, J= 7.8 and 1.2 Hz, 1H), 7.64 (t, J= 7.2 Hz, 1H), 7.56 (t, J= 7.7 Hz, 1H), 7.46-7.41 (m, 3H), 7.31-7.19 (m, 3H), 5.31 (s, 2H), 3.87-3.81 (m, 2H), 3.49-3.31 (m, 6H). MS: m/z 516.2 [M+H]+.
Example 44
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione 1H MR (DMSO- e): 11.69 (s, 1H), 8.00 (d, J= 7.8 Hz, 1H), 7.64 (t, J= 8.0 Hz, 1H), 7.44-7.41 (m5 m), 7.35 (d, J= 5.7 Hz, 1H), 7.28-7.21 (m, 3H), 5.30 (s, 2H), 3.70-3.00 (m, 9H), 2.25-1.60 (m, 6H). MS: m/z 465.3 [M+H]+.
Example 45
1 -(3 -(4-Benzoylpiperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( lH,3H)-dione 1H MR (DMSO- 6): Π .68 (s, 1H), 7.99 (d, J= 7.8 Hz, 1H), 7.70-7.10 (m, 11H), 5.30 (s, 2H), 3.80-3.10 (m, 8H). MS: m/z 487.3 [M+H]+.
Example 46
l-(4-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-i¾): 11.67 (s, 1H), 8.00 (d, J= 7.5 Hz, 1H), 7.75 (d, J= 5.1 Hz, 1H), 7.62 (t, J= 7.7 Hz, 1H), 7.50-7.15 (m, 6H), 7.12 (t, J= 4.4 Hz, 1H), 5.30 (s, 2H), 3.80-3.10 (m, 8H). MS: m/z 493.2 [M+H]+.
Example 47
l-(4-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-i¾): Π .69 (s, 1H), 8.00 (d, J= 6.6 Hz, 1H), 7.83 (s, 1H), 7.64 (t, J= 7.1 Hz, 1H), 7.50-7.35 (m, 2H), 7.30-7.15 (m, 3H), 6.99 (d, J= 3.3 Hz, 1H), 6.70-6.55 (m, 1H), 5.31 (s, 2H), 3.85-3.10 (m, 8H). MS: m/z 477.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(bromomethyl)- 4-fluorobenzoate using a procedure similar to those used for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 48
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione
1H MR (DMSO- e): 11.75 (s, 1H), 8.03 (dd, J= 7.8 and 1.2 Hz, 1H), 7.66 (t, J= 7.8 Hz, 1H), 7.38-7.35 (m, 2H), 7.26 (t, J= 7.7 Hz, 1H), 7.20-7.15 (m, 2H), 5.35 (s, 2H), 3.38-3.15 (m, 9H), 1.70-1.55 (m, 8H). MS: m/z 479.3 [M+H]+. Example 49
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione
1H MR (DMSO- e): 11.75 (s, 1H), 8.04 (d, J= 7.8 Hz, 1H), 7.67 (d, J= 7.4 Hz, 1H), .50-7.10 (m, 5H), 5.37 (s, 2H), 3.70-2.90 (m, 9H), 1.80-1.00 (m, 10H). MS: m/z 493.3 [M+H]+.
Example 50
1 -(6-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione
1H MR (DMSO- 6): 11.71 (s, 1H), 8.35 (d, J= 4.5 Hz, 2H), 8.01 (d, J= 7.6 Hz, 1H), .67 (t, J= 8.4 Hz, 1H), 7.40-7.17 (m, 5H), 6.64 (t, J= 4.8 Hz, 1H), 5.35 (s, 2H), 3.81-3.14 (m, H). MS: m/z 461.2 [M+H]+.
Example 51
1 -(6-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- 6): 11.72 (s, 1H), 8.12 (d, J= 3.3 Hz, 1H), 8.03 (d, J= 6.6 Hz, 1H), .70 (t, J= 8.0 Hz, 1H), 7.56 (t, J= 8.0 Hz, 1H), 7.42-7.18 (m, 5H), 6.76 (d, J= 8.4 Hz, 1H), .67 (dd, J= 6.9 and 5.1 Hz, 1H), 5.38 (s, 2H), 3.70-3.00 (m, 8H). MS: m/z 460.3 [M+H]+.
Example 52
l-(6-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-i¾): 11.71 (s, 1H), 8.01 (d, 7= 8.1 Hz, 1H), 7.76 (d, 7= 4.8 Hz, 1H), .62 (t, 7= 7.8 Hz, 1H), 7.43-7.32 (m, 3H), 7.22-7.12 (m, 4H), 5.35 (s, 2H), 3.80-2.90 (m, 8H). S: m/z 493.2 [M+H]+.
Example 53
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-2,4( 1H, 3H)- dione
1H MR (DMSO- e): 11.71 (s, 1H), 8.02 (d, 7= 7.8 Hz, 1H), 7.65 (t, 7= 8.0 Hz, 1H), .36-7.13 (m, 5H), 5.34 (s, 2H), 3.60-2.80 (m, 9H), 2.20-1.70 (m, 6H). MS: m/z 465.3 [M+H]+.
Example 54
l-(6-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione 1H MR (DMSO- 6): 1 1.71 (s, 1H), 8.01 (d, J = 6.6 Hz, 1H), 7.84 (s, 1H), 7.64 (t, 7 = 7.5 Hz, 1H), 7.43-7.32 (m,2H), 7.25-7.16 (m, 3H), 6.96 (d, 7 = 3.0 Hz, 1H), 7.63-6.62 (m, 1H), 5.35 (s, 2H), 3.80-2.90 (m, 8H). MS: m/z 477.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-6-chlorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(bromomethyl)- 4-chlorobenzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 55
l-(6-Chloro-3-(4-(cyclopentylcarbonyl)piperazine- l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- e): 1 1.75 (s, 1H), 8.05 (d, 7 = 7.8 Hz, 1H), 7.69-7.64 (m, 2H), 7.37 (d, 7 = 8.1 Hz, 1H), 7.28 (t, 7 = 7.3 Hz, 1H), 7.08-7.02 (m, 2H), 5.33 (s, 2H), 3.70-2.80 (m, 9H), 1.80-1.55 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 56
1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
1H MR (DMSO-i¾): 1 1.71 (s, lH), 8.36 (d, 7 = 4.8 Hz, 2H), 8.03 (d, 7 = 6.6 Hz, 1H), 7.69-7.64 (m, 2H), 7.38 (d, 7 = 6.9 Hz, 1H), 7.28 (t, 7 = 7.5 Hz, 1H), 7.09-7.04 (m, 2H), 6.65 (t, 7 = 4.8 Hz, 1H), 5.33 (s, 2H), 3.80-3.00 (m, 8H). MS: m/z 477.2 [M+H]+.
Example 57
l-(6-Chloro-3-(4-(cyclohexylcarbonyl)piperazine- l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- e): 1 1.71 (s, 1H), 8.02 (d, 7 = 7.5 Hz, 1H), 7.75-7.55 (m, 2H), 7.34 (d, 7 = 8.1 Hz, 1H), 7.25 (t, 7 = 7.5 Hz, 1H), 7.10-6.90 (m, 2H), 5.30 (s, 2H), 3.60-2.80 (m, 9H), 1.80-1.00 (m, 10H). MS: m/z 509.3 [M+H]+.
Example 58
1 -(6-Chloro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione 1H MR (DMSO-i¾): 1 1.73 (s, 1H), 8.1 1 (d, 7 = 3.6 Hz, 1H), 8.03 (d, 7 = 7.8 Hz, 1H), 7.80-7.60 (m, 2H), 7.55 (t, 7 = 6.9 Hz, 1H), 7.39 (d, 7 = 6.6 Hz, 1H), 7.30 (t, 7 = 7.5 Hz, 1H), 7.15-7.00 (m, 2H), 6.72 (d, J= 8.4 Hz, 1H), 6.66 (dd, J= 6.8 and 5.0 Hz, 1H), 5.34 (s, 2H), 3.70-3.00 (m, 8H). MS: m/z 476.2 [M+H]+.
The following compounds were prepared from l-(3-carboxyl-2-chlorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(bromomethyl)- 2-chlorobenzoate using a procedure similar to those used for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 59
l-(2-Chloro-3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- e): Π .78 (s, 1H), 8.07 (d, J= 7.8 Hz, 1H), 7.67 (t, J= 7.5 Hz, 1H), 7.45-7.20 (m, 3H), 7.15-6.95 (m, 2H), 5.50-5.15 (m, 2H), 3.80-3.10 (m, 8H), 3.04-2.94 (m, 1H), 1.90-1.35 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 60
1 -(2-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
1H MR (DMSO-i¾): 11.88 (s, 1H), 8.49 (d, J= 4.8 Hz, 2H), 8.16 (d, J= 7.8 Hz, 1H), 7.77 (t, J= 7.8 Hz, 1H), 7.50-7.30 (m, 3H), 7.25-7.05 (m, 2H), 6.78 (t, J= 7.7 Hz, 1H), 5.60- 5.30 (m, 2H), 4.10-3.70 (m, 8H). MS: m/z 477.2 [M+H]+.
The following compounds were prepared from l-(3-carboxy-2-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(bromomethyl)- 2-fluorobenzoate using a procedure similar to those used for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis compound of Example 3.
Example 61
1 -(2-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione
1H MR (DMSO- e): 11.71 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 8.03 (d, J= 6.6 Hz, 1H), 7.66 (t, J= 7.1 Hz, 1H), 7.45-7.05 (m, 5H), 6.66 (t, J= 4.7 Hz, 1H), 5.35 (s, 2H), 3.90-3.60 (m, 8H). MS: m/z 461.3 [M+H]+.
Example 62 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-2-fluorobenzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO- e): 11.74 (s, 1H), 8.03 (d, J= 7.5 Hz, 1H), 7.66 (t, J= 7.7 Hz, 1H), 7.40-7.10 (m, 5H), 5.34 (s, 2H), 3.80-3.20 (m, 8H), 3.10-2.80 (m, 1H), 1.90-1.40 (m, 8H). MS: m/z 479.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-5-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(bromomethyl)- 5-fluorobenzoate using a procedure similar to those used for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis compound of Example 3.
Example 63
l-(5-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO- e): 11.68 (s, lH), 8.36 (d, J= 4.8 Hz, 2H), 8.00 (d, J= 7.8 Hz, 1H), 7.64 (t, J= 8.0 Hz, 1H), 7.30-7.15 (m, 5H), 6.64 (t, J= 4.8 Hz, 1H), 5.34 (s, 2H), 3.80-3.50 (m, 8H). MS: m/z 461.3 [M+H]+.
Example 64
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)-5-fluorobenzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-i¾): 11.69 (s, lH), 8.00 (d, J= 9.0 Hz, 1H), 7.64 (t, J = 7.1 Hz, 1H), 7.31-7.15 (m, 5H), 5.34 (s, 2H), 3.70-3.10 (m, 8H), 2.94-2.86 (m, 1H), 1.80-1.40 (m, 8H). MS: m/z 479.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-4-chlorobenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 5-(bromomethyl)- 2-chlorobenzoate using a procedure similar to those used for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis compound of of Example 3.
Example 65
1 -(4-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (CD3OD): 8.38 (d, J= 4.6 Hz, 2H), 8.16 (d, J= 9.0 Hz, 1H), 7.69 (t, J= 8.7 Hz, 1H), 7.54-7.29 (m, 5H), 6.67 (t, J= 4.6 Hz, 1H), 5.51-5.39 (m, 2H), 3.98-3.57 (m, 8H). MS: m/z 477.2 [M+H]+.
Example 66
l-(4-Chloro-3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- 6): Π .60 (s, 1H), 7.91 (d, J= 7.8 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 7.39 (d, J= 9.0 Hz, 1H), 7.28-7.26 (m, 2H), 7.16-7.07 (m, 2H), 5.31-5.13 (m, 2H), 3.48-2.90 (m, 9H), 1.59-1.09 (m, 10H). MS: m/z 509.3 [M+H]+.
The following compounds were prepared from l-((2-carboxy-furan-5- yl)methyl)quinazoline-2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and ethyl 5-(chloromethyl)furan-2-carboxylate using a procedure similar to those described for the synthesis of compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 67
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO- e) 11.75 (s, 1H), 8.01 (d, J= 7.5 Hz, 1H), 7.74 (t, J= 7.5 Hz, 1H), 7.57 (d, J= 8.1 Hz, 1H), 7.28 (t, J= 7.5 Hz, 1H), 6.96 (d, J= 3.3 Hz, 1H), 6.59 (d, J= 3.3 Hz, 1H), 5.36 (s, 2H), 3.61-3.14 (m, 9H), 1.73-1.54 (m, 8H). MS: m/z 451.3 [M+l]+.
Example 68
l-((2-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO- e) Π.74 (s, 1H), 8.10-8.08 (m, 2H), 8.02 (d, J= 7.8 Hz, 1H), 7.76 (t, J = 4.5 Hz, 1H), 7.61-7.57 (m, 2H), 7.48 (t, J= 7.5 Hz, 1H), 7.30-7.25 (m, 1H), 7.00 (d, J= 3.3 Hz, 1H), 6.60 (d, J= 3.3 Hz, 1H), 5.39 (s, 2H), 3.85-3.78 (m, 4H), 3.49-3.40 (m, 4H). MS: m/z 488.2 [M+l]+.
The following compounds were prepared from l-((2-carboxylpyridin-6- yl)methyl)quinazoline-2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 6-(bromomethyl)pyridine-2-carboxylate using a procedure similar to those described for the synthesis of compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 69
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline-
2,4(lH,3H)-dione
1H MR (CD3OD): 8.16 (d, J= 6.3 Hz, 1H), 7.98-7.96 (m, 1H), 7.64-7.59 (m, 3H ), 7.32- 7.26 (m, 2H), 5.57 (s, 2H), 3.70-3.58 (m, 4H ), 3.31-2.92 (m, 5H ), 1.84-1.70 (m, 8H). MS: m/z 462.3 [M+H]+.
Example 70
l-((2-(4-(Pyridin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline-2,4(lH,3H)- dione
1H MR (CD3OD): 8.15-8.12 (m, 2H), 7.96 (t, J= 7.5 Hz, 1H), 7.67-7.58 (m, 4H), 7.30-7.25 (m, 2H), 6.80-6.71 (m, 2H), 5.57 (s, 2H), 3.81-3.78 (m, 2H), 3.59-3.55 (m, 2H), 3.44-3.41 (m, 2H), 3.23-3.19 (m, 2H). MS: m/z 443.3 [M+H]+.
Example 71
l-((2-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline-2,4(lH,3H)- dione
1H MR (CD3OD): 8.36 (d, J= 4.8 Hz, 2H), 8.14 (d, J= 6.9 Hz, 1H), 7.96 (t, J= 7.5 Hz, 1H), 7.65-7.58 (m, 3H), 7.31-7.28 (m, 2H), 6.64 (t, J= 4.8 Hz, 1H), 5.57 (s, 2H), 3.85-3.82 (m, 2H), 3.78-3.73 (m, 2H), 3.57-3.53 (m, 2H), 3.39-3.35 (m, 2H). MS: m/z 444.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 72
l-(3-(4-(Thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO- e): 11.72 (s, 1H), 8.03 (d, J= 7.3 Hz, 1H), 7.66 (t, J= 7.7 Hz, 1H), 7.46-7.23 (m, 6H), 7.18 (d, J= 3.6 Hz, 1H), 6.88 (d, J= 3.6 Hz, 1H), 5.37 (s, 2H), 3.80-3.40 (m, 8H). MS: m/z 448.3 [M+H]+.
Example 73 1 -(3 -(4-(Cyclohexylmethyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH, 3H)-dione 1H MR (DMSO- e): 11.75 (s, 1H), 8.02 (dd, J= 8.0 and 1.4 Hz, 1H), 7.67-7.62 (m, 1H),
7.41- 7.39 (m, 2H), 7.27-7.23 (m, 4H), 5.35 (s, 2H), 3.54-3.15 (m, 4H), 2.32-2.03 (m, 6H), 1.73- 1.44 (m, 5H), 1.23-1.06 (m, 6H). MS: m/z 461.3 [M+l]+.
Example 74
1 -(3 -(4-(Cyclopentylmethyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione 1H MR (DMSO- e): 11.73 (s, 1H), 8.03 (d, J= 7.5 Hz, 1H), 7.65 (d, J= 7.5 Hz, 1H),
7.42- 7.23 (m, 6H), 5.36 (s, 2H), 3.54-2.87 (m, 6H), 2.25-2.20 (m, 4H), 1.80-1.24 (m, 9H). MS: m/z 447.3 [M+l]+.
Example 75
1 -(3 -(4-(Cyclohexylsulfonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione 1H MR (DMSO- e): 11.69 (s, 1H), 8.01 (dd, J= 8.0 and 1.4 Hz, 1H), 7.64-7.60 (m, 1H), 7.42-7.38 (m, 2H), 7.29-7.16 (m, 4H), 5.35 (s, 2H), 3.56-3.52 (m, 2H), 3.20-3.05 (m, 6H), 1.96- 1.93 (m, 1H), 1.80-1.76 (m, 2H), 1.62-1.58 (m, 2H), 1.27-1.22 (m, 6H). MS: m/z 511.3 [M+l]+.
Example 76
7-Fluoroquinazoline-2,4(lH,3H)-dione
To a mixture of 2-amino-4-fluorobenzoic acid (4.0 g, 26 mmol) and potassium cyanate (3.5 g, 43 mmol) in water (200 mL) was added acetic acid (3 mL, 45 mmol) and the mixture was stirred at room temperature for about 5 h. To the mixture was added NaOH (15 g, 375 mmol) and it was stirred for another 1 h. The mixture was filtered and the solid was mixed in hot water, and it was adjusted to pH=5~6 by addition of acetic acid. The mixture was filtered and washed with water, dried to give the title compound (3.0 g, 65% yield) as gray solid. MS: m/z 181.1 [M+H]+
The following compounds were prepared from l-(3-carboxybenzyl)-7-fluoroquinazoline- 2,4(lH,3H)-dione (prepared from 7-fluoroquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 77 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-fluoroquinazoline-2,4( IH, 3H)- dione
1H MR (DMSO- 6): 11.81 (s, 1H), 8.08 (t, J = 7.6 Hz, 1H), 7.44-7.31 (m, 4H), 7.18-7.12 (m, 2H), 5.34 (s, 2H), 3.70-2.80 (m, 9H), 1.80-1.55 (m, 8H). MS: m/z 479.3 [M+H]+.
Example 78
7-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione
1H MR (DMSO- e): 11.79 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 8.05 (t, J= 7.6 Hz, 1H), 7.45-7.31 (m, 4H), 7.17-7.07 (m, 2H), 6.65 (t, J= 4.8 Hz, 1H), 5.33 (s, 2H), 3.78-3.55 (m, 8H). MS: m/z 461.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)-7-methylquinazoline- 2,4(lH,3H)-dione (prepared from 7-methylquinazoline-2,4(lH,3H)-dioneand methyl 3- (bromomethyl)benzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 79
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-methylquinazoline-2,4( IH, 3H)- dione
1H MR (CD3OD): 8.04 (d, J= 8.1 Hz, 1H), 7.51-7.49 (m, 2H), 7.40-7.38 (m, 2H), 7.15- 7.11 (m, 2H), 5.45 (s, 2H), 3.75-3.50 (m, 8H), 3.12-3.09 (m, 1H), 2.39 (s, 3H), 1.88-1.64 (m, 8H). MS: m/z 475.3 [M+H]+.
Example 80
7-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
1H MR (CD3OD): 8.38-8.36 (m, 2H), 8.04 (d, J= 7.8 Hz, 1H), 7.52-7.50 (m, 2H), 7.42- 7.40 (m, 2H), 7.16-7.13 (m, 2H), 6.66 (t, J= 4.8 Hz, 1H), 5.46 (s, 2H), 3.92-3.56 (m, 8H), 2.40 (s, 3H). MS: m/z 457.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)-6-methylquinazoline- 2,4(lH,3H)-dione (prepared from 6-methylquinazoline-2,4(lH,3H)-dioneand methyl 3- (bromomethyl)benzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3. Example 81
6-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH, 3H)-dione 1H MR (CD3OD): 8.34 (d, J= 4.8 Hz, 2H), 7.94 (s, 1H), 7.49-7.47 (m, 3H), 7.39-7.34 (m, 2H), 7.18 (d, J= 8.4 Hz, 1H), 6.64 (t, J= 4.8 Hz, 1H), 5.44 (s, 2H), 3.89-3.39 (m, 8H), 2.39 (s, 3H). MS: m/z 457.3 [M+H]+.
Example 82
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-methylquinazoline-2,4( IH, 3H)- dione
1H MR (CD3OD): 7.95 (s, 1H), 7.49-7.47 (m, 3H), 7.38-7.35 (m, 2H), 7.18 (d, J= 8.7 Hz, 1H), 5.43 (s, 2H), 3.71-3.69 (m, 4H), 3.49-3.47 (m, 4H), 3.09-3.08 (m, 1H), 2.39 (s, 3H), 1.88- 1.63 (m, 8H). MS: m/z 475.3 [M+H]+.
The following compounds were prepared from l-(3-carboxy-4-fluorobenzyl)- 6-methylquinazoline-2,4(lH,3H)-dione (prepared from 6-methylquinazoline
-2,4(lH,3H)-dione and methyl 5-(bromomethyl)-2-fluorobenzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 83
l-(4-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-6-methylquinazoline-
2,4(lH,3H)-dione
1H MR (CD3OD): 8.37 (d, J= 4.8 Hz, 2H), 7.96 (s, 1H), 7.54-7.51 (m, 2H), 7.40 (dd, J =
6.3 and 2.1 Hz, 1H), 7.28-7.21 (m, 2H), 6.66 (t, J= 4.8 Hz, 1H), 5.41 (s, 2H), 3.93-3.56 (m, 8H), 2.41 (s, 3H). MS: m/z 475.3 [M+H]+.
Example 84
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-methylquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-i¾): Π .54 (s, 1H), 7.71 (s, 1H), 7.38-7.24 (m, 3H), 7.16 (t, J= 9.0 Hz, 1H),
7.04 (d, J= 8.7 Hz, 1H), 5.19 (s, 2H), 3.45-2.99 (m, 9H), 2.22 (s, 3H), 1.59-1.49 (m, 5H), 1.22- 1.13 (m, 5H). MS: m/z 507.3 [M+H]+.
Example 85 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-methylquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO- e): 11.63 (s, 1H), 7.80 (s, 1H), 7.46-7.22 (m, 4H), 7.12 (d, J=8.4 Hz, 1H), 5.27 (s, 2H), 3.55-2.97 (m, 8H), 2.99-2.84 (m, 1H), 2.30 (s, 3H), 1.73-1.49 (m, 8H). MS:
m/z493.3 [M+H]+.
The following compounds were prepared from 6-bromo-l-(3-carboxybenzyl) quinazoline- 2,4(lH,3H)-dione (prepared from 6-bromoquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 86
6-Bromo- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO- e): 11.86 (s, 1H), 8.05 (d, J= 2.4 Hz, 1H), 7.79 (dd, J= 9.0 and 2.4 Hz, 1H), 7.40-7.38 (m, 2H), 7.30-7.27 (m, 2H), 7.16 (d, J= 9.0 Hz, 1H), 5.32 (s, 2H), 3.80-3.11 (m, 9H), 1.68-1.59 (m, 5H), 1.32-1.19 (m, 5H). MS: m/z 553.3 [M+H]+.
Example 87
6-Bromo-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO- e): 11.86 (s, 1H), 8.04 (d, J= 2.4 Hz, 1H), 7.78 (dd, J= 9.0 and 2.4 Hz, 1H), 7.41-7.38 (m, 2H), 7.29-7.27 (m, 2H), 7.15 (d, J= 8.7 Hz, 1H), 5.32 (s, 2H), 3.57-2.90 (m, 9H), 1.71-1.51 (m, 8H). MS: m/z 539.2 [M+H]+.
Example 88
6-Bromo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (CD3OD): 8.38 (d, J= 4.8 Hz, 2H), 8.25-8.24 (m, 1H), 7.78 (dd, J= 8.9 and 2.3 Hz, 1H), 7.52-7.50 (m, 2H), 7.42-7.41 (m, 2H), 7.25 (d, J= 9.3 Hz, 1H), 6.66 (t, J= 4.6 Hz, 1H), 5.45 (s, 2H), 3.93-3.40 (m, 8H). MS: m/z 521.2 [M+H]+.
Example 89
6-Nitroquinazoline-2,4(lH,3H)-dione A mixture of 2-amino-5-nitrobenzoic acid (0.588 g, 3.23 mmol) and urea (1.164 g, 19.38 mmol) was heated at 200°C under N2 for 1 h. The mixture was cooled to room temperature and 4 M NaOH was added until pH = 14. It was acidified to pH = 5.0 via addition of AcOH. The mixture was filtered and the yellow solid was dried to give the title compound (0.49 g, 72.8%) as a yellow solid. MS: m/z 208.1 [M+l] +.
The following compounds were prepared from l-(3-carboxybenzyl)-6-nitroquinazoline- 2,4(lH,3H)-dione (prepared from 6-nitroquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those for compounds of Example 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 90
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline-2,4( IH, 3H)- dione
1H MR (DMSO- e): 12.22 (s, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.51 (dd, J = 9.3 and 2.4 Hz, 1H), 7.52-7.46 (m, 3H), 7.43-7.39 (m, 2H), 5.50 (s, 2H), 3.58-2.96 (m, 9H), 1.68-1.31 (m, 8H). MS: m/z 506.3 [M+H]+.
Example 91
6-Nitro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4
(lH,3H)-dione
1H NMR (DMSO- e): 12.10 (s, 1H), 8.66 (d, J = 2.7 Hz, 1H), 8.44 (d, J = 9.3 Hz, 1H), 8.33 (d, J= 4.5 Hz, 2H), 7.45-7.39 (m, 3H), 7.34-7.32 (m, 2H), 6.65 (t, J = 4.6 Hz, 1H), 5.42 (s, 2H), 3.77-3.46 (m, 8H). MS: m/z 488.3 [M+H]+.
Example 92
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline-2,4( IH, 3H)- dione
1H NMR (DMSO- e): 12.21 (s, 1H), 8.77 (d, J = 2.7 Hz, 1H), 8.51 (dd, J = 9.2 and 2.6 Hz, 1H), 7.52-7.50 (m, 3H), 7.44-7.39 (m, 2H), 5.50 (s, 2H), 3.68-3.24 (m, 9H), 1.78-1.68 (m, 5H), 1.45-1.23 (m, 5H). MS: m/z 520.3 [M+H]+.
The following compounds were prepared from l-(4-carboxybenzyl)quinazoline -2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 4- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 93
l-(4-(4-Benzoylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione
1H MR (CD3OD): 8.17 (d, J= 7.5 Hz, 1H), 7.68-7.63 (m, 1H), 7.53-7.41 (m, 9H), 7.30- 7.27 (m, 2H), 5.46 (s, 2H), 3.76-3.40 (m, 8H). MS: m/z 469.2 [M+H]+.
Example 94
l-(4-(4-(Pyridin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.15 (d, J= 8.1 Hz, 1H), 8.11 (d, J= 5.1 Hz, 1H), 7.67-7.59 (m, 2H), 7.49.7.43 (m5 4H), 7.32-7.27 (m, 2H), 6.86 (d, J= 8.4 Hz, 1H), 6.72 (t, J= 6.0 Hz, 1H), 5.46 (s, 2H), 3.85-3.42 (m, 8H). MS: m/z 442.2 [M+H]+.
Example 95
l-(4-(4-(4-Methoxybenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.15 (d, J= 7.5 Hz, 1H), 7.64 (t, J= 7.5 Hz, 1H), 7.43-7.41 (m, 6H), 7.31-7.26 (m, 2H), 7.02-6.99 (m, 2H), 5.45 (s, 2H), 3.84 (s, 3H), 3.80-3.40 (m, 8H). MS: m/z 499.2 [M+H]+.
Example 96
l-(4-(4-(4-Fluorobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.15 (d, J= 6.9 Hz, 1H), 7.66-7.61 (m, 1H), 7.59-7.44 (m, 6H), 7.28- 7.21 (m, 4H), 5.45 (s, 2H), 3.65-3.40 (m, 8H). MS: m/z 487.2 [M+H]+.
Example 97
l-(4-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.35 (d, J= 4.8 Hz, 2H), 8.16 (dd, J= 8.0 and 1.1 Hz, 1H), 7.65 (t, J = 6.9 Hz, 1H), 7.49-7.41 (m, 4H), 7.32-7.28 (m, 2H), 6.64 (t, J= 4.8 Hz, 1H), 5.46 (s, 2H), 3.80- 3.40 (m, 8H). MS: m/z 443.3 [M+H]+.
Example 98
l-(4-(4-(4-Bromobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H) -dione
1H MR (CD3OD): 8.16 (d, J= 7.8 Hz, 1H), 7.88-7.63 (m, 3H), 7.49-7.39 (m, 6H), 7.32-7.27 (m, 2H), 5.45 (s, 2H), 3.90-3.42 (m, 8H). MS: 547.2 [M+H]+.
Example 99
l-(4-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.15 (dd, J = 8.1 and 1.5 Hz, 1H), 7.64 (t, J= 8.0 Hz, 1H), 7.49-7.42 (m, 4H), 7.31-7.26 (m, 2H), 5.45 (s, 2H), 3.83-3.39 (m, 8H), 3.09-3.00 (m, 1H), 2.02-1.51 (m, 8H). MS: 461.3 [M+H]+.
The following compounds were prepared from 5-chloro-l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from 5-chloroquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 100
5 -Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione
1H MR (CD3OD): 8.38 (d, J= 4.8 Hz, 2H), 7.60-7.50 (m, 3H), 7.45-7.39 (m, 2H), 7.35- 7.20 (m, 2H), 7.26 (d, J= 8.4 Hz, 1H), 6.66 (t, J= 4.7 Hz, 1H), 5.48 (s, 2H), 4.00-3.40 (m, 8H). MS: m/z 477.2 [M+H]+.
Example 101
5-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (CD3OD): 7.60-7.49 (m, 3H), 7.40-7.35 (m, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.23 (d, J= 9.0 Hz, 1H), 5.46 (s, 2H), 3.85-2.90 (m, 9H), 2.00-1.55 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 102
5-Chloro-l-(3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-d6): 11.68 (s, 1H), 7.53 (t, J= 8.3 Hz, 1H), 7.45-7.39 (m, 2H), 7.30-7.20 (m, 3H), 7.15 (d, J= 8.7 Hz, 1H), 5.34 (s, 2H), 3.70-3.00 (m, 9H), 1.80-1.00 (m, 1 OH). MS: m/z 509.3 [M+H]+. The following compounds were prepared from 5-chloro-l-(3-carboxy-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 5-chloroquinazoline-2,4(lH,3H)- dione and methyl 5-(bromomethyl)-2-fluorobenzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 103
5-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.69 (s, 1H), 8.39 (d, J= 4.5 Hz, 2H), 7.50 (t, J= 7.8 Hz, 1H), 7.47-7.39 (m, 2H), 7.32-7.25 (m, 2H), 7.20 (d, J= 9.0 Hz, 1H), 6.67 (t, J= 4.5 Hz, 1H), 5.32 (s, 2H), 3.81-3.33 (m, 8H). MS: m/z 495.2 [M+H]+.
Example 104
5-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.69 (s, 1H), 7.58 (t, J= 7.8 Hz, 1H), 7.47-7.42 (m, 1H), 7.38 (d, J = 6.0 Hz, 1H), 7.31-7.25 (m, 2H), 7.18-7.14 (m, 1H), 5.31 (s, 2H), 3.70-3.00 (m, 9H), 1.85-1.40 (m, 8H). MS: m/z 513.3 [M+H]+.
Example 105
5-Chloro-l-(3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.67 (s, 1H), 7.53 (t, J = 8.3 Hz, 1H), 7.45-7.41 (m, 1H), 7.35 (dd, J = 6.2 and 2.0 Hz, 1H), 7.31-7.20 (m, 2H), 7.15 (s, 1H), 5.29 (s, 2H), 3.70-3.00 (m, 9H), 1.80- 1.00 (m, 10H). MS: m/z 527.3 [M+H]+.
Example 106
5-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.66 (s, 1H), 8.11 (d, J= 1.8 Hz, 1H), 7.57-7.52 (m, 2H), 7.45-7.37 (m, 2H), 7.31-7.20 (m, 2H), 7.17 (d, J= 8.7 Hz, 1H), 6.81 (d, J= 8.7 Hz, 1H), 6.56 (t, J= 6.0 Hz, 1H), 5.30 (s, 2H), 3.80-3.10 (m, 8H). MS: m/z 494.2 [M+H]+.
Example 107 5-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.68 (s, 1H), 7.76 (dd, J= 5.0 and 1.1 Hz, 1H), 7.46 (t, J = 8.4 Hz, 1H), 7.49-7.36 (m, 3H), 7.30-7.19 (m, 2H), 7.15-7.05 (m, 2H), 5.30 (s, 2H), 3.80-3.15 (m, 8H). MS: m/z 527.2 [M+H]+.
The following compounds were prepared from 5-chloro-l-(6-fluoro-3- carboxybenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 5-chloroquinazoline-2,4(lH,3H)- dione and methyl 3-(bromomethyl)-4-fluorobenzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 108
5-Chloro-l-(3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.70 (s, 1H), 7.55 (t, J= 8.7 Hz, 1H), 7.45-7.34 (m, 2H), 7.27 (d, J = 7.5 Hz, 1H), 7.17 (d, J= 6.9 Hz, 1H), 7.13 (d, J= 7.8 Hz, 1H), 5.33 (s, 2H), 3.80-3.00 (m, 9H), 1.80-1.10 (m, 10H). MS: m/z 527.3 [M+H]+.
Example 109
5-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.71 (s, 1H), 7.57 (t, J= 8.3 Hz, 1H), 7.45-7.25 (m, 3H), 7.20 (d, J = 7.5 Hz, 1H), 7.14 (d, J= 8.7 Hz, 1H), 5.35 (s, 2H), 3.70-2.80 (m, 9H), 1.85-1.40 (m, 8H). MS: m/z 513.3 [M+H]+.
Example 110
5-Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.68 (s, 1H), 8.35 (d, J= 4.5 Hz, 2H), 7.56 (t, J= 8.4 Hz, 1H), 7.45-7.27 (m, 3H), 7.22 (d, J= 6.6 Ηζ, ΙΗ), 7.15 (d, J = 8.7 Ηζ, ΙΗ), 6.64 (t, J= 4.5 Hz, 1H), 5.34 (s, 2H), 3.80-3.10 (m, 8H). MS: m/z 495.3 [M+H]+.
The following compounds were prepared from 6-chloro-l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from 6-chloroquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 1 1 1
6-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH, 3H)-dione 1H MR (CD3OD): 8.37 (d, J = 4.8 Hz, 2H), 8.09 (d, J= 2.7 Hz, 1H), 7.64 (dd, J= 9.2 and 2.6 Hz, 1H), 7.55-7.45 (m, 2H), 7.45-7.35 (m, 2H), 7.32 (d, J = 9.0 Hz, 1H), 6.66 (t, J = 4.7 Hz, 1H), 5.45 (s, 2H), 4.00-3.33 (m, 8H). MS: m/z 477.2 [M+H]+.
Example 1 12
6-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine- l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-d6): 1 1.87 (s, 1H), 7.94 (d, J = 2.7 Ηζ, ΙΗ), 7.70 (dd, J= 9.0 and 2.7 Hz, 1H), 7.46-7.38 (m, 2H), 7.31-7.23 (m, 3H), 5.35 (s, 2H), 3.70-2.80 (m, 9H), 1.90-1.40 (m, 8H). MS: m/z 495.2 [M+H]+.
Example 1 13
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 1 1.88 (s, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.74 (dd, J = 9.0 and 2.4 Hz, 1H), 7.46-7.37 (m, 2H), 7.32-7.23(m, 3H), 5.35 (s, 2H), 3.80-3.10 (m, 9H), 1.80-1.10 (m, 10H). MS: m/z 509.3 [M+H]+.
Example 1 14
6-Chloro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO-de): 1 1.95 (s, 1H), 8.21-8.20 (m, 1H), 8.02 (s, 1H), 7.82-7.78 (m, 1H), 7.66-7.60 (m, 1H), 7.49-7.42 (m, 5H), 6.89 (d, J = 3.0 Hz, 1H), 6.75 (t, J= 6.0 Hz, 1H), 5.44 (s, 2H), 3.85-3.29 (m, 8H). MS: m/z 476.3 [M+H]+.
Example 1 15
6-Chloro- 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione 1H MR (DMSO-de): 11.87 (s, 1H), 7.92 (d, J= 2.7 Hz, 1H), 7.76 (d, J= 4.8 Hz, 1H), 7.67 (dd, J= 8.9 and 2.6 Hz, 1H), 7.50-7.35 (m, 3H), 7.32-7.29 (m, 2H), 7.23 (d, J= 9.0 Hz, 1H), 7.12 (dd, J= 4.8 and 3.6 Hz, 1H), 5.33 (s, 2H), 3.79-3.45 (m, 8H). MS: m/z 509.2 [M+H]+.
Example 116
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.87 (s, 1H), 7.93 (d, J= 2.4 Hz, 1H), 7.68 (dd, J= 9.0 and 2.4 Hz, 1H), 7.43-7.35 (m, 2H), 7.31-7.22 (m, 3H), 5.33 (s, 2H), 3.60-3.00 (m, 9H), 2.20-1.60 (m, 6H). MS: m/z 481.3 [M+H]+.
The following compounds were prepared from 6-chloro-l-(3-carboxy-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 6-chloroquinazoline-2,4(lH,3H)- dione and methyl 5-(bromomethyl)-2-fluorobenzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 117
6-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.84 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 7.92 (s, 1H), 7.69 (dd, J = 8.9 and 2.6 Hz, 1H), 7.47-7.36 (m, 2H), 7.30-7.24 (m, 2H), 6.65 (t, J= 4.8 Hz, 1H), 5.30 (s, 2H), 3.78-3.21 (m, 8H). MS: m/z 495.2 [M+H]+.
Example 118
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.85 (s, 1H), 7.92 (d, J= 2.4 Hz, 1H), 7.68 (dd, J= 9.0 and 2.4 Hz, 1H), 7.44-7.41 (m, 1H), 7.36-7.34 (m, 1H), 7.30-7.15 (m, 2H), 5.29 (s, 2H), 3.70-2.80 (m, 9H), 1.80-1.40 (m, 8H). MS: m/z 513.3 [M+H]+.
Example 119
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-de): 11.85 (s, 1H), 7.92 (d, J = 2.1 Hz, 1H), 7.68 (dd, J= 8.7 and 2.4 Hz, 1H), 7.45-7.39 (m, 1H), 7.35 (d, J = 5.4 Hz, 1H), 7.31-7.15 (m, 2H), 5.29 (s, 2H), 3.70-3.00 (m, 9H), 1.80-1.10 (m, 10H). MS: m/z 527.3 [M+H]+.
Example 120
6-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 8.10 (d, J= 3.6 Hz, 1H), 7.92 (s, 1H), 7.69 (d, J= 9.0 Hz, 1H), 7.54 (t, J= 9.0 Hz, 1H), 7.45-7.36 (m, 2H), 7.30-7.23 (m, 2H), 6.81 (d, J= 7.8 Hz, 1H), 6.66 (t, J = 6.3 Hz, 1H), 5.30 (s, 2H), 3.68-3.21 (m, 8H). MS: m/z 494.2 [M+H]+.
Example 121
6-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.86 (s, 1H), 7.92 (s, J= 2.4 Hz, 1H), 7.76 (d, J= 4.2 Hz, 1H), 7.68 (dd, J= 9.0 and 2.4 Hz, 1H), 7.46-7.36 (m, 3H), 7.30-7.22 (m, 2H), 7.12 (dd, J= 5.0 and 3.8 Hz, 1H), 5.30 (s, 2H), 3.68-3.21 (m, 8H). MS: m/z 527.2 [M+H]+.
Example 122
6-Chloro- 1 -(3 -(4-(cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.85 (s, 1H), 7.94 (s, 1H), 7.70 (dd, J= 8.4 and 2.1 Hz, 1H), 7.47-7.23 (m, 4H), 5.31 (s, 2H), 3.59-3.09 (m, 8H), 2.01-1.96 (m, 1H), 0.77-0.69 (m, 4H). MS: m/z 485.3
[M+H]+.
The following compounds were prepared from 6-chloro-l-(6-fluoro-3- carboxybenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 6-chloroquinazoline-2,4(lH,3H)- dione and methyl 3-(bromomethyl)-4-fluorobenzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 123
6-Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.88 (s, 1H), 8.36 (d, J= 4.5 Hz, 2H), 7.93 (d, J= 2.4 Hz, 1H), 7.73 (dd, J= 9.0 and 2.4 Hz, 1H), 7.36-7.20 (m, 4H), 6.65 (t, J= 4.8 Hz, 1H), 5.37 (s, 2H), 3.78-3.21 (m, 8H). MS: m/z 495.2 [M+H]+.
Example 124
6-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.87 (s, 1H), 7.94 (d, J= 2.4 Hz, 1H), 7.71 (dd, J= 9.2 and 2.3 Hz, 1H), 7.42-7.32 (m, 2H), 7.23-7.17 (m, 2H), 5.34 (s, 2H), 3.59-3.09 (m, 9H), 1.71-1.56 (m, 8H). MS: m/z 513.3 [M+H]+.
Example 125
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.87 (s, 1H), 7.93 (d, J= 2.4 Hz, 1H), 7.70 (dd, J= 8.9 and 2.6 Hz, 1H), 7.41-7.31 (m, 2H), 7.22-7.16 (m, 2H), 5.33 (s, 2H), 3.54-3.10 (m, 9H), 1.70-1.15 (m, 10H). MS: m/z 527.3 [M+H]+.
Example 126
6-Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.86 (s, 1H), 7.93 (d, J= 2.4 Hz, 1H), 7.76 (d, J= 4.8 Hz, 1H), 7.67 (dd, J= 9.0 and 1.8 Hz, 1H), 7.43-7.32 (m, 3H), 7.22-7.19 (m, 2H), 7.12 (t, J= 4.2 Hz, 1H), 5.33 (s, 2H), 3.54-3.19 (m, 8H). MS: m/z 527.2 [M+H]+.
The following compounds were prepared from 5-fluoro-l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione (prepared from 5-fluouoquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 127
5-Fluoro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (CD3OD): 8.35 (d, J= 4.8 Hz, 2H), 7.61 (td, J= 8.4 and 5.7 Hz, 1H), 7.50-7.32 (m, 4H), 7.06 (d, J= 8.4 Hz, 1H), 6.99 (dd, J= 10.8 and 8.4 Hz, 1H), 6.64 (t, J= 4.8 Hz, 1H), 5.48 (s, 2H), 3.89-3.38 (m, 8H). MS: m/z 461.2 [M+H]+.
Example 128
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione
1H MR (DMSO-d6): 11.67 (s, 1H), 7.65-7.57 (m, 1H), 7.41-7.39 (m, 2H), 7.31-7.27 (m, 2H), 7.05-6.97 (m, 2H), 5.32 (s, 2H), 3.69-2.90 (m, 9H), 1.81-1.51 (m, 8H). MS: m/z 479.3 [M+H]+.
Example 129
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.69 (s, 1H), 7.62 (td, J= 8.4 and 6.0 Hz, 1H), 7.46-7.41 (m, 2H), 7.32-7.29 (m, 2H), 7.05-6.99 (m, 2H), 5.34 (s, 2H), 3.79-3.11 (m, 9H), 1.71-1.61 (m, 5H), 1.33- 1.17 (m, 5H). MS: m/z 493.3 [M+H]+.
Example 130
5 -Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO-de): 11.67 (s, 1H), 8.10 (d, J= 3.6 Hz, 1H), 7.66-7.51 (m, 2H), 7.44-7.29 (m, 4H), 7.04-6.98 (m, 2H), 6.80 (d, J= 8.7 Hz, 1H), 6.64 (t, J= 6.6 Hz, 1H), 5.33 (s, 2H), 3.79-3.41 (m, 8H). MS: m/z 460.3 [M+H]+.
Example 131
5-Fluoro-l-(3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.67 (s, 1H), 7.77 (d, J= 5.1 Hz, 1H), 7.59 (td, J= 6.0 and 8.4 Hz, 1H), 7.44-7.29 (m, 5H), 7.14 (d, J= 3.9 Hz, 1H), 7.02-6.95 (m, 2H), 5.33 (s, 2H), 3.64-3.41 (m, 8H). MS: m/z 493.2 [M+H]+.
The following compounds were prepared from l-(3-carboxy-4-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione (prepared from 5-fluouoquinazoline-2,4(lH,3H)-dione and methyl 5-(bromomethyl)-2-fluorobenzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 132
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.65 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.95-7.66 (m, 1H), 7.47-7.38 (m, 2H), 7.28 (t, J= 9.0 Hz, 1H), 7.05-6.99 (m, 2H), 6.66 (t, J= 4.8 Hz, 1H), 5.30 (s, 2H), 3.82- 3.79 (m, 2H), 3.69-3.61 (m, 4H), 3.23-3.21 (m, 2H). MS: m/z 479.2 [M+H]+.
Example 133
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.66 (s, 1H), 7.65-7.58 (m, lH), 7.47-7.41 (m, 1H), 7.38 (d, J= 5.7 Hz, 1H), 7.27 (t, J= 9.0 Hz, 1H), 7.05-6.98 (m, 2H), 5.29 (s, 2H), 3.59-2.89 (m, 9H), 1.79-1.45 (m, 8H). MS: m/z 497.3 [M+H]+.
Example 134
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.67 (s, 1H), 7.66-7.59 (m, 1H), 7.47-7.43 (m, 1H), 7.38 (d, J= 6.0 Hz, 1H), 7.28 (t, J= 8.9 Hz, 1H), 7.05-6.99 (m, 2H), 5.30 (s, 2H), 3.55-3.12 (m, 9H), 1.62-1.06 (m, 10H). MS: m/z 511.3 [M+H]+.
Example 135
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-d6): 11.65 (s, 1H), 8.11 (dd, J= 5.0 and 1.7 Hz, 1H), 7.70-7.50 (m, 2H), 7.48-7.37 (m, 2H), 7.27 (t, J= 9.0 Hz, 1H), 7.04-6.98 (m, 2H), 6.81 (d, J= 8.7 Hz, 1H), 6.66 (t, J= 5.7 Hz, 1H), 5.29 (s, 2H), 3.70-3.68 (m, 2H), 3.57-3.54 (m, 2H), 3.38-3.34 (m, 2H), 3.24- 3.22 (m, 2H). MS: m/z 478.2 [M+H]+.
Example 136
5 -Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.64 (s, 1H), 7.77 (d, J= 4.8 Hz, 1H), 7.64-7.56 (m, 1H), 7.46-7.37 (m, 3H), 7.27 (t, J= 9.0 Hz, 1H), 7.13 (t, J= 4.8 Hz, 1H), 7.02-6.97 (m, 2H), 5.30 (s, 2H), 3.70- 3.23 (m, 8H). MS: m/z 511.2 [M+H]+.
Example 137
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione
1H MR (DMSO-de): 11.67 (s, 1H), 7.60-7.27 (m, 9H), 7.05-6.95 (m, 2H), 5.30 (s, 2H), 3.66-3.29 (m, 8H). MS: m/z 505.3 [M+H]+.
Compound of Example 138 was prepared from l-(3-carboxybenzyl)- 8-fluoroquinazoline- 2,4(lH,3H)-dione (prepared from 8-fluouoquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 138
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-8-fluoroquinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.90 (s, 1H), 7.91 (d, J= 7.2 Hz, 1H), 7.59-7.51 (m, 1H), 7.44-7.33 (m, 2H), 7.29-7.28 (m, 3H), 5.40 (s, 2H), 3.59-3.19 (m, 9H), 1.61-1.24 (m, 10H). MS: m/z 493.3 [M+H]+.
The following compounds were prepared from 6-fluoro-l-(3-carboxybenzyl) quinazoline- 2,4(lH,3H)-dione (prepared from 6-fluoroquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using procedures similar to those of compounds of Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 139
6-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -2,4( lH,3H)-dione 1H MR (DMSO-de): 11.86 (s, 1H), 8.38 (d, J= 4.5 Hz, 2H), 7.73 (dd, J= 8.1 and 3.0 Hz, 1H), 7.57 (td, J= 9.0 and 3.3 Hz, 1H), 7.36-7.27 (m, 5H), 6.67 (t, J= 4.7 Hz, 1H), 5.36 (s, 2H), 3.65-3.30 (m, 8H). MS: m/z 461.2 [M+H]+.
Example 140 6-Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH, 3H)-dione 1H MR (DMSO-de): 1 1.85 (s, 1H), 8.13 (d, J = 3.3 Hz, 1H), 7.73 (dd, J = 8.4 and 3.0 Hz, 1H), 7.61-7.53 (m, 2H), 7.46-7.38 (m, 2H), 7.35-7.28 (m, 3H), 6.82 (d, J = 8.4 Hz, 1H), 6.67 (t, J = 4.8 Hz, 1H), 5.36 (s, 2H), 3.76-3.33 (m, 8H). MS: m/z 460.3 [M+H]+.
Example 141
6-Fluoro-l-(3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 1 1.85 (s, 1H), 7.77-7.76 (m, 2H), 7.73 (dd, J = 8.4 and 3.0 Hz, 1H), 7.54-7.14 (m, 6H), 7.13 (t, J = 4.4 Hz, 1H), 5.35 (s, 2H), 3.66-3.30 (m, 8H). MS: m/z 493.2 [M+H] +.
Example 142
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 1 1.86 (s, 1H), 7.74 (dd, J = 8.1 and 3.0 Hz, 1H), 7.56 (m, 1H), 7.43- 7.41 (m, 2H), 7.32-7.29 (m, 3H), 5.36 (s, 2H), 3.60-3.10 (m, 9H), 1.61-1.29 (m, 10H). MS: m/z 493.3 [M+H]+.
Example 143
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline-2,4( IH, 3H)- dione
1H MR (CD3OD): 7.84 (dd, J = 8.4 and 3.0 Hz, 1H), 7.52-7.43 (m, 5H), 7.34 (dd, J= 9.2 and 4.1 Hz, 1H), 5.46 (s, 2H), 3.72-3.1 1 (m, 9H), 1.88-1.66 (m, 8H). MS: m/z 479.3 [M+H]+.
The following compounds were prepared from 6-fluoro-l-(3-carboxy-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 6-fluoroquinazoline-2,4(lH,3H)- dione and methyl 5-(bromomethyl)-2-fluorobenzoate using procedures similar to those of compounds of Examples 1 and 2), and the corresponding substituted piperazine using a procedure similar to those described for the synthesis ofcompound of Example 3.
Example 144
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -
2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.83 (s, 1H), 8.39 (d, J= 4.8 Hz, 2H), 7.74 (dd, J =8.4 and 3.0 Hz, 1H), 7.60-7.54 (m, 1H), 7.41-7.29 (m, 4H), 6.67 (t, J= 4.8 Hz, 1H), 5.32 (s, 2H), 3.81-3.23 (m, 8H). MS: m/z 479.3[M+H]+.
Example 145
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.85 (s, 1H), 8.12 (dd, J= 4.8 and 1.5 Hz, 1H), 7.72 (dd, J= 8.3 and 3.2 Hz, 1H), 7.60-7.53 (m, 2H), 7.47-7.40 (m, 2H),7.32-7.26 (m, 2H), 6.83 (d, J= 8.7 Hz, 1H), 6.68 (dd, J= 6.9 and 5.1 Hz, 1H), 5.33 (s, 2H), 3.72-3.25 (m, 8H). MS: m/z 478.3 [M+H]+.
Example 146
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 7.77-7.70 (m, 2H), 7.57-7.51 (m, 1H), 7.41-7.37 (m, 3H), 7.31-7.25 (m, 2H), 7.12 (t, J= 4.2 Hz, 1H), 5.31 (s, 2H), 3.70-3.16 (m, 8H). MS: m/z 511.2 [M+H] +.
Example 147
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 7.72 (dd, J= 8.3 and 3.2 Hz, 1H), 7.57-7.50 (m, 1H), 7.45-7.41 (m, 1H), 7.36 (d, J= 6.3 Hz, 1H), 7.29-7.23 (m, 2H), 5.30 (s, 2H), 3.53-3.10 (m, 9H), 1.60-1.21(m, 10H). MS: m/z 511.3 [M+H]+.
Example 148
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 7.73 (dd, J= 8.4 and 3.0 Hz, 1H), 7.55 (t, J= 8.4 Hz, 1H), 7.46-7.42 (m, 1H), 7.36 (d, J= 6.0 Hz, 1H), 7.30-7.24 (m, 2H), 5.31 (s, 2H), 3.56-3.12 (m, 9H), 1.60-1.56 (m, 8H). MS: m/z 479.3 [M+H]+.
The following compounds were prepared from 6-fluoro-l-(3-carboxy-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione (prepared from 6-fluoroquinazoline-2,4(lH,3H)- dione and methyl 3-(bromomethyl)-4-fluorobenzoate using procedures similar to those of compounds of Examples 1 and 2), and the corresponding substituted piperazine or piperidine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 149
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.85 (s, 1H), 8.38 (d, J= 4.5 Hz, 2H), 7.74 (dd, J= 8.3 and 3.2 Hz, 1H), 7.62-7.55 (m, 1H), 7.39-7.33 (m, 2H), 7.30-7.20 (m, 2H), 6.66 (t, J= 4.8 Hz, 1H), 5.37 (s, 2H), 3.65-3.30 (m, 8H). MS: m/z 479.3[M+H]+.
Example 150
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.85 (s, 1H), 8.12 (d, J= 3.3 Hz, 1H), 7.74 (d, J= 8.4 Hz, 1H), 7.63- 7.52 (m, 2H), 7.40-7.26 (m, 3H), 7.21 (d, J= 7.2 Hz, 1H), 6.77 (d, J= 8.4 Hz, 1H), 6.66 (t, J = 5.9 Hz, 1H), 5.37 (s, 2H), 3.51-3.32 (m, 8H). MS: m/z 478.3 [M+H]+.
Example 151
6-Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 7.75-7.69 (m, 2H), 7.52-7.49 (m, 1H), 7.39-7.30 (m, 3H), 7.23-7.17 (m, 2H), 7.11(t, J= 4.2 Hz, 1H), 5.33 (s, 2H), 3.70-3.13 (m, 8H). MS: m/z 511.2 [M+H] +.
Example 152
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.86 (s, 1H), 7.76 (dd, J= 8.1 and 3.0 Hz, 1H), 7.60-7.54 (m, 1H), 7.39-7.35 (m, 2H), 7.24 (dd, J= 9.2 and 4.1 Hz, 1H), 7.18 (d, J= 6.9 Hz, 1H), 5.36 (s, 2H), 3.53-3.10 (m, 9H), 1.70-1.25 (m, 10H). MS: m/z 511.3 [M+H]+.
Example 153
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-d6): 7.72 (dd, J= 8.6 and 3.9 Hz, 1H), 7.58-7.51 (m, 1H), 7.36-7.33 (m, 2H), 7.23 (dd, J= 9.5 and 3.8 Hz, 1H), 7.16 (d, J= 7.2 Hz, 1H), 5.33 (s, 2H), 3.31-2.63 (m, 9H), 1.73-1.43 (m, 8H). MS: m/z 479.3 [M+H]+.
The following compounds were prepared from 5-fluoro-l-(3- carboxy-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 154
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.68 (s, 1H), 8.38 (d, J= 4.5 Hz, 2H), 7.67-7.65 (m, 1H), 7.40-7.33 (m, 2H), 7.21 (d, J= 7.2 Hz, 1H), 7.08-7.00 (m, 2H), 6.66 (t, J= 4.8 Hz, 1H), 5.35 (s, 2H), 3.81-3.23 (m, 8H). MS: m/z 479.3[M+H]+.
Example 155
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -2,4( 1H, 3H)- dione
1H MR (DMSO-d6): 11.66 (s, 1H), 8.10 (d, 7= 3.3 Hz, 1H), 7.69-7.61 (m, 1H), 7.53 (t, 7 = 6.9 Hz, 1H), 7.40-7.31 (m, 2H), 7.21 (d, 7 = 6.6 Hz, 1H), 7.08-6.99 (m, 2H), 6.76 (d, 7= 8.7 Hz, 1H), 6.65 (t, 7= 6.9 Hz, 1H), 5.34 (s, 2H), 3.51-3.30 (m, 8H). MS: m/z 478.3 [M+H]+.
Example 156
5 -Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.69 (s, 1H), 7.78 (d, 7= 4.5 Hz, 1H), 7.64-7.60 (m, 1H), 7.38-7.35 (m, 3H), 7.22 (d, 7= 6.0 Hz, 1H), 7.16-7.13 (m, 1H), 7.00-6.94 (m, 2H), 5.33 (s, 2H), 3.32-3.15 (m, 8H). MS: m/z 511.2 [M+H] +.
Example 157
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.70 (s, 1H), 7.68-7.61 (m, 1H), 7.39-7.33 (m, 2H), 7.21 (d, 7= 7.2 Hz, 1H), 7.06-6.97 (m, 2H), 5.34 (s, 2H), 3.53-3.10 (m, 9H), 1.70-1.24 (m, 10H). MS: m/z 511.3 [M+H]+. Example 158
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.68 (s, 1H), 7.67-7.60 (m, 1H), 7.41-7.32 (m, 2H), 7.20 (d, J= 7.5 Hz, 1H), 7.06-6.97 (m, 2H), 5.33 (s, 2H), 3.60-3.15 (m, 9H), 1.60-1.55 (m, 8H). MS: m/z 497.3 [M+H]+.
The following compounds were prepared from 5 -methyl- 1 -(3- carboxybenzyl)quinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 159
5 -Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -2,4( 1H, 3H)-dione
1H MR (CD3OD): 8.37 (d, J= 4.8 Hz, 2H), 7.49-7.47 (m, 3H), 7.42-7.36 (m, 2H), 7.14- 7.08 (m, 2H), 6.66 (t, J= 5.0 Hz, 1H), 5.46 (s, 2H), 3.91-3.62 (m, 8H), 2.79 (s, 3H). MS: m/z 457.3 [M+H]+.
Example 160
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-methylquinazoline-2,4(lH,3H)- dione
1H MR (CD3OD): 7.49-7.36 (m, 5H), 7.14-7.08 (m, 2H), 5.46 (s, 2H), 3.82-3.10 (m, 9H), 2.80 (s, 3H), 1.88-1.56 (m, 8H). MS: m/z 475.3 [M+H]+.
The following compounds were prepared from l-(3-carboxybenzyl)-7-chloroquinazoline- 2,4(lH,3H)-dione and the corresponding substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 161
7-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline -2,4( 1H, 3H)-dione
1H MR (DMSO-d6): 11.81 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 8.00 (d, J= 8.4 Hz, 1H), 7.40-7.27 (m, 6H), 6.65 (t, J= 4.7 Hz, 1H), 5.36 (s, 2H), 3.77-3.63 (m, 8H). MS: m/z 477.2 [M+H]+.
Example 162 7-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.85 (s, 1H), 8.02 (d, J= 9.0 Hz, 1H), 7.44-7.29 (m, 6H), 5.36 (s, 2H), 3.40-3.10 (m, 9H), 1.81-1.51 (m, 8H). MS: m/z 495.3 [M+H]+.
The following compounds were prepared from the corresponding substituted l-(3- carboxybenzyl)quinazoline-2,4(lH,3H)-dione and substituted piperazine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 163
l-(3-(4-(Cyclopropylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.65 (s, 1H), 7.65-7.57 (m, 1H), 7.46-7.41 (m, 1H), 7.38-7.35 (m, 1H), 7.30-7.23 (m, 1H), 7.04-6.98 (m, 2H), 5.29 (s, 2H), 3.75-3.15 (m, 8H), 1.99-1.96 (m, 1H), 0.72-0.69 (m, 4H). MS: m/z 469.5 [M+H]+.
Example 164
6-Chloro- 1 -(3 -(4-benzoylpiperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-2,4( IH, 3H)-dione
1H MR (DMSO-de): 11.85 (s, 1H), 7.91 (s, 1H), 7.68-7.62 (m, 1H), 7.44-7.35 (m, 7H), 7.28-7.22 (m, 2H), 5.29 (s, 2H), 3.64-3.21 (m, 8H). MS: m/z 521.5 [M+H]+.
Example 165
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.66 (s, 1H), 7.64-7.57 (m, 1H), 7.43-7.36 (m, 2H), 7.29-7.26 (m, 2H), 7.04-6.98 (m, 2H), 5.32 (s, 2H), 3.56-3.00 (m, 9H), 2.17-1.66 (m, 6H). MS: m/z 465.6 [M+H]+.
Example 166
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.65 (s, 1H), 7.65-7.57 (m, 1H), 7.46-7.40 (m, 1H), 7.36 (d, J= 5.4 Hz, 1H), 7.26 (t, J= 9.0 Hz, 1H), 7.04-6.99 (m, 2H), 5.28 (s, 2H), 3.55-3.09 (m, 9H), 2.18-1.67 (m, 6H). MS: m/z 483.3 [M+H]+. Example 167
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.87 (s, 1H), 7.95 (d, J= 2.4 Hz, 1H), 7.69 (dd, J= 8.9 and 2.6 Hz, 1H), 7.42-7.30 (m, 2H), 7.22-7.15 (m, 2H), 5.33 (s, 2H), 3.55-3.09 (m, 9H), 2.14-1.72 (m, 6H). MS: m/z 499.3 [M+H]+.
Example 168
5 -Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.69 (s, 1H), 7.55 (t, J= 8.3 Hz, 1H), 7.46-7.42 (m, 1H), 7.37 (d, J = 6.3 Hz, 1H), 7.30-7.24 (m, 2H), 7.18-7.13 (m, 1H), 5.31 (s, 2H), 3.56-3.11 (m, 9H), 2.10-1.73 (m, 6H). MS: m/z 499.3 [M+H]+.
Example 169
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.88 (s, 1H), 7.94 (s, 1H), 7.70 (dd, J= 9.0 and 2.7 Hz, 1H), 7.46- 7.42 (m, 1H), 7.36 (dd, J= 6.3 and 1.8 Hz, 1H), 7.31-7.21 (m, 2H), 5.30 (s, 2H), 3.56-3.11 (m, 9H), 2.50-1.73 (m, 6H). MS: m/z 499.3 [M+H]+.
Example 170
5 -Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.69 (s, 1H), 7.57 (t, J= 8.3 Hz, 1H), 7.38-7.29 (m, 3H), 7.20 (d, J = 6.9 Hz, 1H), 7.15 (d, J= 8.7 Hz, 1H), 5.35 (s, 2H), 3.56-3.00 (m, 9H), 2.12-1.74 (m, 6H). MS: m/z 499.4 [M+H]+.
Example 171
5 -Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.72 (s, 1H), 7.79 (d, J= 5.1 Hz, 1H), 7.54 (t, J= 8.3 Hz, 1H), 7.39-7.36 (m, 3H), 7.23 (m, 2H), 7.14-7.11 (m, 2H), 5.35 (s, 2H), 3.66-3.10 (m, 8H). MS: m/z 527.2 [M+H]+. Example 172
5 -Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.67 (s, 1H), 7.85 (s, 1H), 7.66-7.58 (m, 1H), 7.46-7.39 (m, 2H), 7.29 (t, J= 9.0 Hz, 1H), 7.04-6.98 (m, 3H), 6.64-6.63 (m, 1H), 5.31 (s, 2H), 3.73-3.70 (m, 4H), 3.55-3.54 (m, 2H), 3.23-3.22 (m, 2H). MS: m/z 495.3 [M+H]+.
Example 173
5 -Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.70 (s, 1H), 8.12 (dd, J= 4.8 and 1.2 Hz, 1H), 7 '.62-7 '.52 (m, 2H), 7.45-7.31 (m, 3H), 7.22 (d, J= 7.5 Hz, 1H), 7.15 (d, J= 8.4 Hz, 1H), 6.75 (d, J= 8.7 Hz, 1H), 6.68-6.64 (m, 1H), 5.36 (s, 2H), 3.69-3.21 (m, 8H). MS: m/z 494.3 [M+H]+.
Example 174
6-Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.86 (s, 1H), 8.08 (d, J= 3.9 Hz, 1H), 7.92 (d, J= 2.4 Hz, 1H), 7.72 (dd, J= 9.0 and 2.4 Hz, 1H), 7.66-7.59 (m, 1H), 7.44-7.32 (m, 2H), 7.24 (d, J= 9.0 Hz, 1H),
7.20 (d, J= 7.8 Hz, 1H), 6.84 (d, J= 7.5 Hz, 1H), 6.70 (t, J= 5.4 Hz, 1H), 5.34 (s, 2H), 3.69-
3.21 (m, 8H). MS: m/z 494.3 [M+H]+.
Example 175
6-Chloro- 1 -(5-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 8.36 (d, J= 4.8 Hz, 2H), 7.92 (d, J= 2.4 Hz, 1H), 7.70 (d, J= 8.7 Hz, 1H), 7.24-7.18 (m, 4H), 6.64 (t, J= 4.8 Hz, 1H), 5.34 (s, 2H), 3.69-3.21 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 176
5 -Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.63 (s, 1H), 8.36 (d, J= 4.8 Hz, 2H), 7.66-7.61 (m, 1H), 7.29 (d, J = 9.3 Ηζ, ΙΗ), 7.19-7.16 (m, 2H), 7.05-6.98 (m, 2H), 6.65 (t, J= 4.8 Hz, 1H), 5.33 (s, 2H), 3.80- 3.20 (m, 8H). MS: m/z 479.3 [M+H]+. Example 177
l-(3-(4-Cyclopentylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO-de): 11.71 (s, 1H), 8.02 (dd, J= 8.0 and 1.4 Ηζ, ΙΗ), 7.63 (t, J= 7.1 Hz, 1H), 7.43-7.36 (m, 2H), 7.26-7.21 (m, 4H), 5.34 (s, 2H), 3.65-3.30 (m, 9H), 1.48-1.22 (m, 8H). MS: m/z 433.3 [M+H]+.
Example 178
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.84 (s, 1H), 7.74 (dd, 7= 8.1 and 3.0 Hz, 1H), 7.56 (t, 7= 8.4 Hz, 1H), 7.45-7.39 (m, 2H), 7.31-7.25 (m, 2H), 5.32 (s, 2H), 3.54-3.16 (m, 8H), 1.92 (m, 1H), 0.73- 0.70 (m, 4H). MS: m/z 469.3 [M+H]+.
Example 179
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.86 (s, 1H), 7.75 (dd, 7= 8.3 and 2.9 Hz, 1H), 7.56 (t, 7= 8.7 Hz, 1H), 7.43-7.40 (m, 2H), 7.31-7.26 (m, 3H), 5.35 (s, 2H), 3.52-3.31 (m, 9H), 2.18-1.75 (m, 6H). MS: m/z 465.3 [M+H]+.
Example 180
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.84 (s, 1H), 7.74 (d, 7= 8.1 Hz, 1H), 7.59-7.53 (m, 1H), 7.46-7.44 (m, 1H), 7.37 (d, 7= 5.7 Hz, 1H), 7.31-7.25 (m, 2H), 5.31 (s, 2H), 3.57-3.11 (m, 9H), 2.14-1.74 (m, 6H). MS: m/z 483.3 [M+H]+.
Example 181
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-2,4(lH,3H)-dione
1H MR (DMSO-de): 11.84 (s, 1H), 7.74 (dd, 7= 8.1 and 2.7 Hz, 1H), 7.55-7.53 (m, 1H), 7.46-7.42 (m, 7H), 7.30-7.24 (m, 2H), 5.31 (s, 2H), 3.67-3.20 (m, 8H). MS: m/z 505.3 [M+H]+.
Example 182 l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.68 (s, 1H), Ί .66-1.59 (m, 1H), 7.36-7.33 (m, 2H), 7.18 (d, J= 7.2 Hz, 1H), 7.07-6.96 (m, 2H), 5.32 (s, 2H), 3.60-3.01 (m, 9H), 2.11-1.73 (m, 6H). MS: m/z 483.4 [M+H]+.
Example 183
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.84 (s, 1H), 7.73 (dd, 7= 8.1 and 2.7 Hz, 1H), 7.56 (t, 7= 8.4 Hz, 1H), 7.36-7.30 (m, 2H), 7.24-7.14 (m, 2H), 5.34 (s, 2H), 3.60-3.01 (m, 9H), 2.14-1.72 (m, 6H). MS: m/z 483.3 [M+H]+.
Example 184
5 -Fluoro- 1 -(6-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.70 (s, 1H), 7.86 (s, 1H), 7.67-7.59 (m, 1H), 7.39-7.36 (m, 2H), 7.23 (d, 7= 7.2 Hz, 1H), 7.05-6.97 (m, 3H), 6.65-6.63 (m, 1H), 5.34 (s, 2H), 3.70-3.10 (m, 8H). MS: m/z 495.4 [M+H]+.
Example 185
6-Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.84 (s, 1H), 7.84 (s, lH), 7.74 (dd, 7= 8.4 and 3.0 Hz, 1H), 7.59- 7.53 (m, 1H), 7.45-7.39 (m, 2H), 7.32-7.26 (m, 2H), 7.02 (d, 7= 3.3 Hz, 1H), 6.63 (dd, 7= 3.3 Hz and 1.8 Hz, 1H), 5.32 (s, 2H), 3.67-3.23 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 186
6-Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.83 (s, 1H), 8.39 (d, 7= 4.5 Hz, 2H), 7.74 (dd, 7= 8.3 and 3.2 Hz, 1H), 7.60-7.54 (m, 1H), 7.33-7.29 (m, 2H), 7.27-7.18 (m, 2H), 6.67 (t, 7= 4.8 Hz, 1H), 5.36 (s, 2H), 3.80-3.35 (m, 8H). MS: m/z 479.4 [M+H]+.
Example 187 1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.86 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 7.76-7.69 (m, 1H), 7.65 (d, J = 8.1 Hz, 1H), 7.60-7.59 (m, 1H), 7.38 (dd, J= 8.3 and 1.7 Hz, 1H), 7.13-7.09 (m, 2H), 6.65 (t, J= 4.7 Hz, 1H), 5.32 (s, 2H), 3.73-3.03 (m, 8H). MS: m/z 495.3 [M+H]+.
Example 188
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione
1H MR (DMSO-de): 11.82 (s, 1H), 7.71 (dd, J = 8.4 and 3.0 Hz, 1H), 7.58-7.51 (m, 1H), 7.43-7.38 (m, 2H), 7.30-7.23 (m, 2H), 7.17 (d, J= 3.6 Hz, 1H), 6.88 (d, J= 3.6 Hz, 1H), 5.30 (s, 2H), 3.73-3.26 (m, 8H). MS: m/z 484.3 [M+H]+.
Example 189
5-Fluoro-l-(4-fluoro-3-(4-(thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-de): 11.65 (s, 1H), 7.65-7.57 (m, 1H), 7.43-7.38 (m,2H), 7.27 (t, J= 9.0 Hz, 1H), 7.17 (d, J= 3.6 Hz, 1H), 7.04-6.98 (m, 2H), 6.87 (d, J= 3.6 Hz, 1H), 5.29 (s, 2H), 3.73-3.26 (m, 8H). MS: m/z 484.3 [M+H]+.
Example 190
1 -(4-Fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione 1H MR (DMSO- e): 11.70 (s, 1H), 8.00 (d, J= 8.1 Hz, 1H), 7.64 (t, J= 7.9 Hz, 1H), 7.46-7.38 (m, 2H), 7.30-7.22 (m, 3H), 7.17 (d, J= 3.6 Hz, 1H), 6.87 (d, J= 3.6 Hz, 1H), 5.31 (s, 2H), 3.79-3.23 (m, 8H). MS: m/z 466.3 [M+H]+.
Example 191
1 -(3 -(4-(Cyclohexylcarbamoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione 1H MR (DMSO- e): Π .67 (s, 1H), 8.01 (d, J= 7.8 Hz, 1H), 7.63 (t, J= 7.8 Hz, 1H), 7.40-7.37 (m, 2H), 7.30-7.22 (m, 4H), 6.20 (d, J= 4.0 Hz, 1H), 5.33 (s, 2H), 3.80-3.00 (m, 9H), 1.80-1.00 (m, 10H). MS: m/z 490.4 [M+H]+.
The following salts were prepared from the corresponding free base via stirring the free base in HCl/ethyl acetate for 2.5 h at room temperature, followed by evaporation of the solvents. Example 192
1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione hydrochloride
1H MR (DMSO-d6): 11.71 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 8.00 (d, J= 6.9 Hz, 1H), 7.64 (t, J= 7.8 Hz, 1H), 7.46-7.39 (m, 2H), 7.30-7.21 (m, 3H), 6.67 (t, J= 4.8 Hz, 1H), 5.31 (s, 2H), 3.81-3.78 (m, 2H), 3.67-3.62 (m, 4H), 3.24-3.20 (m, 2H). MS: m/z 461.2 [M+H]+.
Example 193
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione hydrochloride
1H MR (DMSO-d6): 11.66 (s, 1H), 8.41 (d, J= 4.5 Hz, 2H), 7.67-7.59 (m, 1H), 7.47-7.39 (m, 2H), 7.28 (t, J= 4.5 Hz, 1H), 7.06-6.99 (m, 2H), 6.70 (t, J= 4.8 Hz, 1H), 5.3 l(s, 2H), 3.82- 3.81 (m, 2H), 3.69-3.64 (m, 4H), 3.25-3.22 (m, 2H). MS: m/z 479.3 [M+H]+.
Example 194
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione hydrochloride
1H MR (DMSO-d6): 11.72 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 8.01 (d, J= 6.9 Hz, 1H), 7.64 (t, J= 6.9 Hz, 1H), 7.50-7.20 (m, 6H), 6.66 (t, J= 4.7 Hz, 1H), 5.35 (s, 2H), 4.10-3.20 (m, 8H). MS: m/z 443.3 [M+H]+.
Example 195
1 -(3 -((4-(Pyridin-2-yl)piperazin- 1 -yl)methyl)benzyl)quinazoline-2,4( lH,3H)-dione a) l-(3-(Hydroxymethyl)benzyl)quinazoline-2,4(lH,3H)-dione: To the solution of l-(3- methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione (0.5 g, 1.6 mmol) in THF (30 mL) and ethanol (10 mL) was added NaBH4 (1.2 g, 32 mmol) at room temperature under N2. It was stirred at room temperature for 4 h, then refluxed overnight. The reaction mixture was quenched with HCl (2N), then concentrated. The residue was diluted with H20 (10 mL), and it was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2S04, and concentrated to afford the crude product, which was used for the next reaction without purification.
b) l-(3-(Methanesulfonoylmethyl)benzyl)quinazoline-2,4(lH,3H)-dione: To a solution of l-(3- (hydroxymethyl)benzyl)quinazoline-2,4(lH,3H)-dione (0.1 g, 0.35 mmol) and triethylamine (0.1 g, 1.1 mmol) in dry DCM (2 mL) was added MsCl dropwise at 0°C under N2. The mixture was stirred for 2 h, and was used for the next reaction directly. c) 1 -(3 -((4-(Pyridin-2-yl)piperazin- 1 -yl)methyl)benzyl)quinazoline-
2,4(lH,3H)-dione: A solution of l-(pyridin-2-yl)piperazine (0.057 g, 0.35 mmol) in dry DCM (0.2 mL) was added to the above solution at room temperature under N2, and the mixture was refluxed overnight. The reaction mixture was concentrated, and the residue was diluted with H20 (2 mL). It was extracted with ethyl acetate (3 x 10 mL). The combined organic layers was washed with brine, dried with anhydrous Na2S04, and concentrated. The crude product was purified by preparative TLC to give the title compound (5 mg) as white solid. 1H NMR
(DMSO-de): 8.09 (d, J= 3.3 Hz, 1H), 8.02 (d, J = 6.6 Hz, 1H), 7.66-7.61 (m, 1H), 7.54-7.48 (m, 1H), 7.29-7.15 (m, 6H), 6.78 (d, J= 8.7 Hz, 1H), 6.64-6.59 (m, 1H), 5.32 (s, 2H), 3.42-3.39 (m, 4H), 2.40-2.37 (m, 4H). MS: m/z 428.3 [M+H]+.
The following compounds were prepared from l-(3-aminobenzyl)quinazoline-2,4(lH,3H)- dione (prepared from quinazoline-2,4(lH,3H)-dione and l-(bromomethyl)-3 -nitrobenzene followed by reduction) and the corresponding substituted acetic acid using a procedure similar to those described for the synthesis of compound of Example 3.
Example 196
l-(3-(Naphthalen-2-yl)acetamidobenzyl)quinazoline-2,4(lH,3H)-dione 1H NMR (DMSO-de): 11.72 (brs, 1H), 10.23 (s, 1H), 8.10-7.99 (m, 1H), 7.90-7.76 (m, 4H), 7.62-7.56 (m, 2H), 7.46-7.38 (m, 4H), 7.26-7.16 (m, 3H), 7.05-6.90 (m, 1H), 5.25 (s, 2H), 3.75 (s, 2H). MS: m/z 436.4 [M+H]+.
Example 197
l-(3-(3,4-Dimethoxyphenyl)acetamidobenzyl)quinazoline-2,4(lH,3H)-dione 1H NMR (DMSO-de): 11.70 (brs, 1H), 10.03 (s, 1H), 8.01 (dd, J= 7.8 and 1.2 Hz, 1H), 7.65-7.55 (m, 2H), 7.34 (s, 1H), 7.27-7.17 (m, 3H), 6.98 (d, J= 7.8 Hz, 1H), 6.83-6.77 (m, 3H), 5.26 (s, 2H), 3.69(s, 6H), 3.47 (s, 2H). MS: m/z 446.3 [M+H]+.
Example 198
l-(3-([l,2,4]Triazolo[4,3-a]pyridine-6-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione a) l-(3-(N-Methoxy-N-methylcarbamoyl)benzyl)quinazoline-2,4(lH,3H)-dione: To a solution of l-(3-carboxybenzyl)quinazoline-2,4(lH,3H)-dione (0.5 g, 1.68 mmol), HATU (0.96 g, 2.53 mmol) and DIEA (0.9 g, 7 mmol) in dry DCM (20 mL) was added Ν,Ο- dimethylhydroxylamine hydrochloride (0.2 g, 2.0 mmol) at room temperature under N¾ then the mixture was heated to 4°C and stirred overnight. The reaction solution was concentrated, the residue was diluted with H20 and it was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with water and brine, dried over anhydrous Na2S04 and concentrated. The crude product was purified via chromatography to give the title compound (0.4 g, 70% yield),
b) l-(3-([l,2,4]triazolo[4,3-a]pyridine-6-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione: To a solution of 6-bromo-[l,2,4]triazolo[4,3-a]pyridine (35 mg, 0.18mmol) in anhydrous THF (1 mL) was added «-BuLi (0.15 mL, 0.38 mmol) dropwise at -65°C under N2, then it was maintained at this temperature for 3 h. To this solution was added dropwise a solution of 1- (3-(N-methoxy-N-methylcarbamoyl)benzyl)quinazoline-2,4(lH,3H)-dione (50 mg, 0.15 mmol) in THF (1 mL), then it was stirred for 4 h at -65 °C. It was allowed to warm to 0 °C for over 4 h. The reaction solution was poured into saturated aqueous H4C1, extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2S04, and concentrated. The crude product was purified by preparative TLC to give the title compound (6.5 mg, 11% yield) as white solid. 1H MR (CD30D+CDC13): 9.42 (d, J= 7.2 Hz, 1H), 8.41-8.39 (m, 2H), 8.10 (d, J= 7.2 Hz, 1H), 7.95 (d, J= 9.0 Hz, 1H), 7.58-7.45 (m, 4H), 7.18-7.11 (m, 3H), 5.38 (s, 2H). MS: m/z 398.2 [M+H]+.
The following compounds were prepared from the corresponding substituted l-(3- carboxybenzyl)quinazoline-2,4(lH,3H)-dione or l-((2-carboxylpyridin-6- yl)methyl)quinazoline-2,4(lH,3H)-dione and substituted amine using a procedure similar to those described for the synthesis of compound of Example 3.
Example 199
6-Fluoro-l-((2-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-d6): 11.84 (s, 1H), 8.39 (d, J= 4.8 Hz, 2H), 7.94 (t, J = 7.8 Hz, 1H), 7.72- 7.70 (m, 1H), 7.57-7.53 (m, 3H), 7.34-7.30 (m, 1H), 6.67 (t, J= 4.8 Hz, 1H), 5.46 (s, 2H), 3.73- 3.63 (m, 4H), 3.42-3.32 (m, 4H). MS: m/z 462.5 [M+H]+.
Example 200
5-Fluoro-l-(4-fluoro-3-(4-methoxybenzylcarbamoyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.70 (s, 1H), 8.79 (t, J= 5.3 Hz, 1H), 7.66-7.57 (m, 2H), 7.46-7.41 (m, 1H), 7.27-7.20 (m, 3H), 7.08-6.99 (m, 2H), 6.90-6.87 (m, 2H), 5.30 (s, 2H), 4.37 (d, J= 6.0 Hz, 2H), 3.73 (s, 3H). MS: m/z 452.2 [M+H]+. Example 201
l-(3-(3-Chlorobenzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.70 (s, 1H), 9.01 (t, J= 5.1 Hz, 1H), 7.75-7.68 (m, 2H), 7.57-7.52 (m, 1H), 7.48-7.32 (m, 5H), 7.18-7.08 (m, 2H), 5.31 (s, 2H), 4.45 (d, J= 5.7 Hz, 2H). MS: m/z 456.1 [M+H]+.
Example 202
l-(3-(Benzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.70 (s, 1H), 8.87 (t, J= 5.1 Hz, 1H), 7.67-7.59 (m, 2H), 7.47-7.42 (m, 1H), 7.36-7.22 (m, 6H), 7.09-6.99 (m, 2H), 5.31 (s, 2H), 4.45 (d, J= 6.0 Hz, 1H). MS: m/z 422.3 [M+H]+.
Example 203
5- Methoxy-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
1H MR (DMSO-d6): 11.32 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.53 (t, J= 8.4 Hz, 1H), 7.44-7.29 (m, 4H), 6.85 (d, J= 8.4 Hz, 1H), 6.75 (d, J= 8.4 Hz, 1H), 6.67 (t, J= 4.8 Hz, 1H), 5.33 (s, 2H), 3.84 (s, 3H), 3.79-3.42 (m, 8H). MS: m/z 473.3 [M+H]+.
Example 204
6- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione
1H MR (DMSO-d6): 11.71 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.47-7.40 (m, 3H), 7.34-7.26 (m, 3H), 7.20 (d, J= 9.3 Hz, 1H), 6.67 (t, J= 4.8 Hz, 1H), 5.35 (s, 2H), 3.80 (s, 3H), 3.63-3.46 (m, 8H). MS: m/z 473.3 [M+H]+.
Example 205
l-(3-(5-Bromopyrimidin-2-aminocarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.73 (s, 1H), 10.27 (s, 1H), 9.43 (s, 1H), 8.50 (s, 2H), 7.68-7.52 (m, 3H), 7.28 (t, J= 9.3 Hz, 1H), 7.11-7.00 (m, 2H), 5.33 (s, 2H). MS: m/z 503.0 [M+H]+.
Example 206
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-7-(trifluoromethyl)quinazoline-
2,4(lH,3H)-dione 1H MR (300 M, DMSO-de): 511.96 (s, 1H), 8.36 (d, J= 4.8 Hz, 2H), 8.19 (d, 7= 8.1 Hz, 1H), 7.55 (d, 7= 8.4 Hz, 1H), 7.47 (s, 1H), 7.43-7.39 (m, 3H), 7.33-7.30 (m, 1H), 6.65 (t, 7 = 4.7 Hz, 1H), 5.44 (s, 2H), 3.59-3.46 (m, 8H). MS: m/z 511.2 [M+H]+.
Example 207
6, 7-Ethylenedioxo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.55 (s, 1H), 8.39 (d, 7= 4.8 Hz, 2H), 7.44-7.34 (m, 5H), 6.75 (s, 1H), 6.67 (t, 7= 4.8 Hz, 1H), 5.29 (s, 2H), 4.32-4.27 (m, 4H), 3.88-3.56 (m, 8H). MS: m/z 501.2 [M+H]+.
Example 208
5 -Fluoro- 1 -(6-methoxy-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.65 (s, 1H), 8.37 (d, 7= 4.8 Hz, 2H), 7.67-7.60 (m, 1H), 7.39 (dd, 7= 8.4 and 1.8 Hz, 1H), 7.16 (d, 7= 8.4 Hz, 1H), 7.07-6.98 (m, 2H), 6.87 (d, 7= 8.4 Hz, 1H), 6.65 (t, 7= 4.7 Hz, 1H), 5.20 (s, 2H), 3.95 (s, 3H), 3.82-3.16 (m, 8H). MS: m/z 491.2 [M+H]+.
Example 209
7-Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione
1H MR (DMSO-de): 11.54 (s, 1H), 8.37 (d, 7= 4.8 Hz, 2H), 7.92 (d, 7= 8.7 Hz, 1H), 7.42-7.30 (m, 4H), 6.84 (dd, 7= 8.9 and 2.3 Hz, 1H), 6.68-6.63 (m, 2H), 5.34 (s, 2H), 3.76 (s, 3H), 3.71-3.51 (m, 8H). MS: m/z 473.3[M+H]+
Example 210
5-Fluoro-l-(4-fluoro-3-(4-(tetrahydrofuran-2-carbonyl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione
1H MR (DMSO-de): 11.67 (s, 1H), 7.66-7.59 (m, 1H), 7.47-7.42 (m, 1H), 7.38 (d, 7= 6.0 Hz, 1H), 7.28 (t, 7= 9.0 Hz, 1H), 7.10-6.95 (m, 2H), 5.30 (s, 2H), 4.75-4.50 (m, 1H), 3.85-3.45 (m, 8H), 3.25-3.00 (m, 2H), 2.15-1.70 (m, 4H). MS: m/z 499.3 [M+H]+.
Example 211
5 -Fluoro- 1 -(4-nitro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.71 (s, 1H), 8.40 (d, J= 3.9 Hz, 2H), 8.17 (d, J= 8.7 Hz, 1H), 7.63-7.57 (m, 3H), 7.07-6.94 (m, 2H), 6.69 (t, J= 4.4 Hz, 1H), 5.45 (s, 2H), 3.85-3.84 (m, 2H), 3.70-3.69 (m, 2H), 3.61-3.59 (m, 2H), 3.21-3.18 (m, 2H). MS: m/z 506.2 [M+H]+.
Example 212
l-(3-(4-Cyclohexylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione
1H MR (DMSO-d6): 11.68 (s, 1H), 7.66-7.58 (m, 1H), 7.45-7.40 (m, 1H), 7.30-7.23 (m, 2H), 7.06-6.99 (m, 2H), 5.30 (s, 2H), 3.56-3.07 (m, 8H), 2.33-2.25 (m, 1H), 1.72-1.04 (m, 10H). MS: m/z 483.5 [M+H]+.
Example 213
5-Fluoro-l-(4-fluoro-3-(4-phenylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.68 (s, 1H), 7.67-7.60 (m, 1H), 7.48-7.38 (m, 2H), 7.32-7.20 (m, 3H), 7.07-7.00 (m, 2H), 6.94-6.91 (m, 2H), 6.82 (t, J= 7.2 Hz, 1H), 5.31 (s, 2H), 3.85-3.65 (m, 2H), 3.45-3.10 (m, 4H), 3.10-2.90 (m, 2H). MS: m/z 477.4 [M+H]+.
Example 214
5-Fluoro-l-(4-fluoro-3-(4-phenylpiperidine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione 1H MR (DMSO-d6): 11.68 (s, 1H), 7.62-7.56 (m, 1H), 7.45-7.37 (m, 2H), 7.33-7.18 (m, 6H), 7.04-6.93 (m, 2H), 5.45-5.15 (m, 2H), 4.70-4.55 (m, 1H), 3.50-3.05 (m, 2H), 2.95-2.65 (m, 2H), 1.80-1.20 (m, 4H). MS: m/z 476.4 [M+H]+.
Example 215
l-(4-Bromo-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.67 (s, 1H), 8.39 (d, J= 4.8 Hz, 2H), 7.66-7.58 (m, 2H), 7.37 (d, J = 1.8 Hz, 1H), 7.30 (dd, J= 8.4 and 2.1 Hz, 1H), 7.06-6.97 (m, 2H), 6.68 (t, J= 4.8 Hz, 1H), 5.37-5.22 (m, 2H), 3.82-3.11 (m, 8H).MS: m/z 539.3 [M+H]+.
Example 216
6,7-Methylenedioxo- 1 -(3-(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-
2,4(lH,3H)-dione 1H MR (DMSO-de): 11.64 (s, 1H), 8.39 (d, J= 4.5 Hz, 2H), 7.44-7.32 (m, 5H), 6.95 (s, 1H), 6.67 (t, J= 4.4 Hz, 1H), 6.14 (s, 2H), 5.33 (s, 2H), 3.81-3.65 (m, 8H). MS: m/z 487.2
[M+H]+.
Example 217
l-(3-(4-(Cyclohexylmethyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-
2,4(lH,3H)-dione
1H MR (DMSO-de): 11.70 (s, 1H), 7.66-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.32-7.23 (m, 2H), 7.05-6.99 (m, 2H), 5.30 (s, 2H), 3.70-3.50 (m, 2H), 3.20-3.00 (m, 2H), 2.38-2.28 (m, 2H), 2.20-2.10 (m, 2H), 2.05 (d, J= 6.6 Hz, 2H), 1.73-1.63 (m, 5H), 1.45-1.39 (m, 1H), 1.30-1.00 (m, 3H), 0.90-0.70 (m, 2H). MS: m/z 497.3 [M+H]+.
Example 218
8-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione
1H MR (DMSO-de): 11.93 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.89 (d, J= 7.8 Hz, 1H), 7.60-7.52 (m, 1H) , 7.45-7.22 (m, 5H), 6.66 (t, J= 4.8 Hz, 1H), 5.40 (s, 2H), 3.90-3.20 (m, 8H). MS: m/z 461.2 [M+H]+.
Example 219
6- Amino- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \H, 3H)-dione
A mixture of 6-nitro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-quinazoline- 2,4(lH,3H)-dione (50 mg, 0.10 mmol) in EtOH (10 mL) with Fe powder (33.5 mg, 0.60 mmol) and sat. H4C1 solution (0.2 mL) were refluxed under N2 overnight. The mixture was filtered to remove the solid. The solution was concentrated and purified by flash chromatography
(DCM:MeOH = 50:3) to give the titile compound (10.79 mg, 23.6% yield) as yellow solid. 1H MR (DMSO-de): 11.46 (s, 1H), 8.39 (d, J= 4.8 Hz, 2H), 7.42-7.31 (m, 4H), 7.20 (d, J= 2.7 Hz, 1H), 7.00 (d, J= 8.7 Hz, 1H), 6.89 (dd, J= 8.7 and 2.7 Hz, 1H), 6.67 (t, J= 4.8 Hz, 1H), 5.26 (s, 4H), 3.81-3.68 (m, 8H). MS: m/z 458.3 [M+H]+.
Example 220
l-(2-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione The title compound was prepared from l-(2-carboxybenzyl)quinazoline-2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 2-(bromomethyl)benzoate using a procedure similar to those used for compounds of Example 1 and 2), and 2-(piperazin-l- yl)pyrimidine using a procedure similar to that described for the synthesis of compound of Example 3. 1H MR (DMSO-d6): 11.76 (s, 1H), 8.40 (d, J= 4.8 Hz, 2H), 8.03-8.00 (m, 1H), 7.70-7.50 (m, 1H), 7.35-7.00 (m, 6H), 6.68 (t, J= 4.8 Hz, 1H), 5.25 (s, 2H), 4.10-3.60 (m, 8H). MS: m/z 443.2 [M+H]+.
Example 221
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)phenyl)quinazoline-2,4( IH, 3H)-dione a) Methyl 3-(3-(2-bromobenzoyl)ureido)benzoate: To a solution of 2-bromobenzamide (2.0 g, 10.0 mmol) in DCM (30 mL) was added oxalyl chloride (1.65 g, 13.0 mmol) and it was heated under reflux for 23 h. To the reaction mixture was added methyl 3-aminobenzoate (1.66 g, 11.0 mmol) and it was stirred for 20 min. The mixture was poured into water, and the precipitate was filtered. It was recrystallized from ethanol to give the crude product (1.80g, 48%), which was used for the next step without further purification.
b) l-(3-Methoxycarbonylphenyl)quinazoline-2,4(lH,3H)-dione: A mixture of methyl 3-(3-(2- bromobenzoyl)ureido)benzoate (1.8 g, 4.8 mmol), potassium tert-butoxide (2.69 g, 24 mmol) and DMF (20 mL) was stirred at 70-80 °C under nitrogen for 2.25 h. It was cooled, diluted with water, and the mixture was filtered. The crude product was purified by preparative TLC (EtOAc) to give the title compound (0.34 g, 24% yield) as white solid. MS: m/z 297 [M+l]+.
c) l-(3-Carboxyphenyl)quinazoline-2,4(lH,3H)-dione: The title compound was prepared from
1- (3-methoxycarbonylphenyl)quinazoline-2,4(lH,3H)-dione and NaOH using a procedur similar to those of compound of Example 2, and was isolated as white solid. MS: m/z 283 [M+H]+.
d) 1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)phenyl)quinazoline-2,4( 1H, 3H)-dione : The title compound was prepared from l-(3-carboxyphenyl)quinazoline-2,4(lH,3H)-dione and
2- (piperazin-l-yl)pyrimidine using a procedur similar to those of compound of Example 3, and was isolated as white solid. 1H MR (DMSO-d6): 11.72 (s, 1H), 8.36 (d, J = 4.8 Hz, 2H), 8.02 (d, J= 6.6 Hz, 1H), 7.69-7.55 (m, 5H), 7.25 (t, J= 7.5 Hz, 1H), 6.65 (t, J= 4.7 Hz, 1H), 6.48 (d, J= 8.4 Hz, 1H), 3.80-3.20 (m, 8H). MS: m/z 429.1 [M+H]+.
Example 222
8-Chloro-l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione and 8-chloro-3-(3- methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione
To a suspension of 8-chloroquinazoline-2,4(lH,3H)-dione (5.1 g, 25.9 mmol) in toluene (50 mL) and hexamethyldisilazane (HMDS, 10.4 g, 64.9 mmol) was added sulfuric acid (0.25 g, 2.6 mmol). The mixture was heated to reflux and refluxed for 8 h until a clear solution was obtained. The solvent and excessive HMDS was removed via vacuum evaporation, and methyl 3-(bromomethyl)benzoate (5.9 g, 25.9 mmol) and DMF (1 mL) was added to the residue. The reaction mixture was heated to 160°C and was stirred at this temperature for 3 h. It was diluted with 1,4-dioxane (6 mL) at 100°C, and then methanol (10 mL) was added at 70°C and it was stirred for 30 min. The mixture was cooled to 5°C and the precipitates were collected. The solids was washed with methanol (10 mL) and water (20 mL), dried under vacuum for 12 h to give the title compound 8-chloro-3-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione (2.6 g, 29.1% yield) as gray solid. MS: m/z 477.1 [M+H]+. The filtrate was concentrated, and the residue was purified by preparative TLC (PE:EA = 1 : 1) to give the other title compound 8- chloro-l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione (0.2 g, 1.8%) as yellow solid. MS: m/z 477.1 [M+H]+.
Example 223
8-Chloro-3 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione The compound was prepared from 8-chloro-3-(3-carboxybenzyl)quinazoline-2,4(lH,3H)- dione (prepared from 8-chloro-3-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione and NaOH using a procedur similar to those of compound of Example 2), and 2-(piperazin-l- yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H MR (DMSO-d6): 11.15 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.95 (d, J= 7.8 Hz, 1H), 7.82 (d, J= 7.5 Hz, 1H), 7.50-7.30 (m, 4H), 7.23 (t, J= 7.8 Hz, 1H), 6.67 (t, J= 4.8 Hz, 1H), 5.14 (s, 2H), 3.90-3.55 (m, 8H). MS: m/z 477.1 [M+H]+.
Example 224
8-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione The compound was prepared from 8-chloro-l-(3-carboxybenzyl)quinazoline-2,4(lH,3H)- dione (prepared from 8-chloro-l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione and NaOH using a procedure similar to those of compound of Examples 2), and 2-(piperazin-l- yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H NMR (DMSO-d6): 11.94 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 8.05 (d, J= 6.6 Hz, 1H), 7.77 (d, J= 6.6 Hz, 1H), 7.50-7.20 (m, 5H), 6.66 (t, J= 4.8 Hz, 1H), 5.53 (s, 2H), 3.90- 3.50 (m, 8H). MS: m/z 477.1 [M+H]+.
Example 225
8-Methyl-3 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione The compound was prepared from 8-methyl-3-(3-carboxybenzyl)quinazoline-2,4(lH,3H)- dione (prepared from 8-methylquinazoline-2,4(lH,3H)-dione and methyl 3- (bromomethyl)benzoate using a procedure similar to those used for Examples 222 and 223), and 2-(piperazin-l-yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H NMR (DMSO-d6): 10.81 (s, 1H), 8.36 (d, J= 4.5 Hz, 2H), 7.83 (d, J= 7.5 Hz, 1H), 7.52 (d, J= 7.2 Hz, 1H), 7.45-7.30 (m, 4H), 7.13 (t, J= 7.7 Hz, 1H), 6.67 (t, J= 4.7 Hz, 1H), 5.15 (s, 2H), 3.92-3.46 (m, 8H), 2.36 (s, 3H). MS: m/z 457.3 [M+H]+.
Example 226
8-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione a) 8-Methyl- lH-benzo[<i][l,3]oxazine-2,4-dione: To a solution of 2-amino-3-methylbenzoic acid (5.03 g, 33.3 mmol) in THF (50 mL) was added triphosgene (9.92 g, 33.4 mmol). The mixture was stirred at room temperature for 15 min and then filtered. The precipitate was washed by THF and water, dried to give the title compound (5.10 g, 86.4% yield) as white solid. MS: m/z 178.1 [M+H]+.
b) 2-Amino-N-tert-butyl-3-methylbenzamide: To a solution of 8-methyl-lH- benzo[<f][l,3]oxazine-2,4-dione (3.89 g, 22.0 mmol) in DMF (30 mL) were added DMAP (0.27 g, 2.2 mmol) and tert-butylamine (2.55 mL, 24.1 mmol). It was stirred at room temperature overnight, then the mixture was poured into water and the precipitate was filtered. The solid was washed with water and dried to give the product (1.68g, 37.1% yield). MS: m/z 207.2 [M+H]+.
c) 3-Tert-butyl-8-methylquinazoline-2,4(lH,3H)-dione: To a solution of 2-amino-N-tert-butyl- 3-methylbenzamide (0.52 g, 2.5 mmol) in THF (20 mL) were added CDI (0.85 g, 5.2 mmol). It was refluxed overnight, cooled to room temperature, then the mixture was poured into water and the precipitate was filtered. The solid was washed with water and dried to give the title compound (0.25 g, 42.6% yield). 1H NMR (DMSO-d6): 10.33 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.41 (d, J= 7.2 Hz, 1H), 7.04 (t, J= 7.6 Hz, 1H), 2.31 (s, 3H), 1.66 (s, 9H). d) 3-Tert-butyl-8-methyl-l-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione: A mixture of 3-tert-butyl-8-methylquinazoline-2,4(lH,3H)-dione (1.00 g, 4.3 mmol), methyl 3-(bromomethyl)benzoate (0.99 g, 4.3 mmol) and MeONa (0.28 g, 5.2 mmol) in DMF (15 mL) was stirred at 50 °C overnight. The resulting mixture was used directly for next step reaction. MS: m/z 403.2 [M+Na]+.
e) 8-Methyl-l-(3-carboxybenzyl)quinazoline-2,4(lH,3H)-dione: To the reaction mixture from above was added 6N HCl (a.q., 40 mL), and the mixture was heated at 80°C for 6 h. It was cooled to room temperature, poured into water and the precipitate was filtered. The solid was washed with water and dried to give the title compound (0.27 g, 20.1% yield). MS: m/z 311.1 [M+H]+.
f) 8-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione: The title compound was prepared from 8-methyl-l-(3-carboxybenzyl)quinazoline- 2,4(lH,3H)-dione and 2-(piperazin-l-yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H NMR (DMSO-d6): 11.70 (s, 1H), 8.38 (d, J = 4.8 Hz, 2H), 7.92 (d, J = 6.9 Hz, 1H), 7.50-7.26 (m, 5H), 7.17 (t, J = 7.5 Hz, 1H), 6.65 (t, J = 4.8 Hz, 1H), 5.35 (s, 2H), 3.85-3.15 (m, 8H), 2.35 (s, 3H). MS: m/z 457.2 [M+H]+.
Example 227
8-Methoxy-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
The compound was perpared from 2-amino-3-methoxylbenzoic acid using procedures similar to those described for the synthesis of compound of Example 226. 1H NMR (DMSO-d6): 11.76 (s, 1H), 8.38 (d, J= 4.8 Hz, 2H), 7.65 (d, J= 6.6 Hz, 1H), 7.45-7.17 (m, 6H), 6.67 (t, J = 4.7 Hz, 1H), 5.51 (s, 2H), 3.80-3.64 (m, 8H), 3.56 (s, 3H). MS: m/z 473.2 [M+H]+.
Example 228
3 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione a) 3-(3-Methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione: A suspension of quinazoline- 2,4(lH,3H)-dione (2.5 g, 15.4 mmol), methyl 3-(bromomethyl)benzoate (3.56 g, 15.4 mmol) and K2C03 (4.26 g, 30.8 mmol) in DMF (30 mL) was stirred at room temperature overnight. To the mixture was added 150 mL water and the precipitates were collected. The crude product was purified by chromatography on silica (CH2Cl2:MeOH=200: l) to give the title compound (0.87 g, 18.2% yield) as white solid. 1H NMR (DMSO-d6): 11.51 (s, 1H), 8.00- 7.90 (m, 2H), 7.84 (d, J = 7.5 Hz, 1H), 7.75-7.55 (m, 2H), 7.47 (t, J = 7.8 Hz, 1H), 7.30- 7.15 (m, 2H), 5.14 (s, 2H), 3.83 (s, 3H). MS: m/z 311.2 [M+H]+.
b) 3-(3-Carboxybenzyl)quinazoline-2,4(lH,3H)-dione: The title compound was prepared from 3-(3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione using a procedure similar to those described for the synthesis of compound of Example 2. MS: m/z 297.2 [M+H]+.
c) 3 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione : The title compound was prepared from 3-(3-carboxybenzyl)quinazoline-2,4(lH,3H)-dione and 2-(piperazin-l-yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H NMR (DMSO-d6): 11.55 (s, 1H), 8.36 (d, J = 4.8 Hz, 2H), 7.93 (d, J = 6.9 Hz, 1H), 7.66 (t, J = 7.1 Hz, 1H), 7.45-7.26 (m, 4H), 7.25-7.12 (m, 2H), 6.65 (t, J= 4.7 Hz, 1H), 5.11 (s, 2H), 3.90-3.20 (m, 8H). MS: m/z 443.3 [M+H]+.
Example 229
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)phenethyl)quinazoline-2,4( 1H, 3H)-dione The compound was prepared from l-(3-carboxyphenethyl)quinazoline-2,4(lH,3H)-dione (prepared from quinazoline-2,4(lH,3H)-dione and methyl 3-(2-bromoethyl)benzoate using a procedure similar to those used for Examples 1 and 2) and 2-(piperazin-l-yl)pyrimidine using a procedure similar to those described for the synthesis of compound of Example 3. 1H NMR (DMSO-i¾): 11.54 (s, 1H), 8.37 (d, J= 4.8 Hz, 2H), 7.78 (dd, J= 7.8 and 1.5 Hz, 1H), 7.73 (t, J = 6.9 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.35-7.22 (m, 5H), 6.66 (t, J = 4.7 Hz, 1H), 4.28 (t, J = 7.5 Hz, 2H), 3.80-3.20 (m, 8H), 2.95 (t, J= 7.4 Hz, 1H). MS: m/z 457.4 [M+H]+.
Example 230
8-Hydroxy-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione
A solution of BBr3 (4N in DCM, 10 mL, 40 mmol) was added dropwise to a mixture of 8-methoxy-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione (60 mg, 0.13 mmol) in DCM (25 mL) at -70°C. The mixture was warmed to room temperature and stirred at r.t overnight. After cooled at ice-bath, 10 mL MeOH was added dropwise and then NH4C1 (a.q.) was added. The mixture was extracted by DCM (50 mL x 2), the combined organic layer was dried to give crude product which was purified by TLC
(DCM/MeOH = 20: 1) to give the target product (7.64 mg, 13.1% yield). 1H NMR (DMSO-d6): 11.64 (s, 1H), 10.34 (s, 1H), 8.36 (d, J= 4.8 Hz, 2H), 7.51 (dd, J= 6.8 and 2.6 Hz, 1H), 7.39- 7.34 (m, 1H), 7.27-7.23 (m, 3H), 7.10-7.03 (m, 2H), 6.65 (t, J= 4.7 Hz, 1H), 5.63 (s, 2H), 3.85- 3.53 (m, 8H). MS: m/z 459.4 [M+H]+.
Example 231
Evaluation of the synergistic potentiation effects of l-(3-(4-(pyrimidin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione and analogs on the growth inhibiting activity of MMS using a MTT based cell viability assay
The synergistic potentiation effect of PARP inhibitors on the growth inhibiting activity of DNA damaging anticancer drugs such as methyl methanesulphonate (MMS) were measured with SW620 human colorectal cancer cells using a MTT based cell viability assay. Briefly, SW620 human colorectal cancer cells were used to measure the cell growth inhibiting activity of DNA alkylating anticancer drug MMS. The MMS concentration used in the assay was carefully titrated to a level at which MMS only had a minimal inhibitory effect on the cell growth, and under this conditions it was sensitive to detect the potentiation effect of 1- (arylmethyl)quinazoline-2,4(lH,3H)-diones on MMS's inhibiting activity on cell growth. SW620 cells were grown and maintained in RPMI1640 (Gibco) medium supplemented with 10% FBS (Hyclone). In the first day of experiment, 4000 cells were seeded to each well of a 96-well cell culture plate and incubated at 37°C and 5% C02 in a cell culture incubator overnight. In the next day, the cell culture medium was removed. One hundred and eighty μΐ fresh medium containing 1.5 μg/ml MMS and 20 μΐ of 10-fold concentration of testing compounds or reference compounds (AZD2281 and ABT-888) were added to each well sequencially. The serial dilutions of the reference compounds and the compounds to be tested were made with a 1 :3 and 1 : 10 fashion in DMSO. The 10-fold concentrated solutions of these compounds were made by mixing ΙΟμΙ of the serial dilutions in DMSO with 90 μΐ fresh medium. The final concentration of DMSO in the medium was 1%° The cells were incubated at 37°C in 5% C02 cell culture incubator for additional 5 days (120 hours). Afterwards, the 96- well cell culture plate was taken out and 20 μΐ of MTT solution was added to each well and incubated at 37°C for 4 h. The medium was removed and 100 μΐ DMSO was added to each well. The 96-well cell culture plates were shaked adequately for 10 min and readed in a Varioskan Flash plate reader (Thermo Fisher Scientific) at 520 and 690 nm. The data were analyzed by Prism 5 software (GraphPad). The obtained 520 nm absorbance readings substracting corresponding 690 nm reading were analyzed and plotted against the Log scale of the compound concentrations. The curves were fitted using the following equation to calculate the IC50 value of each compound, Y (absorbance)= minimal absorbance value +(maximal absorbance value - minimal absorbance value)/(l+10A(LogC-LogICso)), C was the compound concentration.
The calculated IC50 values are listed in Table 1. These values reflect the potentiation effect of l-(arylmethyl)quinazoline-2,4(lH,3H)-diones on the growth inhibiting activity of a fixed concentration of MMS in a MTT based cell viability assays.
Table 1. Substituted l-(arylmethyl)quinazoline-2,4(lH,3H)-diones potentiate the growth inhibiting activity of MMS (IC50)
Figure imgf000089_0001
Example # 9 10 11 12 13 14 15 16
IC50 (nM) 500 439 618 533 727 102 666 7259
Example # 17 18 19 20 21 22 23 24
IC50 (nM) >10000 >10000 >10000 391 >10000 >10000 8.2 26
Example # 25 26 27 28 29 30 31 32
IC50 (nM) 9.8 149 83 >10000 >10000 119 2595 106
Example # 33 34 35 36 37 38 39 40
IC50 (nM) 130 294 265 >10000 >10000 >10000 604 182
Example # 41 42 43 44 45 46 47 48
IC50 (nM) 11 78 51 6.8 34 21 54 56
Example # 49 50 51 52 53 54 55 56
IC50 (nM) 32 37 33 55 59 217 89 30
Example # 57 58 59 60 61 62 63 64
IC50 (nM) 46 171 >10000 >10000 61 816 50 177
Example # 65 66 67 68 69 70 71 72
IC50 (nM) 417 991 2054 673 352 136 70 80
Example # 73 74 75 76 77 78 79 80
IC50 (nM) 3379 >10000 2661 ND 2964 269 5543 >10000
Example # 81 82 83 84 85 86 87 88
IC50 (nM) 99 459 72 52 25 86 35 137
Example # 89 90 91 92 93 94 95 96
IC50 (nM) D >10000 >10000 >10000 >10000 >10000 >10000 >10000
Example # 97 98 99 100 101 102 103 104
IC50 (nM) >10000 >10000 >10000 202 117 87 45 8.3
Example # 105 106 107 108 109 110 111 112
IC50 (nM) 7.9 105 6.3 78 48 72 27 14
Example # 113 114 115 116 117 118 119 120
IC50 (nM) 9.6 51 19 48 5.1 0.82 0.72 42
Example # 121 122 123 124 125 126 127 128
IC50 (nM) 4.5 Td 15 9.9 6.7 18 13 37
Example # 129 130 131 132 133 134 135 136
IC50 (nM) 18 15 17 4.1 4.1 5.8 6.8 7.1
Example # 137 138 139 140 141 142 143 144
IC50 (nM) 7.0 351 16 37 12 22 15 2.8 Example # 145 146 147 148 149 150 151 152
IC50 (nM) 12 3.4 2.7 2.1 14 25 18 13
Example # 153 154 155 156 157 158 159 160
IC50 (nM) 9.2 7.3 23 28 18 7.8 648 394
Example # 161 162 163 164 165 166 167 168
IC50 (nM) 506 1193 28 6.2 49 4.0 5.2 15
Example # 169 170 171 172 173 174 175 176
IC50 (nM) 3.4 120 70 9.5 228 94 16 15
Example # 177 178 179 180 181 182 183 184
IC50 (nM) >10000 7.9 12 3.1 4.9 16 13 62
Example # 185 186 187 188 189 190 191 192
IC50 (nM) 6.7 24 27 7.8 10 21 192 7.2
Example # 193 194 195 196 197 198 199 200
IC50 (nM) 4.5 18 1440 985 >10000 >10000 19 >10000
Example # 201 202 203 204 205 206 207 208
IC50 (nM) >10000 >10000 >10000 >10000 >10000 >10000 >10000 37
Example # 209 210 211 212 213 214 215 216
IC50 (nM) 103 10 145 19 58 517 1388 >10000
Example # 217 218 219 220 221 223 224 225
IC50 (nM) 2.5 103 481 >10000 >10000 >10000 1113 >10000
Example # 226 227 228 229 230 AZD2281 ABT-888
IC50 (nM) 84 13 >10000 >10000 2.6 28 2642
ND, not determined.
In summary, l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione (Example 4) and analogs have excellent potentiation effects on the growth inhibiting activity of DNA damaging anticancer agent MMS in a MTT based cell viability assay.
Example 232
Determination of the synergistic potentiation effect of l-(3-(4-(pyrimidin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione and analogs on MMS induced apoptosis using a cell based caspase-3 activity assay
Human breast cancer cell line T47D was used to determine the potentiation effect of
PARP inhibitors on the apoptosis inducing activity of DNA damaging anticancer drugs such as
MMS. Intracellular caspase-3 activity was used to measure cell apoptosis. The dose response effect of MMS to induce intracellular caspase activity was carefully titrated and the concentration that only induces a minimal level of caspase activity was used to test the potentiation effect of PARP inhibitors. Briefly, T47D cells were grown in DMEM/F12 cell culture medium (Hyclone) supplemented with 0.2 U/ml insulin (Genview) and 10% FBS (Hyclone). A day before experiment, 20000 of T47D cells were seeded to each well of a 96- well cell culture plate and maintained at 37°C and 5% C02 in a cell culture incubator overnight. On the day of experiment, cell culture medium was removed. One hundred and eighty μΐ of fresh medium containing 100 nM MMS was added to each well and followed by 20 μΐ medium containing 10 folds of the concentrations of experimental drugs or reference compounds (ADZ2281 and ABT-888). The serial dilutions of the compounds to be tested and the reference compounds were made in a 1 :3 and 1 : 10 fashion in DMSO. The 10-fold compound solutions were made by mixing 10 μΐ DMSO serial dilution solutions with 90 μΐ fresh growth medium. Twenty four hours later, the cells in the 96-well plates were centrifuged at 1000 g for 5 min and the supernatants were removed. Fifty μΐ lysis buffer (lOmM Tris, pH7.5, 0.1M NaCl, 1 mM EDTA, 0.01%) Triton X-100) was added to each well and the plates were shaked horizontally for 30 min at 4°C . After centrifugation at 1000 g at 4°C for 10 min, 20 μΐ of supernatant was transferred from each well to a corresponding well in a 384-well black plate. Twenty μΐ of buffer (20mM PIPES, pH7.4, 4 mM EDTA and 0.2% CHAPS) containing 20 μΜ fluorescent caspase-3 substrate ((Ac-DEVD)2-R110, AnaSpec Cat #60304-5) was added to each well afterwards. The plates were shaked to uniformly mix the wells and incubated at 37°C for 3 h. The fluorescence intensity was measured using the following wavelength: ex: 496nm, em: 520nm using a fluorescence plate reader (Varioskan Flash, Thermo Fisher Scientific). The caspase-3 activity induced by the compounds was expressed as a relativefluorescence unit (RFU). The obtained fluorescence readings were analyzed using a commercial graphic software (GraphPad Prism 5) and plotted against the Log value of the compound concentrations. The EC50 values were obtained by fitting the data points with the equation of Y (fluorescence reading) = minimal fluorescence reading + (maximal fluorescence reading - minimal fluorescence reading)/(l+10A(LogEC50-LogC)), where C is the concentration of the testing compound.
The synergistic potentiation effect of compounds on MMS induced apoptosis in T47D cells is expressed as EC50 values and listed in Table 2.
Table 2. Substituted l-(arylmethyl)quinazoline-2,4(lH,3H)-diones potentiate the apoptosis inducing activity of MMS (EC50) Example # 1 2 3 4 5 6 7 8
EC50 (nM) >10000 >10000 56 12 450 2518 2655 120
Example # 9 10 11 12 13 14 15 16
EC50 (nM) 426 400 214 318 6601 39 803 9206
Example # 17 18 19 20 21 22 23 24
EC50 (nM) 5018 >10000 >10000 139 5797 >10000 4.0 20
Example # 25 26 27 28 29 30 31 32
EC50 (nM) 3.9 20 51 5894 >10000 39 112 96
Example # 33 34 35 36 37 38 39 40
EC50 (nM) 96 104 238 >10000 1914 267 614 29
Example # 41 42 43 44 45 46 47 48
EC50 (nM) 2.2 11 18 5.7 11 6.6 2.6 8.2
Example # 49 50 51 52 53 54 55 56
EC50 (nM) 10 13 20 22 18 124 20 16
Example # 57 58 59 60 61 62 63 64
EC50 (nM) 22 108 >10000 >10000 17 379 15 51
Example # 65 66 67 68 69 70 71 72
EC50 (nM) 373 604 4820 635 76 34 67 41
Example # 73 74 75 76 77 78 79 80
EC50 (nM) 811 2111 2869 ND 5206 112 3219 1192
Example # 81 82 83 84 85 86 87 88
EC50 (nM) 63 154 21 18 7.6 27 27 67
Example # 89 90 91 92 93 94 95 96
EC50 (nM) D 4168 1987 2926 >10000 >10000 >10000 >10000
Example # 97 98 99 100 101 102 103 104
EC50 (nM) >10000 >10000 >10000 70 20 26 29 2.6
Example # 105 106 107 108 109 110 111 112
EC50 (nM) 14 217 9.5 68 23 32 1.7 2.9
Example # 113 114 115 116 117 118 119 120
EC50 (nM) 17 19 23 13 5.8 3.1 3.0 8.8
Example # 121 122 123 124 125 126 127 128
EC50 (nM) 4.9 8.4 11 3.8 22 6.5 4.1 12
Example # 129 130 131 132 133 134 135 136
EC50 (nM) 49 87 20 0.93 2.1 4.7 9.8 3.2 Example # 137 138 139 140 141 142 143 144
EC50 (nM) 2.1 281 4.0 8.9 13 3.8 6.0 3.4
Example # 145 146 147 148 149 150 151 152
EC50 (nM) 6.5 4.1 3.4 2.3 5.8 16 5.2 5.1
Example # 153 154 155 156 157 158 159 160
EC50 (nM) 2.0 6.7 12 14 26 8.6 220 261
Example # 161 162 163 164 165 166 167 168
EC50 (nM) 405 495 42 2.1 18 1.6 5.0 3.8
Example # 169 170 171 172 173 174 175 176
EC50 (nM) 1.0 43 23 3.2 122 37 14 10
Example # 177 178 179 180 181 182 183 184
EC50 (nM) 743 11 7.4 1.4 2.4 14 6.1 18
Example # 185 186 187 188 189 190 191 192
EC50 (nM) 2.1 6.8 30 ND ND ND ND 3.1
Example # 193 194 195 196 197 198 199 200
EC50 (nM) 1.6 11 471 >10000 >10000 >10000 4.9 >10000
Example # 201 202 203 204 205 206 207 208
EC50 (nM) >10000 >10000 >10000 >10000 >10000 >10000 >10000 24
Example # 209 210 211 212 213 214 215 216
EC50 (nM) 294 15 166 45 590 654 743 >10000
Example # 217 218 219 220 221 223 224 225
EC50 (nM) 19 37 445 >10000 >10000 >10000 274 >10000
Example # 226 227 228 229 230 AZD2281 ABT-888
EC50 (nM) 24 40 >10000 >10000 3.2 24 3494
ND, not determined.
In summary, as measured by the intracellular caspase activity, l-(3-(4-(pyrimidin-2- yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione (Example 4) and its analogs have shown excellent potentiation effect on DNA damaging anticancer drug MMS induced cancer cell apoptosis.
Exmaple 233
Determination of the cell growth inhibiting activity of l-(3-(4-(pyrimidin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione and analogs on BRCA-2 deficient CAPAN-1 pancreatic duck cancer cells using a MTT based cell viability assay BRCA-deficient cancer cells are sensitive to PARP inhibition. In the presence of PARP inhibitors, BRCA-deficient cancer cells could not grow and eventually will lead to death of cells. BRCA-2 deficient CAPAN-1 human pancreatic cancer cells were used to test the growth inhibiting activity of substituted l-(aiylmethyl)quinazoline-2,4(lH,3H)-diones. Briefly,
CAPAN-1 cells are grown and maintained in IMEM medium supplemented with 20% FBS. The assay takes 10 days to finish. On day 1, 6000 CAPAN-1 cells are seeded to each well of a 96- well plate. The cells are incubated at 37°C in a cell culture incubator overnight. In the next day, serial dilutions of compounds to be tested and reference compound (AZD2281) were prepared with a 1 :3 and 1 : 10 fashion in DMSO. Ten-fold compound solutions were made by mixing 10 μΐ DMSO serial dilution solutions with 90 μΐ fresh growth medium. The cell culture medium was removed and 180 μΐ fresh media with FBS and 20 μΐ of compound solutions were added to each well. The final concentration of DMSO was 1%. Cells were then returned to the C02 cell culture incubator and incubated at 37°C for two days (day 3 and day 4). On day 5, the same procedure as what was done on day 2 was repeated. Cell culture medium was removed and fresh medium containing serial dilutions of compounds or reference compounds were added. Cells were returned to the C02 cell culture incubator and incubated for two more days. On day 8, same procedure was repeated again and fresh medium containing the testing compounds or reference compounds were added and incubated for an additional 2 days. On day 10, 20 μΐ of MTT reagent (5mg/ml) was added to each well of the cell culture plate and incubated for 4 h. The cell culture media was removed and 100 μΐ DMSO was added to each well. The 96-well cell culture plates were shaked horizontally for 10 min and readed in a Varioskan Flash plate reader (Thermo Fisher Scientific) at 520 and 690 nm. The obtained 520 nm absorbance readings substracting corresponding 690 nm reading were analyzed using a commercial graphic software (GraphPad Prism 5) and plotted against the Log scale of the compound concentrations. The curves were fitted using the following equation to calculate the IC50 value of each compound, Y (520 nm - 690 nm) = minimal absorbance value + (maximal absorbance value - minimal absorbance value) /(l+10A(LogC-LogICso)), where C was the concentration of testing compounds.
The inhibitory effect of compounds on the CAPAN-1 cell growth is expressed as IC50 values and listed in Table 3.
Table 3. Growth inhibition of CAPAN-1 cells by selected substituted l-(arylmethyl)quinazoline-
2,4(lH,3H)-diones (IC50)
Figure imgf000095_0001
IC50 (nM) 445 55 2360 1841 >10000 4942 160 735
Example # 25 26 27 30 40 41 42 43
IC50 (nM) 98 400 281 1785 1739 208 2539 974
Example # 44 45 46 48 49 50 51 56
IC50 (nM) 318 668 446 168 421 173 402 1181
Example # 65 69 70 81 83 85 100 101
IC50 (nM) 3189 1982 339 421 746 291 312 1049
Example # 103 104 105 107 111 112 113 117
IC50 (nM) 665 452 97 161 77 767 170 39
Example # 118 119 123 124 127 128 132 133
IC50 (nM) 54 56 111 137 44 442 17 22
Example # 134 136 139 140 142 143 144 145
IC50 (nM) 45 40 36 155 223 73 78 146
Example # 147 149 150 152 154 155 157 161
IC50 (nM) 47 52 176 121 56 142 202 3547
Example # 168 172 176 185 186 188 189 190
IC50 (nM) 1465 389 187 358 167 472 736 1383
Example # 199 210 212 217 AZD2281
IC50 (nM) 25 948 3445 >10000 460
In summary, l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione (Example 4) and analogs are excellent inhibitors of CAPAN-1 cell growth, suggesting that they are good PARP inhibitors.
Exmaple 234
Measurement of the inhibitory effect of l-(3-(4-(pyrimidin-2-yl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione and analogs on PARP-1 enzymtic activity The measurement of PARP- 1 enzymtic activity was achieved by using a commercial 96- well colorimetric assay kit (4676-096-K, Trevigen, Inc. Gaithersburg, MD 20877 USA). Briefly, PARP-1 catalyzes the NAD-dependent addition of poly(ADP-ribose) to its nuclear protein substrates such as histones. The assay kit measures the incorporation of biotynylated
poly(ADP-ribose) onto histone proteins in a 96-well format.
Reference compound (AZD2281) and compounds to be tested are serially diluted 1 : 10 with a IX buffer. To each well of histone pre-coated plate 10 μΐ of 5-fold concentrations of testing compounds or reference compound, 15 μΐ of PARP-1 enzyme (0.5 unit) and 25 μΐ reaction buffer were added and the plates were incubated at room temperature for 60 min. The plates were washed with 200 μΐ PBS with 0.1% Triton X-100 twice and then with 200 μΐ PBS twice. The residual liquid was removed by carefully tapping the plates on paper towels. Equal volumes of PeroxyGlow™ solution A and B were mixed and 100 μΐ of the solution was added to each well. The luminescence readings were read immeidately in a Varioskan Flash plate reader (Thermo Fisher Scientific). The obtained luminescence readings were analyzed using a commercial graphic software (GraphPad Prism 5) and plotted against the Log scale of the compound concentrations. The IC50 values were obtained by fitting the data points with the equation of Y (Luminescence reading) = minimal luminescence reading + (maximal luminescence reading - minimal luminescence reading)/(l+10A(LogC - LogECso)), where C is the concentration of the testing compound.
The inhibitory effect of compounds on the PARP-1 enzymatic activity is expressed as IC50 values and listed in Table 4.
Table 4. The inhibitory effect of substituted l-(aiylmethyl)quinazoline-2,4(lH,3H)-diones on
PARP-1 enzymatic activity (IC50)
Figure imgf000097_0001
In summary, as measured in the PARP-1 enzymatic assay, l-(3-(4-(pyrimidin-2- yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione (Example 4) and analogs are potent PARP-1 inhibitors. Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

Claims

WHAT IS CLAIMED IS:
1. A compound having the Formula I:
Figure imgf000098_0001
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
Ar is an aryl or heteroaryl, substituted with a substituted carbonyl or methyl at the meta- position; and
R1-R6 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, ethylenedioxo, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido or optionally substituted alkylthiol.
2. The compound of claim 1, wherein R5 and R6 is hydrogen, Ar is phenyl, pyridyl or furanyl, substituted with a substituted carbonyl at the meta-position.
3. The compound of claim 1, wherein said compound has Formula II:
Figure imgf000098_0002
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
R1-R4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, ethylenedioxo, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido or optionally substituted alkylthiol,
R7-R10 independently are hydrogen, halo, optionally substituted amino, alkoxy, C1-10 alkyl, haloalkyl, aryl, heteroaryl, a carbocyclic group, a heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alkylthiol, or substituted carbonyl, and
Rii is an optionally substituted amino, hydrazino, alkoxy, C1-10 alkyl, haloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, acylamido, hydroxy, thiol, acyloxy, carbonylamido, or alkylthiol.
4. The compound of claim 1 wherein said compound has Formula III:
Figure imgf000099_0001
or pharmaceutically acceptable salts or prodrugs thereof, wherein:
R1-R4 independently are hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, cyano, ethylenedioxo, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido or optionally substituted alkylthiol;
R7-R10 independently are hydrogen, halo, optionally substituted amino, alkoxy, C1-10 alkyl, haloalkyl, aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, hydroxyalkoxy, aminoalkyl, aminoalkoxy, carboxyalkyl, carboxyalkoxy, nitro, cyano, acylamido, aminocarbonyl, hydroxy, thiol, acyloxy, azido, carboxy, carbonylamido, alkylsulfonyl, aminosulfonyl, dialkylaminosulfonyl, alkylsulfiniyl, alkylthiol, or substituted carbonyl; and
R12 is an optionally substituted C1-10 alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkylcarbonyl, acyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl, aminocarbonyl, alkylsulfonyl, cycloalkylsulfonyl, or aminosulfonyl.
5. The compound of claim 4, wherein Ri or R2 is hydrogen, fluoro, chloro, bromo or methyl; R4 is hydrogen, fluoro, methyl, methoxy or hydroxy; R7, R8, R9, or R10 is hydrogen or fluoro.
6. The compound of claim 4, wherein Ri2 is cycloalkyl, aryl, heteroaryl, carbocyclic group, heterocyclic group, arylalkyl, heteroarylalkyl, carbocycloalkyl, heterocycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl or heterocyclocarbonyl.
7. The compound of claim 1, wherein said compound is selected from the group consisting of:
l-(3-Methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-Carboxybenzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-Cyclohexylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
l-(3-(4-([l,2,4]Triazolo[4,3- )]pyridazin-6-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Ethylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-(4-Fluorobenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(4-Chlorobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-(4-Bromobenzoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; l-(3-(4-(4-Methoxybenzoyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(Tetrahydro-2H-pyran-4-yl)carbonylpiperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(3-(4-(Ethylsulfonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-Acetylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-Phenylpiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-Phenylpiperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
l-(3-(4-(Pyrazin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(4-Fluoro-3-methoxycarbonylbenzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-Carboxy-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione; 1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( ΙΗβΗ)- dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(3-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Piperidin- 1 -yl)piperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Pyridin-4-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)-dione; 1 -(3 -(4-(6-Fluorobenzo[<JJisoxazol-3 -yl)piperidine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H,3H)- dione;
l-(3-(4-(Furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-(Furan-3-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; l-(3-(4-(Thiophene-3-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Pyridine-3 -carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(3 -(4-(Pyridine-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Pyridine-4-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-Phenoxypiperidine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(pyrazin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Benzo[<JJisothiazol-3 -yl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)quinazoline-2,4(lH,3H)-dione; l-(4-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(4-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(6-Fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(6-Fluoro-3-(4-(thiophene-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
l-(6-Fluoro-3-(4-(furan-2-carbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(6-Chloro-3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(6-Chloro-3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
l-(2-Chloro-3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(2-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(2-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-2-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione; l-(5-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)-5-fluorobenzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
1 -(4-Chloro-3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Benzo[i¾isothiazol-3-yl)piperazine-l-carbonyl)furan-5-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Pyridin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-((2-(4-(Pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6-yl)methyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylmethyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; l-(3-(4-(Cyclopentylmethyl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 1 -(3 -(4-(Cyclohexylsulfonyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( lH,3H)-dione; 1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-fluoroquinazoline- 2,4(lH,3H)-dione;
7-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-7-methylquinazoline- 2,4(lH,3H)-dione;
7-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
6-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-methylquinazoline- 2,4(lH,3H)-dione; l-(4-Fluoro-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-6-methylquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- methylquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- methylquinazoline-2,4(lH,3H)-dione;
6-Bromo- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Bromo-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Bromo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \H, 3H)- dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline- 2,4(lH,3H)-dione;
6-Nitro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-nitroquinazoline- 2,4(lH,3H)-dione;
5 -Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
5-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro-l-(3-(4-(cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 5-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5- Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
6-Chloro- 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline)-2,4(lH,3H)-dione;
6-Chloro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione; 6-Chloro- 1 -(3 -(4-(cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6-Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5- Fluoro-l-(3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
5 -Fluoro-( 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline)- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclohexylcarbonyl)piperazine-l-carbonyl)benzyl)-8-fluoroquinazoline- 2,4(lH,3H)-dione;
6- Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
6-Fluoro- 1 -(3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
6-Fluoro- 1 -(3 -(4-(thiophene-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclohexylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopentylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-5- fluoroquinazoline-2,4(lH,3H)-dione; 5 -Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
l-(3-(4-(Cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)-5-methylquinazoline- 2,4(lH,3H)-dione;
7-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)- dione;
7-Chloro-l-(3-(4-(cyclopentylcarbonyl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-5- fluoroquinazoline)-2,4(lH,3H)-dione;
6-Chloro-( 1 -(3 -(4-benzoylpiperazine- 1 -carbonyl)-4-fluorobenzyl)quinazoline)- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5 - Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
6- Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5 -Chloro- 1 -(3 -(4-(cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6- fluorobenzyl)quinazoline-2,4(lH,3H)-dione;
5 - Chloro- 1 -(6-fluoro-3 -(4-(thiophene-2-carbonyl)piperazine- 1 - carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Chloro- 1 -(6-fluoro-3 -(4-(pyridin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Chloro- 1 -(5-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione; 5 -Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Cyclopentylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclopropylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6- fluoroquinazoline-2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Benzoylpiperazine-l-carbonyl)-4-fluorobenzyl)-6-fluoroquinazoline-2,4(lH,3H)- dione;
l-(3-(4-(Cyclobutylcarbonyl)piperazine-l-carbonyl)-6-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Cyclobutylcarbonyl)piperazine- 1 -carbonyl)-6-fluorobenzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(furan-2-carbonyl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(5 -fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(6-Chloro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-6-fluoroquinazoline- 2,4(lH,3H)-dione;
6-Fluoro- 1 -(4-fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- l-(4-fluoro-3 -(4-(thiazol-2-yl)piperazine-l-carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
1 -(4-Fluoro-3 -(4-(thiazol-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( 1H, 3H)- dione;
1 -(3 -(4-(Cyclohexylcarbamoyl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
1 -(4-Fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione hydrochloride;
5 -Fluoro 1 -(4-fluoro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione hydrochloride; 1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( IH, 3H)-dione hydrochloride;
l-(3-([l,2,4]Triazolo[4,3-a]pyridine-6-carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione; 6-Fluoro-l-((2-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)pyridin-6- yl)methyl)quinazoline-2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-methoxybenzylcarbamoyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(3-(3-Chlorobenzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione; l-(3-(Benzylcarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline-2,4(lH,3H)-dione;
5- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
6- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(5-Bromopyrimidin-2-aminocarbamoyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
1 -(3 -(4-(Pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)-7-(trifluoromethyl)quinazoline- 2,4(lH,3H)-dione;
6, 7-Ethylenedioxo- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5 -Fluoro- 1 -(6-methoxy-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
7- Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-(tetrahydrofuran-2-carbonyl)piperazine-l- carbonyl)benzyl)quinazoline-2,4(lH,3H)-dione;
5 -Fluoro- 1 -(4-nitro-3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-Cyclohexylpiperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
5-Fluoro-l-(4-fluoro-3-(4-phenylpiperazine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
5-Fluoro-l-(4-fluoro-3-(4-phenylpiperidine-l-carbonyl)benzyl)quinazoline-2,4(lH,3H)- dione;
l-(4-Bromo-3-(4-(pyrimidin-2-yl)piperazine-l-carbonyl)benzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione; 6,7-Methylenedioxo- 1 -(3-(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
l-(3-(4-(Cyclohexylmethyl)piperazine-l-carbonyl)-4-fluorobenzyl)-5-fluoroquinazoline- 2,4(lH,3H)-dione;
8-Fluoro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
6- Amino- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \H, 3H)- dione;
8-Chloro- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
8-Methyl- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline-2,4( \Η Η)- dione;
8-Methoxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
8-Hydroxy- 1 -(3 -(4-(pyrimidin-2-yl)piperazine- 1 -carbonyl)benzyl)quinazoline- 2,4(lH,3H)-dione;
or a pharmaceutically acceptable salt or prodrug thereof.
8. A method of treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of any of claims 1 to 7.
9. The method of claim 8, wherein said disorder is cancer.
10. The method according to claim 9, wherein said cancer is liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphomas, acute or chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoide, head or neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, or prostatic carcinoma.
11. The method of claim 10, further comprising administering at least one known anticancer agent, or a pharmaceutically acceptable salt of said agent.
12. The method according to claim 10, wherein said compound is administered together with at least one compound selected from the group consisting of busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 5- fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, campath, Panitumumab, Ofatumumab, Avastin, Herceptin®, Rituxan®, imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thalidomide or lenalidomide.
13. The method of claim 10, further comprising treating said mammal with radiation-therapy.
14. A pharmaceutical composition comprising the compound of any of claims 1 to 7 and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14, further comprising at least one known anticancer agent, or a pharmaceutically acceptable salt of said agent.
16. The pharmaceutical composition of claim 14, further comprising at least one compound selected from the group consisting of busulfan, melphalan, chlorambucil, cyclophosphamide, ifosfamide, temozolomide, bendamustine, cis-platin, mitomycin C, bleomycin, carboplatin, camptothecin, irinotecan, topotecan, doxorubicin, epirubicin, aclarubicin, mitoxantrone, elliptinium, etoposide, 5-azacytidine, gemcitabine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, fludarabine, nelarabine, ara-C, alanosine, pralatrexate, pemetrexed, hydroxyurea, thioguanine, colchicine, vinblastine, vincristine, vinorelbine, paclitaxel, ixabepilone, cabazitaxel, docetaxel, campath, Panitumumab, Ofatumumab, Avastin, Herceptin®, Rituxan®, imatinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, nilotinib, dasatinib, pazopanib, temsirolimus, everolimus, vorinostat, romidepsin, tamoxifen, letrozole, fulvestrant, mitoguazone, octreotide, retinoic acid, arsenic trioxide, zoledronic acid, bortezomib, thalidomide or lenalidomide.
17. Use of the compound of any of claims 1-7 in the manufacture of a medicament for treating or preventing a disorder responsive to the inhibition of PARP activity in a mammal suffering therefrom.
PCT/CN2012/073362 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof WO2012130166A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SG2013071543A SG193599A1 (en) 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
PL12765230T PL2709990T3 (en) 2011-04-01 2012-03-31 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer
EP12765230.3A EP2709990B1 (en) 2011-04-01 2012-03-31 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer
US14/006,722 US9290460B2 (en) 2011-04-01 2012-03-31 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
JP2014501428A JP6270713B2 (en) 2011-04-01 2012-03-31 1- (Allylmethyl) quinazoline-2,4 (1H, 3H) -dione as a PARP inhibitor and uses thereof
CN201280001822.0A CN103097361B (en) 2011-04-01 2012-03-31 1-(aryl methyl)-quinazoline-2,4-dione as parp inhibitor and its application
DK12765230.3T DK2709990T3 (en) 2011-04-01 2012-03-31 1 - ((3 - ((1-Piperazinyl) carbonyl) phenyl) methyl) -2,4 (1H, 3H) -quinazoline dione derivatives as PARP inhibitors for the treatment of cancer
AU2012237776A AU2012237776B2 (en) 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
SI201231630T SI2709990T1 (en) 2011-04-01 2012-03-31 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer
CA2831015A CA2831015C (en) 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
ES12765230T ES2736299T3 (en) 2011-04-01 2012-03-31 Derivatives of 1¿ ((3¿ ((1¿piperazinyl) carbonyl) phenyl) methyl) ¿2,4 (1H, 3H) ¿quinazolinadione as inhibitors of PARP to treat cancer
RS20190877A RS59091B1 (en) 2011-04-01 2012-03-31 1-((3-((1-piperazinyl)carbonyl)phenyl)methyl)-2,4(1h,3h)-quinazolinedione derivatives as parp inhibitors for treating cancer
US15/042,366 US9926304B2 (en) 2011-04-01 2016-02-12 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
US15/935,694 US10316027B2 (en) 2011-04-01 2018-03-26 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
US16/415,803 US11358955B2 (en) 2011-04-01 2019-05-17 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
HRP20191273TT HRP20191273T1 (en) 2011-04-01 2019-07-16 1-((3-((1-piperazinyl)carbonyl)phenyl)methyl)-2,4(1h,3h)-quinazolinedione derivatives as parp inhibitors for treating cancer
CY20191100769T CY1121847T1 (en) 2011-04-01 2019-07-18 1-((3-((1-PIPERAZINYL)CARBONYL)PHENYL)METHYL)-2,4(1H,3H)-QUINAZOLINODIONE DERIVATIVES AS PARP INHIBITORS FOR THE TREATMENT OF CANCER

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2011100824756A CN102731416A (en) 2011-04-01 2011-04-01 1-(aryl methyl)-quinazoline-2,4-dione as PARP inhibitor and its application
CN201110082475.6 2011-04-01
CN2011077034 2011-07-11
CNPCT/CN2011/077034 2011-07-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/006,722 A-371-Of-International US9290460B2 (en) 2011-04-01 2012-03-31 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
US15/042,366 Continuation US9926304B2 (en) 2011-04-01 2016-02-12 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof

Publications (1)

Publication Number Publication Date
WO2012130166A1 true WO2012130166A1 (en) 2012-10-04

Family

ID=46929484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/073362 WO2012130166A1 (en) 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof

Country Status (19)

Country Link
US (4) US9290460B2 (en)
EP (1) EP2709990B1 (en)
JP (1) JP6270713B2 (en)
CN (2) CN104230827B (en)
AU (1) AU2012237776B2 (en)
CA (1) CA2831015C (en)
CY (1) CY1121847T1 (en)
DK (1) DK2709990T3 (en)
ES (1) ES2736299T3 (en)
HR (1) HRP20191273T1 (en)
HU (1) HUE046121T2 (en)
PL (1) PL2709990T3 (en)
PT (1) PT2709990T (en)
RS (1) RS59091B1 (en)
SG (1) SG193599A1 (en)
SI (1) SI2709990T1 (en)
TR (1) TR201910675T4 (en)
TW (1) TWI527800B (en)
WO (1) WO2012130166A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174541A1 (en) * 2014-07-28 2017-06-07 Technische Universität Dresden Thymine derivatives and quinazoline-dione derivatives for the inhibition of hsp27
KR20170132881A (en) * 2015-04-03 2017-12-04 임팩트 테라퓨틱스, 인코포레이티드 PARP inhibitor solid drug formulation and uses thereof
EP3438096A4 (en) * 2016-04-01 2019-08-21 Impact Therapeutics, Inc. Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2020229595A1 (en) * 2019-05-14 2020-11-19 Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) Quinazoline-2,4-dione derivatives as parp inhibitors
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
WO2022100577A1 (en) * 2020-11-10 2022-05-19 Impact Therapeutics (Shanghai) , Inc Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1h,3h)-dione and preparation thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090568B2 (en) 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
TWI527800B (en) 2011-04-01 2016-04-01 南京英派藥業有限公司 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
WO2013064083A1 (en) 2011-11-01 2013-05-10 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
BR112014026266A2 (en) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd quinazolidinedione derivative
SG11201406860SA (en) 2012-04-24 2014-11-27 Chugai Pharmaceutical Co Ltd Quinazolinedione derivative
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CN106083741A (en) * 2016-02-22 2016-11-09 南京中医药大学 2 sulfur are for quinazolinedione derivatives
CN107098886B (en) * 2016-02-26 2020-07-14 中国医学科学院药物研究所 Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108727343A (en) * 2017-04-21 2018-11-02 中国医学科学院药物研究所 Quinazolinones PARP-1/2 inhibitor containing 3- amino nafoxidines and preparation method thereof, pharmaceutical composition and purposes
CN111269216A (en) * 2018-12-05 2020-06-12 中国医学科学院药物研究所 Piperazinone-containing quinazoline dione compound, preparation method, pharmaceutical composition and application thereof
US20230263801A1 (en) * 2020-07-24 2023-08-24 Impact Therapeutics (Shanghai), Inc Combination therapy of parp inhibitors
KR20230163467A (en) * 2021-03-26 2023-11-30 임팩트 테라퓨틱스 (상하이), 인코포레이티드 Oral capsule of PARP inhibitor and method for preparing same
WO2023138667A1 (en) * 2022-01-21 2023-07-27 上海瑛派药业有限公司 Compound preparation of senaparib and temozolomide and preparation method therefor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
DE2652144A1 (en) 1976-11-16 1978-05-18 Merck Patent Gmbh Quinazoline:di:one derivs. - useful as analgesics, antiinflammatory agents and sedatives
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302515A (en) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd Poly(adp-ribose)polymerase inhibitor
JP2002284699A (en) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd Curative for visual cell degenerative disease
WO2006003148A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
JP2007137818A (en) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd 8-hydroxy-2,4(1h,3h)-quinazolinedione derivative
WO2012125521A1 (en) 2011-03-14 2012-09-20 Eternity Bioscience Inc. Quinazolinediones and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1161036A (en) 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
MX7829A (en) 1986-08-21 1993-08-01 Pfizer QUINAZOLINDIONAS AND PIRIDOPIRIMINDIONAS AND THE PROCEDURE FOR THEIR PREPARATION
DE69622148T2 (en) 1995-09-28 2002-10-31 Suntory Limited, Osaka CHINAZOZINE DERIVATIVES AND THEIR USE
US6201121B1 (en) 1995-12-28 2001-03-13 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
AU1743997A (en) 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
AUPO440496A0 (en) 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives
CA2283514A1 (en) 1997-03-17 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Process for producing quinazoline derivatives
JP2005501021A (en) * 2001-06-19 2005-01-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Antibacterial agent
DE10201240A1 (en) 2002-01-15 2003-07-24 Bayer Ag New 1-substituted fused bicyclic uracil derivatives, are poly-(ADP-ribose) synthase inhibitors useful for treating e.g. ischemia, reperfusion damage, cardiovascular diseases, arthritis, asthma and neurodegenerative diseases
JP5323063B2 (en) 2007-05-31 2013-10-23 塩野義製薬株式会社 Oxyimino compounds and uses thereof
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5464609B2 (en) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Quinazolinone derivatives as tubulin polymerization inhibitors
US20140018376A1 (en) * 2009-10-20 2014-01-16 Hans Allgeier Use of 1H-Quinazoline-2,4-Diones
TWI527800B (en) 2011-04-01 2016-04-01 南京英派藥業有限公司 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
DE2652144A1 (en) 1976-11-16 1978-05-18 Merck Patent Gmbh Quinazoline:di:one derivs. - useful as analgesics, antiinflammatory agents and sedatives
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302515A (en) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd Poly(adp-ribose)polymerase inhibitor
JP2002284699A (en) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd Curative for visual cell degenerative disease
WO2006003148A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
CN1980913A (en) 2004-06-30 2007-06-13 詹森药业有限公司 Quinazolinedione derivatives as parp inhibitors
JP2007137818A (en) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd 8-hydroxy-2,4(1h,3h)-quinazolinedione derivative
WO2012125521A1 (en) 2011-03-14 2012-09-20 Eternity Bioscience Inc. Quinazolinediones and their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AKINORI IWASHITA ET AL., J. PHARMACOL. EXP. THERA., vol. 310, 2004, pages 425
ANDREW TUTT ET AL., J. CLIN. ONCOL, vol. 27, 2009, pages 18
ANDREW TUTT ET AL., LANCET, vol. 376, 2010, pages 235
KRISHNAKUMAR; KRAUS, MOLECULAR CELL, vol. 39, 2010, pages 8
RA DENT ET AL., J. CLIN. ONCOL., vol. 28, 2010, pages 15
SHUNSUKE GOTO ET, ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 7, 2003, pages 700 - 706

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
EP3174541A1 (en) * 2014-07-28 2017-06-07 Technische Universität Dresden Thymine derivatives and quinazoline-dione derivatives for the inhibition of hsp27
US10940150B2 (en) 2014-07-28 2021-03-09 Technische Universitaet Dresden Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
US11179392B2 (en) 2015-04-03 2021-11-23 Impact Therapeutics, Inc. Solid pharmaceutical formulation of PARP inhibitors and use thereof
US20180071290A1 (en) * 2015-04-03 2018-03-15 Impact Therapeutics, Inc. Solid Pharmaceutical Formulation of PARP Inhibitors and Use Thereof
KR20170132881A (en) * 2015-04-03 2017-12-04 임팩트 테라퓨틱스, 인코포레이티드 PARP inhibitor solid drug formulation and uses thereof
KR102013440B1 (en) * 2015-04-03 2019-08-22 임팩트 테라퓨틱스, 인코포레이티드 PARP inhibitor solid drug formulation and use thereof
EP3278803A4 (en) * 2015-04-03 2018-11-07 Impact Therapeutics, Inc. Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
AU2016239141B2 (en) * 2015-04-03 2019-04-18 Impact Therapeutics (Shanghai), Inc Solid pharmaceutical formulation of PARP inhibitors and the use thereof
US10562889B2 (en) 2016-04-01 2020-02-18 Impact Therapeutics, Inc. Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones
EP3438096A4 (en) * 2016-04-01 2019-08-21 Impact Therapeutics, Inc. Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
WO2020229595A1 (en) * 2019-05-14 2020-11-19 Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) Quinazoline-2,4-dione derivatives as parp inhibitors
CN114206864A (en) * 2019-05-14 2022-03-18 苏州四体康宸医药科技有限公司 Quinazoline-2, 4-dione derivatives as PARP inhibitors
AU2020274407B2 (en) * 2019-05-14 2023-09-28 Suzhou Four Health Pharmaceuticals Co., Ltd Quinazoline-2,4-dione derivatives as PARP inhibitors
CN114206864B (en) * 2019-05-14 2024-05-24 苏州四体康宸医药科技有限公司 Quinazoline-2, 4-dione derivatives as PARP inhibitors
WO2022100577A1 (en) * 2020-11-10 2022-05-19 Impact Therapeutics (Shanghai) , Inc Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1h,3h)-dione and preparation thereof
WO2022099442A1 (en) * 2020-11-10 2022-05-19 上海瑛派药业有限公司 Crystalline forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1h,3h)-dione and preparation therefor

Also Published As

Publication number Publication date
ES2736299T3 (en) 2019-12-27
TR201910675T4 (en) 2019-08-21
PL2709990T3 (en) 2020-03-31
US20190270732A1 (en) 2019-09-05
US10316027B2 (en) 2019-06-11
AU2012237776A1 (en) 2013-10-10
CA2831015C (en) 2020-03-24
SI2709990T1 (en) 2019-09-30
CY1121847T1 (en) 2020-07-31
DK2709990T3 (en) 2019-07-29
CA2831015A1 (en) 2012-10-04
US20180215741A1 (en) 2018-08-02
CN104230827B (en) 2016-10-26
JP2014509615A (en) 2014-04-21
JP6270713B2 (en) 2018-01-31
AU2012237776B2 (en) 2016-09-15
US11358955B2 (en) 2022-06-14
US20140023642A1 (en) 2014-01-23
HRP20191273T1 (en) 2019-10-18
EP2709990A1 (en) 2014-03-26
CN103097361A (en) 2013-05-08
HUE046121T2 (en) 2020-02-28
PT2709990T (en) 2019-07-24
RS59091B1 (en) 2019-09-30
CN104230827A (en) 2014-12-24
TWI527800B (en) 2016-04-01
US9926304B2 (en) 2018-03-27
EP2709990B1 (en) 2019-06-12
EP2709990A4 (en) 2014-11-26
SG193599A1 (en) 2013-10-30
US9290460B2 (en) 2016-03-22
CN103097361B (en) 2014-08-06
US20160237070A1 (en) 2016-08-18
TW201245161A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
US11358955B2 (en) 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
US9102631B2 (en) 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
EP3543242B1 (en) 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6h)-ketone compound
ES2765031T3 (en) Anti-cancer benzopyrazines through inhibition of fgfr kinases
CN102686591B (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
CA2879448C (en) N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof
ES2731216T3 (en) New compounds
MX2014014110A (en) Pteridines as fgfr inhibitors.
US11345710B2 (en) Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
MX2014004857A (en) Quinolines as fgfr kinase modulators.
MX2014014112A (en) New compounds.
EP3896059B1 (en) Pan-kit kinase inhibitor having quinoline structure and application thereof
TWI548637B (en) Phthalazinone derivatives, preparation process and pharmaceutical use thereof
WO2024179547A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
JP2022548055A (en) Substituted imidazoquinoxaline compounds and their applications

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280001822.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12765230

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2831015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 14006722

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014501428

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012237776

Country of ref document: AU

Date of ref document: 20120331

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012765230

Country of ref document: EP